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1 Introduction 
1.1 Transition Metal-Catalyzed C–H Functionalizations 
Carbon–carbon (C−C) and carbon–heteroatom (C−X) bonds are the basis of organic molecules in 
medicinal agents, functional materials, and natural products.
[1]
 Therefore, many organic chemists 
have focused on the development of novel methods for the construction of these bonds. In the past 
few decades, transition metal-catalyzed transformations, such as cross-coupling reactions, became 
one of the most powerful and reliable tools for the formation of C–C and C–X bonds (Scheme 1).[2] 
In particular, the importance of this class of reactions was recognized with the Nobel Prize for 
Chemistry in 2010, the Mizoroki–Heck reaction,[3] the Negishi coupling,[4] and the Suzuki-Miyaura 
coupling.
[5]
 Despite the indisputable advances, the major drawback of cross-coupling reactions is the 
necessity for pre-activation of both reactive components, which add costly chemical steps to the 
overall synthesis. Inspired by the need for green and sustainable chemistry, synthetic chemists hence 
seek more efficient ways to construct C−C and C−X bonds. 
 
 
Scheme 1. Palladium-catalyzed cross-coupling reactions. 
 
Recently, transition metal-catalyzed C−H bond activation has emerged as an attractive alternative for 
C−C and C−X bond formation. This approach avoids the need of prefunctionalization of starting 
materials, and reduces or eliminates salt wastes, which result in high atom- and step-economy. 
Various transition metal catalysts such as palladium,
[6]
 ruthenium,
[7]
 rhodium,
[8]
 copper,
[9]
 iridium,
[10]
 
manganese,
[11]
 and others,
[12]
 have made a significant progress in enhancing the efficiency of C–H 
bond transformation of heteroaromatic compounds. The direct C–H bond functionalization of 
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heterocycles can be arbitrarily classified into the following three general types (Scheme 2): (i) 
coupling of heteroarenes with electrophilic reactants, such as aryl-, alkyl-, alkenyl-, or alkynyl 
(pseudo)halides,
[13]
 (ii) reactions of heteroarenes with nucleophilic coupling partners, including aryl-, 
alkyl-, or alkenyl boronic acids,
[14]
 and (iii) cross-dehydrogentative couplings of heteroarenes with 
either another type of heteroarenes or hydrocarbons, including arenes, alkenes, alkynes, or 
alkanes.
[15]
 
 
Scheme 2. The general methods for C–C/C–Het formation. 
 
The challenges in transition metal-catalyzed C−H activation chemistry are mostly the chemo- and 
site-selectivities. Site selectivity can be controlled by the close proximity of C–H bonds to the 
reactive metal center. In the most cases, this is achieved by the introduction of directing group into 
the substrate core, which contains heteroatoms able to coordinate to metal center. The interaction of 
substrates and catalyst is then promoted through the coordination of heteroatoms to the transition 
metal catalysts (Scheme 3).
[16]
 Consequently, coordination of transition metals with directing groups, 
namely the chelation-assisted C–H activation strategy, is usually considered as an essential step 
involved in these catalytic C–H bond activation processes. 
 
Scheme 3. Site-selective C–H activation by chelation-assistance. 
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Various functional groups, including amide,
[17]
 anilide,
[18]
 imine,
[19]
 heterocycles,
[20]
 as well as 
weakly coordinating functional group, like carboxylic acid,
[21]
 ester,
[22]
 ketone,
[23]
 and hydroxyl 
groups,
[24]
 have been employed as directing groups for catalytic C–H bond activation (Figure 1). 
 
Figure 1. Selected examples of important directing groups employed in C–H activation reactions. 
 
1.2 Ruthenium-Catalyzed C–H Functionalizations 
In the past decades, the catalytic functionalization of C−H bonds has emerged as a powerful tool for 
the production of pharmaceuticals and natural products and also it opened new routes for synthesis of 
materials and polymers.
[25]
 The regioselective direct transformation of C−H bonds to C−C bonds 
offers a unique opportunity to replace the classical catalytic cross-coupling reactions.
[3, 5b, 26]
 
Tremendous progress has been made in transition metal-catalysed C−H activation, most notably in 
the area of palladium and rhodium catalysis.
[6c, 8c]
 Futermore, inexpensive ruthenium complexes 
(Figure 2) also have been widely explored for efficient catalytic conversion of C−H bonds.[7c, 27] 
 
 
Figure 2. The prices of transition metals in 06.2018. 
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For example, the inert C(sp
2
)−H bonds have been successfully functionalized by inexpensive and 
active ruthenium(0) catalyst [RuH2(CO)(PCy3)2].
[28]
 It was shown that an organometallic ruthenium 
complex can insert into C−H bonds to generate a reactive C−Ru−H species via unsaturated substrate 
insertion processes. Versatile ruthenium(II) complexes have also been employed as the catalysts in 
C−H activation transformations. The major contribution into this area have made by the Ackermann 
group, they focused on the application of ruthenium(II) complexes for C–H bond activations,[29] 
following the pioneering but not robust work of Oi and Inoune in 2001.
[30]
 The 
ruthenium(II)-catalyzed C–H activation procceeds via a chelation-assisted C–H metalation to deliver 
cyclometalated ruthenium(II) complex 1.
[31]
 Then, further activation steps for C–H activation via 
oxidative addition of organohalides or insertion of unsaturated substrates delivered the products 2 or 
3 respectively (Scheme 4).
[27a, 32]
 
 
 
Scheme 4. Ruthenium-catalyzed C–H activation. 
 
1.2.1 Ruthenium Catalyzed C–H Alkenylation 
Styrene derivatives are useful intermediates in synthetic organic chemistry.
[33]
 They can be obtained 
by Mizoroki-Heck reaction between arylhalides and alkenes in the presence of a palladium catalyst 
and base.
[15a]
 In the most atom- and step-economical fashion, synthesis of alkenylarenes can be 
achieved by a C–H activation reaction.  
Based on an early report by Fujiwara and Moritani,
[34]
 a wealth of palladium- and rhodium-catalyzed 
oxidative alkenylations were developed. Less expensive ruthenium complexes were also explored in 
oxidative C–H alkenylations reactions.[35] 
  Introduction  
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In 2001, an early example of oxidative alkenylaton of an alkene 5 with aromatic C–H bond was 
reported by Milstein and co-workers using RuCl3·3H2O, [Ru(CO)3Cl2]2, [(ŋ
6
-C6H6)RuCl2]2 or 
Ru(NO)Cl3·5H2O catalyst complexes under an atmosphere of CO and O2 at 180 C (Scheme 5).
[36]
 
low yield of up to 40% of alkenylated arenes 6 were obtained. The optimizied results show that O2 or 
alkene can serve as oxidant and ruthenium(II) and ruthenium(III) had the same catalytic activity, 
whereas the ruthenium(0) precursor Ru3(CO)12 was much less active. Directing groups were not 
required under the reaction conditions, however only poor site-selectivities were obtained. 
 
  
 
Scheme 5. Ruthenium-catalyzed C–H alkenylation of arenes 4 with olefins 5. 
 
Later, Brown and co-workers reported the oxidative Heck reaction of arene boronic acids 7 with 
acrylate 5a catalyzed by [RuCl2(p-cymene)2]2 in the presence of Cu(OAc)2 as the oxidant (Scheme 
6).
[37]
 In contrast to palladium catalyst system, in this reaction halides on the arenes 7 were tolerated.  
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Scheme 6. Ruthenium-catalyzed oxidation Heck reaction. 
 
 
Later, the cross-coupling of C(Sp
2
)–H bonds between an alkene and an arene was achieved by Yi and 
co-workers using cationic ruthenium hydride complex [(η6-C6H6)-(PCy3)(CO)RuH]
+
BF4
-
 as the 
catalyst precursor.
[38]
 The cationic ruthenium hydride complex was found to be a highly site-selective 
catalyst for the oxidative C–H bond alkenylation of aryl-substituted amides 9 and unactivated 
alkenes 10 to give o-alkenylamide products 11 (Scheme 7a). In addition, kinetic experiments were 
performed to gain mechanistic insights into the coupling reaction. To examine the H/D exchange 
pattern on the amide substrate, the treatment of C6D5C(O)NEt2 ([D]5-9a) and cyclopentene (10a) in 
the presence of the catalyst was performed. The result indicated a reversible arene C–H activation 
step (Scheme 7b). In support of this notion, a negligible isotope effect of kH/kD = 1.1 was found for 
the competition reaction between C6H5C(O)NEt2 (9a) and C6D5C(O)NEt2 ([D]5-9a) with 
cyclopentene (10a). Further detailed kinetic studies supported a mechanism involving a rapid vinyl 
C–H activation followed by a rate-limiting C–C bond forming reductive elimination. In these 
reactions, no external oxidant was added, the alkene as well as the newly formed alkenylated product 
severed here as hydrogen scavenger. Therefore the alkenylated product 11 was formed along with 
hydrogenated benzamides 12 as an insepeable mixture.  
 
  Introduction  
7 
 
 
Scheme 7. Ruthenium-catalyzed oxidative alkenylations of benzamides 9.  
 
 
In 2011, the Ackermann group showed that the weakly-coordinating carboxylic group could direct 
the alkenylation with ruthenium(II) catalyst at the ortho-position of benzoic acid derivatives 13 with 
acrylates 5 or acrylonitrile 14 with 2 equivalent of oxidant Cu(OAc)2·H2O (Scheme 8).
[39]
 This 
reaction occurred efficiently in environmentally benign water, in contrast to related palladium- or 
rhodium-catalyzed reactions,
[40]
 which were thus far could have been performed only in organic 
solvents. The alkenylated product underwent oxo-Michael addition, thus leading to a variety of 
lactones 15. The catalytic system tolerated valuable electrophilic functional groups, such as fluoro or 
bromo substituents, and even sterically hindered ortho-substituted acids 13a-13f were also accepted. 
 
  Introduction  
8 
 
 
Scheme 8. Ruthenium-catalyzed oxidative alkenylation of benzoic acid in water. 
 
 
Furthermore, the Ackermann group expanded the ruthenium(II)-catalyzed oxidative alkenylations 
process to other valuable substrates, such as anilides 16 and amides 9 (Scheme 9a). The high 
selectivity monoalkenylated products 18 were achieved using the [RuCl2(p-cymene)]2 17 catalyst 
with the non-coordinating salt KPF6 (20 mol %) in the presence of Cu(OAc)2·H2O.
[41]
 The 
intermolecular competition experiments revealed electron-rich anilides 16b to be preferentially 
functionalized (Scheme 9b). However, when using N-benzoyl anilines 19 as the substrates, the 
alkenylation reaction peformed only at the ortho C–H bond of the aromatic ring linked to the amide 
carbonyl showing the preferential activation/alkenylation by the –C(O)NHPh than the –NHC(O)Ph 
group (Scheme 9c). 
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Scheme 9. Ruthenium-catalyzed C–H alkenylation of anilides and amides. 
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In contrast to the chelation-assisted alkenylations of benzamides, ruthenium-catalyzed oxidative 
functionalizations of weakly coordinating esters 21,
[42]
 aldehydes 23
[43]
 have also been reported by 
the research groups of Ackermann and Jeganmohan. By reacting the catalyst [RuCl2(p-cymene)]2 
with AgSbF6 to abstract the chlorides from the ruthenium(II) complex, in the presence of 
Cu(OAc)2·H2O as an acetate provider and oxidant, they succeeded here towards the alkenylation 
process (Scheme 10). 
 
 
Scheme 10. Ruthenium(II)-catalyzed C–H alkenylation with weakly coordinating esters 21 and 
aldehydes 23 as directing groups. 
 
 
Based on H/D-exchange experiments of ruthenium(II)-catalyzed C–H alkenylation, the Ackermann 
group proposed the catalytic cycle to involve an initial reversible acetate-assisted cycloruthenation to 
form complex 26 (Scheme 11). Subsequent migratory insertion of alkene 5 and β-hydride elimination 
furnish desired product 22, while reductive elimination and reoxidation by Cu(OAc)2 regenerate the 
catalytically active cationic species 25. 
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11 
 
 
Scheme 11. Proposed catalytic cycle of ruthenium(II)-catalyzed C–H alkenylation of arenes. 
 
 
The hydroxyl group of phenols does not direct ruthenium(II)-catalyzed C–H bond activation, but it’s 
derivatives such as carbamates
[44]]
 and the strongly coordinating 2-pyridyl group
[45]
 have been shown 
to direct the ortho-selective C–H cleavage to obtain the alkenylated products 28. In 2012, the 
Ackermann group showed that carbamate derivatives of phenols 29 could undergo 
ortho-alkenylation with acrylates 5b in the presence of catalytic amount of [RuCl2(p-cymene)]2 and 
AgSbF6 with Cu(OAc)2 as oxidant in DME. The reaction was compatibles with a wide range of 
functional groups, including alkyl fluoro, chloro or bromo (Scheme 12).
[44]
 The carbamate directing 
group was easily removed to provide ortho-alkenylated phenol under basic reaction condition. 
  Introduction  
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Scheme 12. Oxidative C–H alkenylation of aryl carbamates 29. 
 
Oxidative alkenylations of arenes with heterocyclic directing groups were also achieved in recent 
years. Dixneuf and co-workers reported on the synthesis of ortho-alkenylated N-arylpyrazoles 33 via 
ruthenium-catalyzed oxidative C–H alkenylation of N-phenylpyrazole 31a using 
[Ru(OAc)2(p-cymene)] as the catalyst in HOAc at 100 C (Scheme 13a).
[46]
 For this reaction, in 
many cases the alkenylated products 33 were obtained with by-product 33' generated through 
dehydrogenative homocoupling. Later, Miura and Satoh reported the direct alkenylation of 
1-phenylpyrazoles 31 with alkenes 32 using [RuCl2(p-cymene)]2 instead of [Ru(OAc)2(p-cymene)] 
as catlyst in the presence of a copper (II) oxidant (Scheme 13b).
[47]
 The reaction was shown to 
tolerate various substituents on the arene ring, such as chloro, ester and nitrile groups.
[48]
 Here the 
formation of mixtures of mono- and bisalkenylated product (33 and 34) was observed. Under the 
same reaction conditions, a low yield was obtained for the phenylbenzothiazole 35 with acrylate 5. 
  Introduction  
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The C–H alkenylation efficiency was considerably improved by the addition of AgSbF6 as the 
cocatalyst (Scheme13b).  
 
Scheme 13. Ruthenium-catalyzed C–H alkenylation. 
 
 
Futhermore, in 2015, the Ackermann group reported the C–H alkenylation of aromatic compounds 
with alkenes assisted by the 1,2,3-triazole group (Scheme 14).
[49]
 Under the optimal reaction 
conditions, the authors showed that various acrylates 5 and functional groups substituted aromatic 
rings 37 were tolerated. Particularly, a very good site-slectivity at a less hindered side of aromatics 
for the meta Me and CF3 substituted aromatics was observed. It is worth to note that heteroarenes 
37c can be succesfully converted to indol derivative 38c. 
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Scheme 14. Ruthenium-catalyzed alkenylation of triazole derivatives 37.  
 
 
Subsequently, the Ackermann group reported the efficient oxidative C–H alkenylation of sulfonic 
acid, sulfonyl chlorides, and sulfonamides (39 and 41) with ample substrate scope. For the 
alkenylation of sulfonic acids, not only acrylates, but also vinyl sulfones, nitriles, phosphonates and 
ketones proved to be viable substrates. For the reaction of sulfonamides 41, the alkenylation was 
followed by intramolecular aza-Michael reaction leading to cyclization into sultams 42 in good 
yields when increasing the temperature to 150 C (Scheme 15).[50] 
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Scheme 15. Ruthenium-catalyzed C–H alkenylation of sulfonic acid, sulfonyl chlorides, and 
sulfonamides 39. 
 
Recently, the direct alkenylation of α,α-disubstituted benzylamines catalyzed by [RhCp*Cl2]2 or 
low-cost [RuCl2(p-cymene)]2 in the presence of Cu(OAc)2 as oxidant was reported by Miura and 
co-workers.
[51]
 This was the first example of ruthenium(II)-catalysed C–H bond functionalisation 
directed by a free NH2 group. When treating the α,α-disubstituted benzylamines 43 with alkenes 5 in 
the presence of [RuCl2(p-cymene)]2 and Cu(OAc)2 in dioxane at room temperature, the cyclization 
product 44 was formed in good yield (Scheme 16). 
 
 
Scheme 16. Ruthenium-catalyzed alkenylation of α,α-disubstituted benzylamines 43. 
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The mechanism was suggested to involve the initial formation of a Ruthenium(II)–OAc species 
leading to form a five-membered metallacycle intermediate 46, then alkene insertion into aryl-metal 
bond to form 47 (Scheme 17).
[51]
 Subsequently, the β-hydrid elimination and the intramolecular 
Michael addition occur.  
 
 
Scheme 17. A plausible pathway for the ortho-alkenylation of α,α-disubstituted benzylamines 43. 
 
 
1.2.2 Ruthenium-Catalyzed Hydroarylation  
Alkene derivatives are present various natural products, drug molecules and organic materials. They 
are also widely used in organic transformations. Based on the presented above transformation, alkene 
derivatives can be prepared by metal-catalyzed chelation-assisted oxidative alkenylation at the C–H 
bond of arenes (Scheme 18a).
[35]
 Another efficient way to synthesize alkene derivatives is 
represented by metal-catalyzed hydroarylation of alkynes (Scheme 18b).
[52]
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Scheme 18. Synthesis of alkene derivatives by C–H activation. 
 
 
As early as 1986, Lewis and Smith demonstrated ortho-metalation of aryl phosphites under 
Ru-catalyzed conditions.
[53]
 By catalytically generating the P-based directing group, they developed a 
hydroarylation approach to ortho-alkylated phenols. Subsequently, the Murai group reported a 
ruthenium-catalyzed chelation-assisted ortho-alkylation of aromatic ketones with alkenes via C–H 
bond activation in the presence of RuH2(CO)(PPh3)3 53.
[54]
 Later, under the similar reaction 
conditions, the Murai group demonstrated that alkynes can successfully insert to aromatic ketones 
via chelation-assisted ortho C–H cleavage (Scheme 19). When heating the mixure of ketone 54, 
internal alkyne 51 and RuH2(CO)(PPh3)3 in toluene under 135 C, trisubstituted alkene 55 was 
achieved after 1-2 days. It is noteworthy that heteroaromatic ketons 56 were also tolerated.
[55]
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Scheme 19. Ruthenium(0)-catalyzed chelation-assisted hydroarylation of ketones 54. 
 
The hydroarylation of alkynes proceeds via oxidative addition parthway, which introduce a 
five-membered hydrometallacycle intermediate 60 (Scheme 20), then the alkyne insertion into the 
metal–hydride bond of intermediate 60 occurs and is followed by reductive elimination, giving the 
final trisubstituted alkene 59 regenerating the ruthenium(0) catalyst. However, this type of 
hydroarylation reaction is not completely regio- and stereoselective.  
 
Scheme 20. Mechanism for ruthenium(0)-catalyzed chelation-assisted hydroarylation. 
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In recent years, it was clearly revealed that this type of regio- and stereoisomeric issues can be 
overcome by carrying out the hydroarylation reaction via base-assisted pathway. For instance, Zhang 
proposed alkenylation reactions of arylpyridines 61 with terminal alkynes 51 in the presence of 
benzoyl peroxide (Scheme 21).
[56]
  
 
Scheme 21. Ruthenium-catalyzed hydroarylations of arylpridines 61. 
 
Subsequently, a significant number of ruthenium-catalyzed hydroarylation reactions via base-assisted 
C–H activation appeared in the literature, and these transformation were rapidly expanded to a 
variety of directing groups, including benzamides,
[53b, 57]
 isoquinolones,
[58]
 carbamates,
[59]
 among 
others.
[60]
 In these transformations, substituted arenes reacted with alkynes in the presence of a 
ruthenium catalyst, giving alkene derivatives in a regio- and stereoselective manner. It is noteworthy 
that the copper oxidant is inherently not necessary for the hydroarylation reaction.  
 
1.2.3 Ruthenium-Catalyzed C–H Oxygenation  
During the past few years, ruthenium(II)-catalyzed C–H oxygenations of C–H bonds were reported 
by Ackermann and Rao group.
[29a, 61]
 In contrast, DuBois and coworkers developed a protocol for the 
selective hydroxylation of tertiary C–H bonds that uses catalytic amounts of RuCl3, an inexpensive 
terminal oxidant−KBrO3, and pyridine as an essential additive (Scheme 22).
[62]
 However, this 
reaction only has a good selectivity for tetiary
 
C−H centers and do not proceed through C–H 
activation, but outer-sphere vadical processes.  
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Scheme 22. Ruthenium-catalyzed outer-sphere oxygenation. 
 
However, the Ackermann group developed ruthenium-catalyzed C−H oxygenation using 
[RuCl2(p-cymene)]2, as well as well-defined ruthenium(II) biscarboxylate complex 
[Ru(O2CMes)2(p-cymene)], or even inexpensive [RuCl3·nH2O] as catalysts, and PhI(OAc)2 as 
oxidant (Scheme 23a). Around the same time, Rao and co-workers used the complex 
[RuCl2(p-cymene)]2 as the precatalyst and K2S2O8 or HIO3 as the oxidant in the oxygenation of C−H 
bonds in arenes (Scheme 23b).
[63]
 TFA/TFAA cosolvent system and oxidants serve as the critical 
factors for oxygenation of arenes with esters 21.
[61b]
 
 
Scheme 23. Ruthenium-catalyzed C–H bond oxygenation of ketones 58 and esters 21. 
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The group of Ackermann
[64]
 and Rao
[61a]
 further expaned the scope of ruthenium-catalyzed C−H 
oxygenation process to valuable aryl carbamates 67 and anilides 18 (Scheme 24). 
 
 
Scheme 24. Ruthenium-catalyzed C–H bond oxygenation of aryl carbamates 67 and anilides 18. 
 
 
In 2014, the Ackermann group reported the first C−H oxygenation by assistance of very weakly 
coordinating aldehydes 23 using a ruthenium(II) complex as the catalyst (Scheme 25).
[65]
 Under the 
optimal reaction conditions, electrophilic halide functional groups were well tolerated by the highly 
chemoselective ruthenium(II) catalyst.  
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Scheme 25. Ruthenium(II)-catalyzed C−H oxygenation of aromatic aldehydes 23. 
 
 
Competition studys between arenes with different directing groups clearly showed the challenges 
that are associated with the use of very weakly coordinating aldehydes (Scheme 26). The success of 
this reaction highlighted the remarkable power of versatile and mild ruthenium(II) catalysis for the 
selective functionalization of unactivated C−H bonds. 
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Scheme 26: Competition experiments for ruthenium(II)-catalyzed C−H oxygenations of aldehydes 
23. 
 
 
Base on the above reaserch, Hong and co-workers reported ruthenium(II)-catalyzed direct C−H 
oxygenation of flavones and chromones 73 (Scheme 27).  
 
Scheme 27. Ruthenium(II)-catalyzed C−H oxygenations of flavone and chromone. 
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A plausible catalytic cycle was proposed as depicted in Scheme 28. First, the five-membered 
ruthenacycle 77 can be formed via the C−H bond activation of substrate, and then the ruthenium(IV) 
species 78 is formed through the oxidiation by the hypervalent iodine. Subsequent reductive 
elimination introduce 5-(trifluoroacetyloxy)-flavone 79 and regenerate the ruthenium(II) catalyst 76. 
Finally, the desired product is afforded from the trifluoroacetate 74 by aqueous work-up. 
 
 
Scheme 28. A proposed mechanistic pathway for ruthenium(II)-catalyzed C−H oxygenations.  
 
 
1.3 Cobalt Catalyzed C−H Activation 
Transition metal-catalyzed C−H functionalizations are increasingly viable tools for sustainable 
syntheses. Until now, most of metal-catalyzed C−H functionalizations were achieved by second- and 
third-row transition metals catalyst.
[7a, 13a, 16a]
 Thus, the second-row transition metals, such as 
ruthenium, palladium and rhodium, have played a major role in C−H functionalizations.[3, 7b, 8c] 
Despite of the great reactivity, the precious metal complexes are rather expensive and toxic. So the 
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development of catalysts based on earth-abundant first-row transition metals catalysts for C−H 
activation reactions that allow mild reaction conditions are meaningful. 
Among the first-row transition metals, inexpensive cobalt acted as powerful catalyst and has been 
successfully used in C−H interactive alkylations, arylations, hydroarylations, benzylations and 
alkenylations.
[66]
 In 1955, Murahashi and co-workers reported an early example of cobalt used in a 
chelation-assisted C−H functionalization reaction.[67] The reaction of a benzaldimine 80 with carbon 
monoxide in the presence of Co2(CO)8 at extremely high temperature and pressure thus afforded 
phthalmidine 81 (scheme 29a). Later, it was found that under similar reaction conditions, azobenzene 
82a reacted with carbon monoxide at 150 atmospheres of pressure to form indazolone 83 (Scheme 
29b).
[68]
 
 
 
Scheme 29. Cobalt-catalyzed carbonylative cyclization. 
 
 
While reports of cobalt-catalyzed C−H activation were rarely, until in 1994, Kisch and co-workers 
reported an ortho-alkenylation reaction of an azobenzene derivative 82 with alkyne 51b using a 
cobalt(I) catalyst Co(H)(N2)(PPh3)3 to afford the anti-addition product 84 (Scheme 30).
[66c]
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Scheme 30. Cobalt-catalyzed hydroarylation of alkyne 51b with azobenzenes 82. 
 
Around the same time, Klein and co-workers reported an example of well-defined cyclometalation 
reaction using Co(Me)(PMe3)4 and azobenzene 82a through a stoichiometric C–H activation 
(Scheme 31).
[69]
 Based on these findings, their group reported the synthesis of cobaltacycles by C−H 
activation, directed by aromatic and olefinic substrates bearing nitrogen, oxygen, sulfur, and 
phosphorus directing groups. Those findings implied that cobalt have significant potential for 
catalytic C−H functionalization, particularly for directed ortho C−H functionalization of arenes. 
 
 
Scheme 31. Stoichiometric formation of cobaltacycle 85 through C–H activation.  
 
1.3.1 Low-Valent Cobalt Catalyzed C−H Activation 
Since the first cobalt-catalyzed hydroarylation of alkynes using cobalt(I) complex (Scheme 30),
[66c]
 
the development of cobalt-catalyzed hydroarylation of alkynes and olefins gained a significant 
attention during the last few years. Especially through the work of Yoshikai and co-workers, who in 
2011, reported similar addition reactions of arylpyridines 61a to internal alkynes 51c to give 
trisubstituted olefins 86 in the presence of CoBr2 as the catalyst, the phosphine ligand PMePh2 and 
the stoichiometric reductant MeMgCl (Scheme 32a).
[70]
 Furthermore, their group managed to expand 
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the scope of aromatic substrates to include aryl imines 87.
[71]
 Trisubstituted olefins 59 were hence 
obtained at room temperature (Scheme 32b). Potentially sensitive chloro and cyano substituents in 
substrates 87d and 87e were well tolerated. It is worth noting that the substrates bearing m-methoxy, 
m-chloro, m-cyano and m-fluoro substituents 87c-87f reacted preferentially at the more sterically 
hindered C2-positions.  
Scheme 32. Cobalt-catalyzed hydroarylation of alkynes 51.  
 
 
With the successful development of alkyne hydroarylation reactions, the hydroarylation of olefins 
also proved to be viable by low valent cobalt catalysis. Hence, Yoshikai and co-workers explored the 
addition reaction of 2-phenylpyridine (61a) to styrene (32a) under conditions similar to 
hydroarylation of alkynes. A cobalt catalyst generated from CoBr2, PCy3, and Me3SiCH2MgCl 
promoted the reaction to afford the branched adduct 88a with high regioselectivity, while the use of 
  Introduction  
28 
 
an NHC ligand instead of PCy3 caused the reversal of the regioselectivity, leading to the formation of 
the linear adduct 88b (Scheme 33).
[72]
 
 
 
Scheme 33. Cobalt-catalyzed hydroarylation of 2-phenylpyridine 61. 
 
 
A mechanism addressing these findings was proposed (Scheme 34). First, reversible oxidative 
addition of the ortho C−H bond to cobalt takes place, then reversible insertion of styrene 32a into the 
Co−H bond occurs leading to a branched or a linear intermediate 89a or 89b. This is followed by 
reductive elimination to form the 1,1- or 1,2-diarylethane 88a or 88b and regenerate the cobalt 
species. 
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Scheme 34. Proposed catalytic cycles for cobalt-catalyzed hydroarylations of styrenes 32. 
 
 
Based on the above research, a protocol for the synthesis of alkylated arenes by cobalt catalysis was 
viable through hydroarylations of alkenes. Synthesis of alkylated arenes was also successful through 
cobalt-catalyzed C−H alkylations with organic electrophiles, such as alkyl halides.[73] In 2011, a 
cobalt-catalyzed ortho-alkylation using alkyl chlorides 90 as alkyl regent was reported. In this 
catalytic system, the alkylation of benzamides 91 was accomplished with various alkyl chlorides 90, 
notaly without NHC or phosphine ligand (Scheme 35).
[74] 
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Scheme 35. Cobalt-catalyzed direct alkylation of benzamides 18. 
 
 
Later, the Ackermann group reported first C−H arylation reactions with organic electrophiles. The 
catalytic system consisting of Co(acac)2, IMesHCl as a NHC precursor and cyclohexylmagnesium 
chloride allowed for the arylation of arylpyridines 61 with organic electrophiles, such as phenol 
derived aryl carbamates 92a, sulfamates 92b, as well as aryl chlorides 92c. (Scheme 36a).
[75]
 
Furthermore, the Yoshikai group contributed to extend the scope of cobalt-catalyzed C−H arylation 
with organic electrophiles by using ketimines 87 as the directing groups (Scheme 36b).
[76]
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Scheme 36. Cobalt-catalyzed C−H arylation of arylpyridines 61 and ketimines 87.  
 
 
Apart from alkylation and arylation reactions,
[74, 75]
 Ackermann and co-workers showed that low 
valent cobalt catalysis could be applied for the C−H alkenylation of arenes. In 2015, Ackermann and 
co-workers presented the first direct alkenylation of (hetero)arenes 95 with easily accessible enol 
esters 96 (Scheme 37). Under optimal reaction conditions highlighting 10 mol % CoI2, 10 mol % 
preligand IPrHCl, 2.0 equivalent of base in DMPU, a varieties of differently substituted heteroarenes 
95 were successfully alkenylated.
[77]
 Pleasantly, 2-pyridylferrocene 95g was successfully alkenylated 
as well, giving the alkenyl ferrocene 97g. 
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Scheme 37. Cobalt-catalyzed C−H alkenylation of heteroarenes 95. 
 
 
1.3.2 High Valent Cobalt(III)-Catalyzed C−H Activation 
In recent years, C−H activation using Cp*Rh(III)-based catalysts has underwent a remarkable 
development, a variety of C–C, C–N, and C–O bond formation by means of C−H activation have 
been achieved under oxidative conditions.
[8b, 8c]
 Although Cp*Rh
III
-catalyzed processes are useful 
and versatile, their high cost limites futher applications. Hence, it is necessary to search for an 
inexpensive base metal catalyst as an alternative to the cationic rhodium catalysis.
[78, 8b, 8c]
 In 2013, 
Kanai and co-workers found that a cationic high-valent cobalt complex [Cp*Co
III
(arene)](PF6)2 100 
promoted the addition of 2-aryl pyridines 61 to imines 98, enones 101a, and α,β-unsaturated N-acyl 
pyrroles 101b as ester and amide surrogates (Scheme 38).
[79]
 It is worth noting that β-substituted 
α,β-unsaturated esters and amides have not been used successfully in the corresponding direct 
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addition of a C–H bond catalyzed by Cp*RhIII complexes, which indicated the unique reactivity 
profile of cobalt(III)-catalysis. 
 
 
Scheme 38. Cobalt(III)-catalyzed addition reaction of 2-arylpyridines 61 to imines 98 and 
α,β-unsaturated ketones 101. 
 
 
Later, their group developed a C2-selective indole 103 alkenylation/annulation sequence proceeded 
smoothly in the presence of cobalt complex 100 and KOAc, giving pyrroloindolones 104 in 58−89% 
yield. By changing the directing group and reaction conditions selectivity alkenylation product 105 
can be obtained (Scheme 39).
[80]
 In contrast, Cp*Rh(III)-based catalysts did not afford annulation 
products under any of the investigated conditions, and only the alkenylation product was observed 
here. This result highlighted the unique nucleophilic activity of the organocobalt species. 
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Scheme 39. Cobalt(III)-catalyzed chemoselective C–H alkenylation/annulation of indoles 103. 
 
 
Futhermore, the authors proposed a catalytic cycle (Scheme 40). The catalytically active 
monocationic species 106 was formed by a ligand exchange from cobalt comple 100. Subsequently, 
a reversible metalation delivers the cobaltacycle 108 via an acetate-assisted C–H activation 
mechanism. Then by insertion of alkyne 51d into the Co–C bond delivers the seven-membered 
cobaltacycle intermiedate 109. Next, two ways are possible depending on the directing group, the 
annulation product 104 was formed by release of morpholine, or protodemetalation delivers the 
alkenylated indole 105 and regenerates the active monocationic species 106. 
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Scheme 40. Proposed catalytic cycle for cobalt(III)-catalyzed hydroarylation/annulation reaction. 
 
 
Encouraged by the addition reaction of 2-aryl pyridines to amines,
[79]
 the Ellman group reported 
Cp*Co
III
-catalyzed addition of C–H bond to aldehydes 23 to obtain heterocycles. Various indazoles 
112 and furans 114 were synthesized from azobenzene 82 and α,β-unsaturated oxime ethers 113 with 
aldehydes 23 (Scheme 41).
[81]
 
 
  Introduction  
36 
 
 
Scheme 41. Cobalt(III)-catalyzed synthesis of indazoles 112 and furans 114.  
 
 
In addition, the isohypsic synthesis of heterocyles, such as quinolines 116,
[82]
 isoquinolines 117,
[83]
 
indenones 118,
[84]
 indoles 103,
[85, 81b]
 by cobalt(III)-catalyzed C–H functionalizations proved viable 
(Scheme 42). These transformations employed anilides 16, oximes 87b, benzoates 21, nitrones 115, 
as the directing groups, respectively. The synthesis of heterocyles proceeded smoothly in the 
presence of Cp*Co(III) complexes and silver additives in good yields. These reports demonstrated 
that Cp*Co(III) is a prominent catalyst for tandem alkenylation/nucleophilic addition reactions. 
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Scheme 42. Cobalt(III)-catalyzed synthesis of heterocyles.  
 
Cp*Co(III) complexes, as have been shown above, have successfully been used in C–H 
hydroarylation and annulation reactions. Later, the Kanai group found that the air-stable 
[Cp*CoI2(CO)] complex 120, which was first prepared by Li and Jin in 2004,
[86]
 could be applied for 
C2 selective C–H amidation of indoles 95 with sulfonyl azides 119 (Scheme 43).[87] 
 
 
Scheme 43. Cobalt(III)-catalyzed C2 selective amidation of indoles 95. 
 
In 2015, the Ackermann group reported the Cp*Co(III)-catalyzed C–H cyanation of arenes 95 using 
N-cyano-N-phenyl-p-toluenesulfonamid (122) as an easy to handle cyanating reagent (Scheme 44). 
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The C–H cyanation proved to be highly chemo- and regioselective in the presence of 2.5 mol % of 
[Cp*CoI2(CO)], 5 mol % of AgSbF6, and 5 mol % of KOAc (Scheme 44a).
[88]
 Thereafter, the 
Glorius group also developed cobalt-catalyzed cyanation under similar conditions. They also 
achieved cobalt-catalyzed C–H allylation using pivalic acid instead of acetate salt as a key catalyst 
component (Scheme 44b).
[89]
  
 
 
Scheme 44. Cobalt(III)-catalyzed C−H cyanation and allylation. 
 
 
Based on the experimental results, the Ackermann group proposed a catalytic cycle for the 
cobalt(III)-catalyzed C–H cyanation (Scheme 45). The catalytic cycle is intitiated by a reversible C–
H metalation, involving an acetate-assisted deprotonation pathway to form the cyclometalated 
complex 127. Subsequently, coordination and insertion of the cyanation reagent 122 provide the 
intermideate 128 and 129. Then proto-demetalation with the in situ generated acetic acid provides the 
desired product 123 and regenerates the catalytically active cobalt(III) catalyst 126.  
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Scheme 45. Proposed catalytic cycle for cobalt(III)-catalyzed cyanation. 
 
 
Very recently, the Ackermann group developed the cobalt(III)-catalyzed aminocarbonylation of aryl 
pyrazoles 31 (Scheme 46).
[90]
 The aminocarbonylation with isocyanates 130 as the electrophiles 
provide high yield under the reaction conditions consist of 5 mol % of [Cp*Co(CO)I2] 120 as the 
precatalyst, along with 10 mol % of AgSbF6 and 10 mol % AgOPiv as the additives (Scheme 46a). 
As isocyanates are frequently generated in situ from acyl azides by a Curtius rearrangement, the 
aminocarbonylation with acyl azides 119 as the electrophiles also gave high yields with 
[Cp*Co(CO)I2] 120 as the precatalyst (Scheme 46b). 
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Scheme 46. Cobalt-catalyzed C−H aminocarbonylations of aryl pyrazole 31. 
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2 Objectives 
Substituted arylacetamide moieties are found in many biologically active compounds, drugs and 
agrochemicals.
[91]
 Ruthenium-catalyzed ortho-selective functionalizations of substituted benzamides 
via five-membered metallacycles have been reported.
[92, 40]
 In contrast, contributions on 
ortho-selective functionalizations of weakly coordinating arylacetamides via six-membered 
metallacycles continue to be limited.
[93]
 There is no report on ruthenium-catalyzed C−H 
functionalizations of substituted arylacetamides. Within our program on cost-effective C−H 
activation, we herein developed uniquely effective oxidative C−H alkenylations of weakly 
coordinating acetamides 132. 
 
 
Scheme 47. Ruthenium-catalyzed C−H alkenylation of arylacetamides 132. 
 
While arenes bearing weakly coordinating directing groups, such as amides,
[94]
 esters,
[64]
 ketones,
[61b]
 
or aldehydes
[65]
 were efficiently converted into the corresponding phenol derivatives, C−H 
oxygenation of distal weakly coordinating acetamides or esters via unfavorable six-membered 
metallacycles have unfortunately proven thus far elusive. Within our research program on 
ruthenium(II)-catalyzed C−H alkenylation of arylacetamides, we developed a ruthenium-catalyzed 
C−H oxygenation of weakly coordinating acetamides 132 and phenylacetyl esters 134.  
 
 
Scheme 48. Ruthenium(II)-catalyzed C–H oxygenation of acetamides 132 and esters 134. 
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Organosilicon compounds are useful and ubiquitous synthetic reagents in modern organic chemistry. 
Among these arylsiloxanes are of particular interest due to their low toxicity and safe handling.
[95]
 
Although noble transition metals, such as palladium,
[96]
 rhodium,
[97]
 nickel,
[98]
 iridium
[99]
 and 
ruthenium
[100]
 have previously been used in C–H arylation reactions with arylsilanes as the arylating 
reagents, cobalt(II)-catalyzed C–H arylation reactions of arylsiloxanes have not been explored yet. 
Therefore, we report herein a new cobalt-based catalytic system for the direct C−H arylation of 
various benzamides 9 using organosilanes 136. 
 
 
Scheme 49. Cobalt-catalyzed C–H arylation of benzamides 9 with organosilanes 136. 
 
In the past few years, high-valent Cp*Co
III
-derivatives have been identified as increasingly viable 
tools for the site-selective functionalization of unactivated C–H bonds, yet almost exclusively 
leading to hydroarylations,
[79, 101]
 allylations
[77, 89]
 or alkynylations.
[102]
 In spite of undisputed 
advances, cobalt(III)-catalyzed C–H/C–C activations remain highly challenging. In this regard, we 
developed a cobalt-catalyzed C–H/C–C activation of heteroarenes with vinylcyclopropanes 138, for 
which we performed detailed mechanistic studies also. 
 
 
Scheme 50. Cobalt(III)-catalyzed C–H/C–C functionalization. 
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3 Results and Discussion 
3.1 Distal Weak Coordination of Acetamides in Ruthenium(II)-Catalyzed C–H Activation  
Substituted acetamides are key structural motifs in a plethora of bioactive compounds, drugs, and 
crop protection agents (Figure 3).
[91c, 103]
 C–H activation reactions of distal weakly coordinating 
acetamides via unfavorable six-membered metallacycles continue to be scarce.
[91a, 104]
 For less 
expensive ruthenium catalysis,
[7c, 105]
 C–H functionalizations of challenging arylacetamides have thus 
far remained elusive. Thus, we wanted to explore an efficient C–H activation of challenging 
arylacetamides by ruthenium(II) catalysis.  
 
 
Figure 3. Selected bioactive compounds featuring arylacetamides. 
 
 
3.1.1 Optimization Studies 
Based on the optimized reaction conditions for the ruthenium-catalyzed C–H alkenylation of 
secondary arylacetamide 132i developed by my colleague Dr. Vladislav Kotek, various reaction 
parameters for the envisioned oxidative C–H olefination of challenging primary arylacetamide 132a 
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were explored (Table 1). The results showed that the reaction was most efficient with AgSbF6 as the 
additive and Cu(OAc)2·H2O as the oxidant at 110 C for 24 h, giving the desired product 133aa in 64% 
yield (entry 13). A significant solvent effect was also observed and the best yields were obtained in 
1,4-dioxane (entries 1–7). Other oxidants, such as Ag2CO3, V2O5 or MnO2, were not effective and 
only gave the product 133aa in low yields (entries 10-12). We found that the same yield was 
obtained using Cu(OAc)2·H2O instead of Cu(OAc)2 (entries 2, 13). The use of AgBF4 or AgSO3CF3 
instead of AgSbF6 resulted in decreased yields (entries 13-15). The crucial importance of the additive 
and ruthenium catalyst was verified through control experiment (entries 8 and 18). 
 
Table 1. Development of oxidative C–H alkenylation of acetamide 132a.a 
 
 
Entry Solvent Additive Oxidant Yield (%)
b
 
1 THF AgSbF6 Cu(OAc)2 48% 
2 1,4-dioxane AgSbF6 Cu(OAc)2 64% 
3 toluene AgSbF6 Cu(OAc)2 <5% 
4 H2O AgSbF6 Cu(OAc)2 -- 
5 
6 
7 
8 
9 
10 
11 
MeOH 
o-xylene 
DCE 
1,4-dioxane 
1,4-dioxane 
1,4-dioxane 
1,4-dioxane 
AgSbF6 
AgSbF6 
AgSbF6 
-- 
AgSbF6 
AgSbF6 
AgSbF6 
Cu(OAc)2 
Cu(OAc)2 
Cu(OAc)2 
Cu(OAc)2 
Cu(OTf)2 
Ag2CO3 
V2O5 
<5% 
<5% 
48% 
-- 
-- 
         -- 
-- 
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12 1,4-dioxane AgSbF6 MnO2 -- 
Entry Solvent Additive Oxidant Yield (%)
b
 
13 
14 
15 
16
 
17 
1,4-dioxane 
1,4-dioxane 
1,4-dioxane 
1,4-dioxane 
1,4-dioxane 
AgSbF6 
AgBF4 
AgSO3CF3 
AgSbF6 
AgSbF6 
Cu(OAc)2·H2O 
Cu(OAc)2 
Cu(OAc)2 
Cu(OAc)2 
Cu(OAc)2 
64% 
53% 
40% 
42%
c
 
53%
d
 
18 1,4-dioxane AgSbF6 Cu(OAc)2 --
e
 
a
 Reaction conditions: 132a (0.50) mmol, 5a (1.00 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), additive 
(20 mol %), oxidant (1.10 mmol), 110 C, solvent (2.0 mL), reaction time 24 h. b Yields of isolated 
products. 
c
 80 C. d 120 °C. e Without [RuCl2(p-cymene)]2. 
3.1.2 Scope of Ruthenium(II)-Catalyzed C–H Alkenylation 
3.1.2.1 Scope of Primary Amides  
With the optimized catalytic system in hand, we explored the scope of primary amides-assisted C–H 
alkenylations with diversely decorated substrates 132 (Scheme 51). Pleasingly, a range of 
substituents at the meta- or para- positions (132b-132f) were tolerated to provide various alkenylated 
phenylacetamides 133ba-133fa in high yields. Amides containing a napthyl moiety were also 
effective, providing the desired product 133. Ortho-substitution 132g slowed the reaction somewhat, 
but acceptable yields could be obtained nonetheless (Scheme 51). Different alkenes, such as methyl 
acrylate 5c, naphthalen-2-yl acrylate 5f, vinylsulfonylbenzene 5g, performed very well as the alkene 
reaction partners. Finally, an ortho-alkenylated arylacetamide 133ah containing sensitive cholesteryl 
moiety was synthesized in moderate yield as well. 
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Scheme 51. Scope of primary amides group for the ruthenium(II)-catalyzed C–H alkenylation.  
 
3.1.2.2 Scope of Secondary and Tertiary amides  
With the optimized reaction condition of C–H alkenylation of secondary amide in hand, and together 
with Dr. Vladislav Kotek, we explored the scope of the olefination with respect to the amide group, 
which was expected to have a significant effect on the reaction outcome (Scheme 52). For different 
substitution on the arene, both electron-donating and electron-withdrawing substituents were 
tolerated. Olefination of bromo-substituted amide 132t was carried out on a gram scale and the 
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resulting product 133tc could be easily isolated in very good yields by simple aqueous work-up and 
recrystallization. Ortho-substitution was also acceptabled and delivered the alkenylated product 
133yc in acceptable yield. Naphthalene derived substrate 132x was also viable. The robustness of the 
ruthenium(II) catalysis was highlighted by racemization-free reaction conditions (133na). 
 
 
Scheme 52. Scope of secondary and tertiary amides group for the ruthenium(II)-catalyzed C–H 
alkenylation. 
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However, some substrates also turned out to be less compatible with the catalytic conditions (Scheme 
53). Thus, challenging directing groups, like 2-phenylacetic acid 134e and ethyl 2-phenylacetate 
134d, were unsuccessful under the developed reaction conditions. 
 
 
Scheme 53. Limitations of the ruthenium(II)-catalyzed C–H alkenylation with different directing 
groups. 
 
 
3.1.3 Weak O-Coordination for C–H Activation/Alkyne Hydroarylation 
Intrigued by the versatility of the ruthenium(II)-carboxylate catalysis, we became attracted to C–H 
alkenylations through redox-neutral alkyne hydroarylations. By replacing Cu(OAc)2·H2O with 
1-AdCO2H, the hydroarylation of alkynes 51 could be facilitated (Scheme 54). The 
ruthenium(II)-catalyzed C–H hydroarylations of acetamides 132 provided a excellent 
stereoselectivity in accessing trisubstituted alkenes 133', again with both secondary and challenging 
primary amides 132, respectively. 
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Scheme 54. Ruthenium(II)-catalyzed hydroarylation of alkynes 51.  
 
3.1.4 Mechanistic Studies 
3.1.4.1 Intermolecular Competition Experiments 
To gain insights into the reaction mechanism, a set of competition experiments was performed. 
Intermolecular competition experiment between 2-phenylacetamide 132a and 
2,2-dimethyl-1-phenylpropan-1-one 58a revealed that although both substrates contain weakly 
coordinating directing groups, primary amides 132 were found to be even more difficult substrates 
than ketones 58 in ruthenium-catalyzed C–H functionalizations (Scheme 55).  
 
 
Scheme 55. Intermolecular competition experiment between acetamide 132a and ketone 58a. 
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We also performed an intermolecular competition experiment between benzamide 132a and 
2-phenylacetamide 9a (Scheme 56). It turned out that almost exclusive functionalization of 
benzamide 142 was observed. Therefore, it could be concluded that formation of the five-membered 
ruthenacycle is preferred over formation of the six-membered metallacycle. 
 
 
Scheme 56. Competition experiment between benzamide 132a and 2-phenylacetamide 9a. 
 
Additionally, a competition experiment between primary and secondary amides showed that the 
secondary amide 132i is more reactive and revealed that alkyl-subsititution on the amide nitrogen 
increases the reactivity (Scheme 57). 
 
 
Scheme 57. Competition experiment between primary amide 132a and secondary amide 132i. 
 
A competition experiment between electron-rich substrate 132i and electron-deficient substrate 132d 
revealed a preferred functionalization of 132i (Scheme 58), which is not in agreement with a 
concerted metalation/deprotonation (CMD) mechanism. Instead, the observations are better 
rationalized by a base-assisted internal electrophilic-type substitution (BIES) process. 
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Scheme 58. Competition experiment between electron-rich and electron-deficient amides 132. 
 
 
3.1.4.2 C–H Alkenylation in the Presence of Isotopically Labelled Cosolvent 
To rationalize the C–H activation mechanism, the catalytic reaction was carried out in the presence 
of deuterated cosolvent CD3OD under otherwise identical reaction conditions. A significant H/D 
exchange occurring in the ortho-position of the product [D]n-133qc and reisolated starting material 
[D]n-132q was observed (Scheme 59). The result suggests that the C–H metalation is reversible. 
 
 
Scheme 59. H/D-exchange study of ruthenium-catalyzed C–H alkenylation. 
 
 
3.1.4.3 Kinetic Isotope Effect 
Kinetic isotope effect (KIE) studies using in situ IR spectroscopy to determine the independent 
reaction rates of undeuterated substrate 132i and deuterated substrate [D]5-132i, resulted in a minor 
value of kH/kD≈1.0 (Scheme 60). The observed KIE is in good agreement with the results obtained 
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from the H/D-exchange experiments, suggesting the reaction to proceed via a reversible 
cycloruthenation process. 
 
 
Scheme 60. KIE experiment for the ruthenium-catalyzed C–H alkenylation. 
 
 
3.1.5 Proposed Catalytic Cycle 
Based on our experimental studies, a plausible catalytic cycle was proposed (Scheme 61). The active 
catalytic species is formed by reaction of the ruthenium(II) precursor with silver 
hexafluoroantimonate. The key six-membered ruthenacycle 144 is then formed by a 
carboxylate-assisted base-assisted internal electrophilic substitution (BIES) event. Additionally, 
extensive computational studies by DFT calculations were performed by T. Rogge. Comparison 
between the corresponding five-membered analogue 144' with the six-membered ruthenacycle 144, 
found that 144 is destabilized by 6.9 kcal mol
-1
, while the deprotonative transition state is 2.8 kcal 
mol
-1
 higher in energy. Therefore, these results show again that the C–H activation of arylacetamides 
is more challenging. Accordingly, a coordination of acrylate 5a leads to intermediate 145, in which a 
migratory insertion of the coordinated acrylate 5a into the carbon-ruthenium bond delivers 
eight-membered ruthenacycle 146. Finally, ruthenacycle 146 undergoes -hydride elimination to 
form alkene-coordinated complex 143. 
 Results and Discusstion 
53 
 
 
 
Scheme 61. Plausible catalytic cycle for ruthenium-catalyzed C–H alkenylation. 
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3.2 Ruthenium(II)-Catalyzed C−H Oxygenation of Weakly-Coordinating  
The catalytic direct oxygenation of arene C(sp
2
)–H bonds represents the most step-economical 
approach to substituted phenols.
[106]
 Although significant advances have been accomplished, many 
challenges remain. To date, most research have been focused on metals such as palladium
[107]
 and 
copper.
[108]
 In contrast, ruthenium was rarely reported in C–H oxygenation reaction. Such kind of 
transformation was accomplished with versatile ruthenium(II) catalysts.
[7c, 18c]
 Arenes bearing weakly 
coordinating directing groups, such as amides,
[94]
 esters,
[64]
 ketones,
[61b]
 or aldehydes,
[65]
 were 
efficiently converted into the corresponding phenol derivatives via five-membered metallacycles. 
While C–H oxygenation with distal weakly coordinating acetamides via unfavorable six-membered 
metallacycles have unfortunately thus far prove elusive.
[93a, 104b]
 Based on the former results of 
ruthenium(II)-catalyzed C–H activations of weakly O-coordinating arylacetamides performed by our 
group,
[109]
 we herein present the unique C–H oxygenation of weakly coordinating acetamides. 
 
3.2.1 Optimization Studies for Ruthenium(II)-Catalyzed C−H Oxygenation 
We commenced our studies by probing various oxidants and solvents for the envisioned oxygenation 
of N-(tert-butyl)-2-phenylacetamide 132i (Table 2). At the outset, experiments identified hypervalent 
iodine(III) reagents as the oxidants of choice, the transformation failed to proceed in 1,4-dioxane in 
the presence of a ruthenium complex and an oxidant (entry 1). DCE was found to be the solvent of 
choice, whereas PhCl, toluene, DMF, m-xylene or CH3CN gave inferior results (entries 2-6). 
TFA/TFAA, which acted as a good choice in a previous report of ruthenium-catalyzed C–H 
oxygenations, turned out to be unsuitable for this reaction (entry 7). 30% of benzofuran-2(3H)-one 
byproduct was observed when using solvent mixure of DCE/TFA (entry 8). Among a set of oxidants, 
such as PhI(TFA)2, K2S2O8, (NH4)2S2O4, Cu(OAc)2 and PhI(OAc)2, PhI(TFA)2 gave the best results 
(entries 9-13). We also tried to increase or decrease the reaction temperature, but superior results 
were obtained at a reaction temperature of 110 C (entries 9, 14-16). There was no conversion of the 
starting material 132i in absence of the RuCl2(p-cymene)]2 catalyst (entry 17). At last, we found that 
5.0 mol % of [RuCl2(p-cymene)]2 was best effective to promote the desired reaction (entry 18). 
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Table 2. Development of oxidative C–H oxygenation of acetamide 132i.a 
 
Entry Oxidant Solvent T (C) Yield 
1 PhI(TFA)2 1,4-dioxane 110 NR 
2 PhI(TFA)2 PhCl 110 10% 
3 PhI(TFA)2 toluene 110 16% 
4 PhI(TFA)2 DMF 110 NR 
5 PhI(TFA)2 m-xylene 110 15% 
6 PhI(TFA)2 CH3CN 110 ND 
7 
8 
PhI(TFA)2 
PhI(TFA)2 
TFA/TFAA (3:1) 
DCE/TFA (4:1) 
110 
110 
ND 
30%
b
 
9 PhI(TFA)2 DCE 110 54% 
10 K2S2O8 DCE 100 NR 
11 (NH4)2S2O4 DCE 100 NR 
12 Cu(OAc)2 DCE 100 NR 
13 PhI(OAc)2 DCE 100 25% 
14 PhI(TFA)2 DCE 120 51% 
15 PhI(TFA)2 DCE 80 35% 
16 PhI(TFA)2 DCE rt NR 
17 PhI(TFA)2 DCE 110 NR
c
 
18 PhI(TFA)2 DCE 100 62%
d
 
a
 Reaction conditions: 132i (0.50) mmol, oxidant (1.00 mmol), [RuCl2(p-cymene)]2 (2.5 mol %), 
solvent (2.0 mL), reaction time 16 h. 
b
 Yields of isolated products. 
c
 without [RuCl2(p-cymene)]2. 
d
 5 
mol % of [RuCl2(p-cymene)]2. 
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3.2.2 Scope of Acetamides in Ruthenium(II)-Catalyzed C−H Oxygenation  
Having optimized the reaction condition, we next set out to explore the scope of the C–H 
oxygenation reaction. As displayed in Scheme 62, a variety of phenylacetamides 132 were smoothly 
transformed into the corresponding monohydroxylated products 135 in good yields. The reaction 
yields roughly correlated with the basicity of the amines incorporated in the amide moiety, and good 
yields were obtained with secondary amides. The ortho-, meta-, and para-substituted aryl group, as 
well as electron-withdrawing and electron-donating functional group such as halides and nitro were 
tolerated. Especially the substrates with eletro-withdrawing group gave the higher yields, such as 
fluoro and nitro (132p and 132w). meta-bromo-substituted substarte 132t gave the corresponding 
compound 135ta as the sole product with good regioselectivity. The sterically hindered ortho-bromo 
substituted acetamide 132'a was converted to the desired product 135'aa in moderate yield. Next, we 
continued to test the feasibility of employing phenylacetyl esters as directing groups in this C–H 
transformation. We were pleased to find that less reactive phenylacetyl esters were also suitable for 
this challenging transformation.  
 
Scheme 62. Scope of the ruthenium(II)-catalyzed C–H oxygenation. 
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3.3 Low-Valent Cobalt-Catalyzed C−H Arylation  
Biaryl motifs are an important class of building blocks in medicinal chemistry and biochemistry, 
leading to a great interest in the development of novel and efficient methods to asseable biaryl 
compounds.
[110]
 Among the available methods, the formation of C–C bonds between two substrates 
by transition metal-catalyzed functionalization of C–H bonds presents the advantages of less 
synthetic steps and an overall high atom economy.
[111]
 Hiyama cross-couplings have proven to be 
among the most powerful and reliable ways for C–C bond formation reactions in organic synthesis. 
Meanwhile, direct arylation of aromatic C–H bonds has received much attention as a potentially 
more efficient and complementary approach to the conventional cross-coupling methodology.
[13b, 112]
 
In 2007, the direct arylation of acetanilide with organosilanes was reported.
[113]
 Subsequently, 
significant progress has been achieved using organosilanes as coupling partners in the 
transition-metal-catalyzed C–H arylations, with pioneering work demonstrating the utility of direct 
Hiyama C–H arylation based on palladium,[96a, 114] nickel,[98] rhodium,[97, 115] iridium[99] and 
ruthenium
[100]
 catalysis. However, the use of organosilanes as viable cross-coupling partners in 
cobalt-catalyzed C–H functionalization remains unknown. Herein, we report the first 
cobalt-catalyzed the direct C–H arylation of benzamides with organosilanes, which notably avoids 
the use of stoichiometric amounts of Grignard reagents.
[66b, 76, 116]
 
 
3.3.1 Optimization Studies 
We began our studies by the treatment of benzamide derivative 9a and trimethoxyphenylsilane 136a 
with 20 mol % of Co(OAc)2, 3.0 equivalents of CsF and 2.0 equivalents of CuF2 in DMSO at 120 
o
C 
(Table 3, entry 1). The desired arylation product 137aa was formed in 20% yield. Encouraged by this 
promising result, a variety of solvents were probed (entries 2-9), and NMP was found to be the 
reaction medium of choice with a yield of 65% (entry 8). It is worth noting that a moderate yield was 
obtained when the reaction was performed in green biomass-derived -valerolactone (GVL) (entry 7), 
showing the potential of the use of such green solvents in arylation reactions. Next, we investigated 
the effect of several oxidants in this reaction. The desired product 137aa was obtained in 36% yield 
in the presence of Cu(OAc)2 (entry 13), while no product was observed when replacing on CuF2 by 
other oxidants, such as air, Mn(OAc)2 or AgOPiv (entries 14-16). Decreasing the amount of CuF2 to 
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1.0 equivalent or less gave inferior results (entries 11-12). To our delight, the desired product 137aa 
could be isolated in 72% yield, when decreasing the reaction temperature to 100 C.  
Table 3. Optimization of the cobalt-catalyzed C–H arylation of benzamide 9a.a  
 
Entry Solvent Oxidant (equiv) Isolated yield 
1 DMSO CuF2 (2.0) 20% 
2 DCE CuF2 (2.0) 18% 
3 DMF CuF2 (2.0) 53% 
4 Toluene CuF2 (2.0) – 
5 THF/H2O CuF2 (2.0) – 
6 DMA CuF2 (2.0) – 
7 GVL CuF2 (2.0) 50% 
8 NMP CuF2 (2.0) 65% 
9 pyridine CuF2 (2.0) – 
10 NMP CuF2 (2.0) 10%
b
 
11 NMP CuF2(1.0) 36% 
12 NMP CuF2(0.5) 17% 
13 NMP Cu(OAc)2 (2.0) 36% 
14 NMP air – 
15 NMP Mn(OAc)2 (2.0) – 
16 NMP AgOPiv (2.0) Trace 
17 NMP CuF2 (2.0) 72%
c
 
18 NMP CuF2 (2.0) 71%
d
 
a 
Reaction conditions: 9a (0.25 mmol), 136a (0.5 mmol), Co(OAc)2 (20 mol %), CsF (3.0 equiv), 
oxidant (2.0 equiv), solvent (1.0 mL), under N2. 
b 
without Co(OAc)2. 
c 
100 C. d CsF (1.5 equiv).  
We next examined the effect of the directing groups (Scheme 63). No phenylation took place when 
N-methyl benzamide 9b' was used instead of substrate 9a. Furthermore, the use of N-methyl amide 
9c' also failed to deliver the phenylation product, indicating that the presence of an NH-motif on the 
amide nitrogen is required for the reaction to proceed. The reaction appears to be more successful for 
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the 8-aminoquinoline motif. Directing groups, such as found in compounds 9d', 9e' and 9f' which 
have been extensively used in the transition-metal-catalyzed functionalization of C−H bonds,[117] 
were also ineffective. Therefore, the presence of an NH bond as well as the strougly-coordinatiy 
quinoline nitrogen is neccessary for the success of the reaction. 
 
 
 
Scheme 63. Effect of N-substituents on cobalt-catlyzed C–H arylation. 
 
3.3.2 Scope of Cobalt-Catalyzed C–H Arylation 
3.3.2.1 Scope of benzamides 
With the optimized reaction conditions in hand, we explored the scope of the cobalt(II)-catalyzed C–
H arylation of arenes 9. As shown in Scheme 64, various benzamide substrates 9 were successfully 
applied to the C–H arylation. Both electron-donating and electron-deficient substituents were 
tolerated, giving the biaryl products 137 in moderate to high yields. A broad range of functional 
groups, such as fluoro were compatible with the C–H activation. Naphthamide and 
dimethyl-substituted benzamide 9h and 9i were also viable substrates, giving 137ha and 137ia in 60% 
and 68% yield, respectively. 
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Scheme 64. Scope of cobalt-catalyzed C–H arylation of amides 9. 
 
 
3.3.2.2 Scope of Arylsilanes 
The scope of various organosilanes under the standard reaction conditions was then investigated 
(Scheme 65). Under the optimized reaction conditions, triethoxyarylsilane gave a lower yield, while 
trimethylarylsilane was not a viable arylating regent at all. Next, a range of trimthoxyarylsilanes 136 
were tested. It is worth noting that triethoxyarylsilanes bearing a methyl group or dimethyl group at 
the ortho- or diortho- position gave the desired arylated products 137ae and 137ab in 80% and 62% 
yields respectively, showing that the reaction is not sensitive to steric hindrance. It should be noted 
that ortho- substituted trimthoxyarylsilanes 136b gave a higher yield with a lower amount of CsF 
(137ab). Furthermore, naphthyl organosilane 136j could also participate in the C–H arylation, 
affording the desired product 137aj in 80% yield.  
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Scheme 65. Scope of cobalt-catalyzed C–H arylation of amides 9 with organosilanes 136. 
 
 
3.3.2.3 Scope of the Cobalt(II)-Catalyzed C–H Arylation of benzamides in GVL 
During the optimization of the reaction conditions, the reaction was found to proceed with a 
moderate yield when using the biomass-derived solvent GVL. We subsequently became interested to 
explore the scope of the C–H arylation reaction in thid green medium (Scheme 66). Surprisingly, 
under this reaction conditions, a minor decrease in reactivity was observed, with yields being around 
10%-20% less than under the optimized reaction conditions, except for naphthyl benzamide 9h.  
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Scheme 66. Scope of cobalt-catalyzed C–H arylation of amides 9 in biomass-derived GVL. 
 
 
3.3.3 Mechanistic Studies ─ H/D-Exchange Experiment 
In order to gain insights into the reaction mechanism, a catalytic reaction in the presence of 
deuterated cosolvent D2O was carried out under otherwise identical reaction conditions (Scheme 67). 
The results indicated a significant H/D scrambling in the reisolated starting material [D]n-9d as well 
as in the product [D]n-137da. This observation is indicative of a facile C–H activation by the cobalt 
catalyst. 
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Scheme 67. H/D-exchange study of cobalt-catalyzed C–H arylation. 
 
 
3.3.4 Proposed Catalytic Cycle 
Based on the above results, we propose a catalytic cycle to initiate by the formation of the cobalt(III) 
species 147 by oxidation (Scheme 68). Thereafter, a C–H activation step occurs to give the cobalt 
complex 148. A fluoride-promoted transmetalation
[118]
 then afforded the cobalt(III)−aryl 
intermediate 149. Subsequent reductive elimination provide the arylated product 137ba together with 
the formation of a cobalt(I) species 150, which is reoxidized to cobalt(III) species by the action of 
CuF2 to complete the catalytic cycle.  
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Scheme 68. Plausible catalytic cycle for the cobalt-catalyzed C–H arylation. 
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3.4 Cobalt(III)-Catalyzed C−H/C−C Functionalization  
In recent years, the use of naturally abundant 3d transition metal catalysts for C−H functionalizations 
has been identified as an increasingly powerful tool for molecular syntheses.
[11a, 12a, 119]
 Particularly, 
inexpensive cobalt catalysts bear high potential due to the efficient transformations catalyzed by its 
congeners rhodium and iridium. In early examples, low-valent cobalt catalyzed C−H 
functionalizations generally required a Grignard reagents as the additives.
[12b]
 More recently, the 
importance of high-valent Co(III)-catalyzed chelate-assisted C−H bond functionalizations has been 
demonstrated by Ackermann,
[102c, 120]
 Glorius,
[82b, 89]
 Ellman,
[121]
 and Chang
[122]
 following early work 
by Matsunaga and Kanai.
[83a, 123]
 High-valent [Cp*Co
III
] complexes have been applied for the 
site-selective functionalization of unactivated C−H bonds.[85, 124]  
Within our research program on [Cp*Co
III
]-catalyzed C−H functionalizations,[12a, 83b] we decided to 
explore the distinct selectivity features of cobalt(III) catalysis. Therefore, we selected the reaction of 
indoles with vinylcyclopropanes as a model system to realize C−H/C−C functionalizations with high 
selectivity control. 
 
3.4.1 Optimization Studies 
Optimization studies on the cobalt(III)-catalyzed C−H/C−C activation are summarized in Table 4. 
Solvent optimization revealed that DCE was the most efficient reaction medium. When the reaction 
was conducted in DCE using [Cp*Co(CO)I2] as the catalyst and PivOH as the additive at 50 
o
C, the 
desired product 151aa was isolated in 87% yield (entry 1). Keeping PivOH as the additive, switching 
the solvent to MeOH or TFE, the yield of product 151aa significantly decreased. An even lower 
conversion of the starting material 95a was observed using H2O as the solvent (entry 3). Moreover, 
the additive had a significant impact on the reaction efficiency. Only trace of product 151aa was 
detected when Mg(OPiv)2 was used. The yield was improved when 10 mol % of [Cp*Co(CO)I2] and 
NaOPiv was employed. This reaction was performed by Dr. Daniel Zell during his study on the 
effect of various acetate and pivalate bases, which resulted in finding that sodium pivalate was the 
optimal base. Furthermore, different cobalt(III) sources were tested, the results indicated that silver 
additives are not necessary for the reaction (entry 8) and other ligands are inferior to 
cyclopentadienyl group (entries 9 and 10).  
Notably, all tested reaction conditions exclusively furnished the thermodynamically less favored Z 
diastereomer in very good selectivities. When treating the substrates with the related [Rh
III
Cp*] 
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catalyst, a mixure of the E/Z diastereomers was obtained with a minor bias for the E diastereomer 
(entry 11).  
 
Table 4. Optimization study for the Co(III)-catalyzed C–H/C–C functionalization.a 
 
Entry Solvent  Additive Yield [%]  
1  DCE  PivOH  87  
2 TFE PivOH 45 
3 H2O  PivOH 30 
4 CH3OH  PivOH 76 
5  DCE  Mg(OPiv)2  70
b
  
6  DCE  (tBuCO)2O  61  
7  DCE  NaOPiv  93
c
  
8 DCE  NaOPiv  77
d
  
9 DCE  NaOPiv  18
e
  
10 DCE  NaOPiv  10
f
  
11 DCE NaOPiv 77
g
 
a 
Reaction conditions: 95a (0.50 mmol), 138a (0.60 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 
(20 mol %), additive (20 mol %), solvent (1.0 mL), 50 C, 20 h, isolated yield. py = pyridyl, all E/Z 
= 1:11. 
b 
Mg(OPiv)2 (10 mol %). 
c
 performed by Dr. Daniel Zell.
 d 
[CoCp*(CH3CN)3](SbF6)2.. 
e 
[Co(CO)Cp
1,3-tBu
I2]. 
f 
[Co(CO)CpI2]. 
g 
[Cp*Rh(CH3CN)3](SbF6)2 (10 mol %), E/Z = 2:1. 
 
3.4.2 Scope of the Cobalt(III)-Catalyzed C–H/C–C Functionalization 
With the optimized reaction conditions in hand, the scope of viable indoles 95 and cyclopropanes 
133 was examined (Scheme 69). First, substituents in the C5-position of indole 95b were tested, 
good yields and diastereoselectivities were achieved. Moreover, the utility of this method was further 
demonstrated by the 5 mmol-scale reaction, which provided the corresponding product 151aa in 90% 
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yield. A sterically demanding substituent in C3-position was tested, furnishing the desired product 
151ca in good yield and excellent E/Z selectivity of 1:25. The observed selectivity is totally different 
from the one obtained in the rhodium-catalyzed C−H/C−C bond activation.[125] A reasonable 
explanation for this unexpected finding could be the involvement of stabilizing London dispersion 
interactions,
[126]
 partly exhibited by the pyridyl-ring, which was highlighted by the DFT-calculations 
performed by Dr. Feldt.
[127]
  
Second, various vinylcyclopropane substrates 138 were tested. Vinylcyclopropanes could easily be 
obtained from the corresponding activated methylene compounds and (E)-1,4-dibromobut-2-ene.
[128]
 
Electron-withdrawing groups such as methyl ester and ethyl ester were successfully employed in this 
reaction, giving the corresponding products in good to excellent yields and good E/Z selectivity 
ranging from 1:11 to 1:25. In contrast, the use of dicyano vinylcyclopropane 138c provided the 
desired product in moderate yields and rather moderate E/Z selectivity.  
 
 
Scheme 69. Scope of the cobalt(III)-catalyzed C–H/C–C functionalization of indoles 95 and 
vinylcyclopropanes 138. 
 
 Results and Discusstion 
68 
 
3.4.2.1 Comparison between Cobalt(III) and Rhodium-catalyzed C–H/C–C Functionalization  
Next, under otherwise identical reaction conditions, we also probed the reactivity and selectivity of 
the related rhodium(III) catalyst (Scheme 70). While the less stable Z diastereomer was formed with 
high selectivity in all cases under cobalt catalysis, rhodium(III) complexes delivered 
difficult-to-separate mixtures of the E/Z diastereomers, with a minor bias for the E diastereomer. 
These findings emphasize the unique diastereo-selectivities of the cobalt(III)-catalyzed C–H/C–C 
activation. 
 
 
Scheme 70. Cobalt/Rhodium-catalyzed C–H/C–C functionalization. 
 
3.4.2.2 Scope of Arenes  
The cobalt catalyst was not restricted to the functionalization of 1-pyridylindoles. Indeed, the 
heteroarene-assisted diversification of arenes 152 proved broadly applicable and proceeded with high 
Z-diastereoselectivity (Scheme 71). Phenylpyridines were successfully converted to the desired 
products 153 with comparable efficiency under cobalt catalysis. It is worth to note that the cobalt 
catalyst was characterized by excellent chemoselectivity in that the monofunctionalized arene 
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products 153ba was formed as the sole products. In contrast, the rhodium catalyst gave difficult to 
separate mixtures of mono- and di-substituted arenes 153ba' and 153ba'' with low selectivity.  
In the cobalt catalysis reaction, both electron-rich and electron-deficient 2-phenylpyridines provided 
the desired products 153 in good yield and high Z-diastereoselectivity, while under the same reaction 
conditions, the rhodium catalyst gave lower yields and poor E-diastereoselectivity. These findings 
show the unique diastereo- and site-selectivities of the cobalt(III)-catalyzed C–H/C–C activation. 
Additionaly, the reaction was found to be compatible with 1-phenyl-1H-pyrazole substrates 
152c-152e, giving the desired products 153ca-153ea in higher yields and excellent 
diastereoselectivities compared with the rhodium catalyst. To our delight, 
1-(pyridin-2-yl)-1H-pyrrole-2-carbaldehyde 152g was successfully employed in this reaction, giving 
the corresponding product 153ga. 
 
Scheme 71. Cobalt-catalyzed arene C–H/C–C functionalization. 
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Furthermore, some limititations in the substrate scope were observed (Scheme 72). 
2-(Furan-2-yl)pyridine 152h, 5-(pyridin-2-yl)thiazole 152i as well as 
1-(pyridin-2-yl)-1H-benzo[d]imidazole 152j unfortunately delivered no or only traces of the desired 
products under the optimal reaction conditions. 
 
 
Scheme 72. Limitations of the cobalt(III)-catalyzed C–H/C–C functionalization. 
 
3.4.3 Isomerization Experiments  
Next, we performed several experiments to determine whether a post C–C-cleavage alkene 
isomerization process takes place during the catalytic reaction (Scheme 73). First, we submitted the 
product 151aa isolated from the cobalt(III)-catalyzed transformation to the rhodium(III) catalysis 
procedure, and did not observe any post-catalytic isomerization of the double bond (Scheme 73a). 
Likewise, the product of the rhodium catalyzed C–H allylation did not undergo isomerization in the 
presence of the cobalt(III) catalyst (Scheme 73b). An E/Z ratio change was observed when the 
product from cobalt(III) catalysis was exposed to UV light in the presence of 5 mol % of I2 in 
CH2Cl2 (Scheme 73c). All the results suggested that no catalytic isomerization of the double bond 
occured when the E-configurated product is subjected to the optimal reaction conditions, hence 
excluding a post C–C cleavage isomerisation process. 
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Scheme 73. Isomerization experiments. 
 
3.4.4 Proposed Catalytic Cycle 
Based on our mechanistic studies, we propose the cobalt(III)-catalyzed C–H/C–C functionalization 
to commence by a reversible C–H activation, which is assisted by the pivalate additive and 
presumably proceeds via a base-assisted internal electrophilic-type substitution (BIES)-type 
mechanistic pathway
[129, 120a]
 to furnish the cobaltacycle 155. Starting from the next step, 
computational studies by DFT calculations was performed by Dr. M. Feldt.
[127]
 The coordination of 
vinylcyclopropane 138a then delivers intermediate 156, in which migratory insertion of the double 
bond of the coordinated vinylcyclopropane 138a into the Co–C bond occurs. Thereafter, an ester 
group coordinates to the metal center, thereby leading to intermediate 157. Then, the rate- and 
diastereoselectivity-determining C–C cleavage of vinylcyclopropane take place to form the 
Z-configurated intermediate 158 (Scheme 74). 
Comparing the energetic span
[130]
 for the vinylcyclopropane C–C cleavage step, the Z diastereomer is 
clearly preferred under cobalt(III) catalysis, with an activation barrier of 13.1 kcalmol
-1
 compared to 
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19.6 kcalmol
-1
 for the E diastereomer. In contrast, with the rhodium(III) catalyst, the E diastereomer 
is preferred with an energetic span of 20.9 kcalmol
-1
 compared to 23.2 kcalmol
-1
 for the Z 
diastereomer. This observation is likely due to the significantly shorter Co–C bonds translating into 
more compact organometallic species. Finally, the desired product 151aa is released by a 
protodemetalation step, which also regenerates the active catalyst 154.  
 
 
 
 
Scheme 74. Proposed catalytic cycle for the cobalt(III)-catalyzed C–H/C–C activation.  
[Co] = Cp*Co
II
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4 Summary and Outlook 
In the first project, an efficient C–H alkenylation of challenging arylacetamides by ruthenium(II) 
catalysis through challenging six-membered ruthenacycles was developed (Scheme 75). Under the 
optimal reaction conditions, various acetamides 132 including tertiary, secondary, and even primary 
amides could be converted to the corresponding olefins with high levels of chemo-, position and 
stereo-selectivity. By simply switching the carboxylate source from Cu(OAc)2·H2O to 1-AdCO2H, 
substituted olefins 133 were also obtained by step- and atom economical alkyne hydroarylations. 
 
 
Scheme 75. Ruthenium(II)-catalyzed C–H alkenylation of weakly O-coordinating arylacetamides 
132. 
 
Inspired by the above-mentioned ruthenium(II)-catalyzed C–H activations of arylacetamides, we 
subsequently achieved the first ruthenium-catalyzed C–H oxygenation of weakly O-coordinating 
arylacetamides (Scheme 76). This powerful synthetic tool allowed for the rapid and site-selective 
installation of hydroxyl groups into acetamides. Furthermore, the ruthenium(II) catalyst also allowed 
for the direct C–H functionalization on more challenging weakly-coordinating phenylacetyl esters. 
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Scheme 76. Ruthenium(II)-catalyzed C–H oxygenation by weakly coordinating acetamides or esters. 
 
In the third project, we developed an efficient cobalt catalyst for the direct Hiyama-type C–H 
arylation of beazamides with a variety of organosilanes (Scheme 77). The reaction tolerated a broad 
variety of functional groups and numerous ortho-arylated benzamides 137 were efficiently 
synthesized in good to excellent yields. The steric hindrance of the organosilanes was especially 
tolerated, providing arylated products 137 in good to excellent yields. Additionaly, the cost-effective 
cobalt catalyst was also viable in biomass-derived GVL as a green reaction medium.  
 
 
Scheme 77. Cobalt-catalyzed C–H arylation. 
 
Finally, we developed a cobalt-catalyzed C−H/C−C functionalization of valuable heteroarenes and 
arenes 152 with vinylcyclopropanes 138 (Scheme 78). The thermodynamically less stable 
Z-configurated diastereomer was obtained using a versatile cobalt catalyst under exceedingly mild 
reaction conditions with high diastereo-selectivity, ample scope and excellent functional group 
tolerance. The obtained selectivity was different using the related rhodium(III) complex,
[125]
 which 
delivered difficult to separate mixtures of E/Z diastereomers, with a minor bias for the E 
diastereomer. Additionally, detailed mechanistic studies including DFT calculations provided strong 
support for a rate-and selectivity-determining C−C cleavage. 
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Scheme 78. Cobalt(III)-catalyzed C–H/C–C functionalization. 
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5 Experimental Section 
5.1 General Remarks 
Unless otherwise noted, all catalytic reactions were performed under an Ar or N2 atmosphere using 
pre-dried glassware and standard Schlenk techniques.  
Solvents  
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored under 
an inert atmosphere according to the following standard procedures.  
1,4-Dioxane was dried over Na, benzophenone and distilled afterwards.  
Dichloromethane (DCM), N,N-dimethylformamide (DMF) and tetrahydrofuran (THF) were 
purified using a solvent purification system (SPS) from Mbraun.  
Methanol (MeOH) was distilled from MgOMe. 
1,2-Dichloroethane (DCE) and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) 
were dried over CaH2 for 8 h, degassed and distilled under reduced pressure.   
N-Methyl-2-pyrrolidone (NMP) was dried over CaH2 for 4 h at 150 °C and subsequently distilled 
under reduced pressure. 
tert-amylalcohol (t-AmOH) was used as supplied by Merck or stirred over sodium chips for 5 h at 
120 °C and then distilled at ambient pressure.  
Water (H2O) was degassed before its use, applying a repeated freeze-pump-thaw degassing 
procedure.  
Toluene was pre-dried over KH followed by distillation from sodium benzophenone.  
 
Vacuum  
The following pressures were measured on the used vacuum pump and were not corrected: 
membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
 
Melting Points (M. p.) 
Melting points were measured, using a Stuart® Melting Point Apparatus SMP3 from 
Barloworldscientific. Reported values are uncorrected.  
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Chromatography  
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates (Merck) 
with 254 nm fluorescent indicator from Merck. Plates were visualized under UV-light or developed 
by treatment with a KMnO4 solution followed by carefully heating. Chromatographic purification of 
products was accomplished by flash column chromatography on MERCK silica gel, grade 60 
(0.040–0.063 mm and 0.063–0.200 mm).  
 
Gas Chromatography (GC) 
The conversion of the reactions was monitored by coupled gas chromatography/mass spectrometry 
using G1760C GCDplus with mass detector HP 5971, 5890 Series II with mass detector HP 5972 
from HEWLETT-PACKARD and 7890A GC-System with mass detector 5975C 
(Triplex-Axis-Detector) from AGILENT TECHNOLOGIES equipped with HP-5MS columns (30 m 
× 0.25 mm, Ø 0.25 m). 
 
High Performance Liquid Chromatography (HPLC) 
Preparative and analytical separations were performed on an HPLC-System from KNAUER 
(Smartline Pump 100, Dynamic Mixing Chamber, Injection-and Control-Valve, Smartline UV 
Detector 2500). Separation normal phase column (250×10 mm) from MACHEREY-NAGEL (MN) 
was used. Organic solvents of HPLC grade were employed. All samples were filtered through 
Polytetrafluoroethylene Filter from ROTH (Ø 25 mm, 0.2 μm) or VWR (Ø 13 mm, 0.2 μm) prior to 
separation.  
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300, 400, 500 or 600 MHz (
1
H 
NMR), 75, 100 or 125 MHz (
13
C NMR, APT) and 283 MHz or 471 MHz (
19
F NMR) on BRUKER 
AM 250, VARIAN Unity-300 and Inova 500 instruments. Chemical shifts were reported as δ-values 
in ppm relative to the residual proton peak of the deuterated solvent or its carbon atom, respectively, 
or the standard trimethylsilyl (TMS) peak.  
 
Infrared Spectroscopy (IR) 
Infrared spectra were recorded on a BrukerAlpha-P ATR-spectrometer. Liquid probes were 
measured as films between the plates of NaCl and solid probes neat applying Attenuated Total 
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Reflection (ATR) technique, which enabled the samples to be examined directly. Analysis of the 
spectral data has been done by using the OPUS 3.1 software from Bruker, respectively OPUS 6. 
Absorption (ṽ) was given in wave numbers (cm–1). Spectra were recorded in the range of 4000 to 400 
cm
–1
.  
 
Mass Spectrometry (MS) 
MS (EI) and HR-MS (EI) were measured on a Time-of-Flight mass spectrometer AccuTOF from 
JOEL. ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from FINNIGAN or 
on a Time-of-Flight mass spectrometer microTOF from BRUKER. ESI-HR-MS spectra were 
recorded on a BRUKER APEX IV or a BRUKER DALTONIC mass spectrometer. The ratios of mass 
to charge (m/z) were indicated, intensities relative to the base peak (I = 100) were written in 
parentheses. 
 
Reagents  
Chemicals obtained from commercial sources with purity above 95% were used without further 
purification. The following compounds are known and were synthesized according to previously 
described methods: Arylacetamides 132,
[131]
 [Cp*CoI2(CO)],
[132]
 
[Cp*CoI2]2,
[133]
[Cp*Co(MeCN)3](SbF6)2,
[134]
indoles 95.
[135]
  
The following compounds were obtained by the generous courtesy of the persons indicated below: 
Karsten Rauch: [Ru(O2CMes)2(p-cymene)], [RuCl2(p-cymene)]2, [Cp*Rh(CH3CN)3](SbF6)2. 
M. Sc. Joachim Loup: [Co(CO)Cp
1,3-t- Bu
I2], [Co(CO)CpI2]. 
Dr. Vladislav Kotek: N-(tert-butyl)-2-phenylacetamide 132i, 1-morpholino-2-phenylethanone 132k, 
2-phenyl-1-(pyrrolidin-1-yl)ethanone 132l, N-(tert-butyl)-2-(4-fluorophenyl)acetamide 132p, 
N-(tert-butyl)-2-(4-methoxyphenyl)acetamide 132q. 
M. Sc. Krzysztof Kuciński: (2,6-Dimethylphenyl)trimethoxysilane 136b, mesityltrimethoxysilane 
131c, trimethoxy(4-methoxyphenyl)silane 136h. 
M. Sc. Yujiao Zhang: 1-(Pyridin-2-yl)-1H-indole 95a, 5-fluoro-1-(pyridin-2-yl)-1H-indole 95b. 
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5.2 General Procedures 
5.2.1 General Procedure A: Ruthenium-Catalyzed Oxidative C−H Alkenylations  
A suspension of arylacetamide 132 (0.5 mmol, 1.0 equiv), acrylate 5 (1.0 mmol, 2.0 equiv), 
[RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %), Cu(OAc)2·H2O (1.0 mmol, 
2.0 equiv) in 1,4-dioxane or THF (2.0 mL) was stirred at 110 C for 24 h under N2 atmosphere. At 
ambient temperature, the reaction mixture was diluted with sat. aq. NH4Cl (10 mL) and extracted 
with EtOAc (3 x 25 mL). The combined organic layers were dried over Na2SO4. After filtration and 
evaporation of the solvents in vacuo, the remaining residue was purified by column chromatography 
on silica gel (n-hexane/acetone). 
5.2.2 General Procedure B: Ruthenium-Catalyzed Hydroarylation of Alkynes 
A suspension of acetamide 132 (0.5 mmol, 1.0 equiv), alkyne 51 (1.0 mmol, 2.0 equiv), 
[RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %), 1-AdCO2H (0.5 mmol, 1.0 
equiv) in DCE (2.0 mL) was stirred at 120 C for 24 h under N2 atmosphere. At ambient temperature, 
the solvent was removed in vacuo and the remaining residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc). 
5.2.3 General Procedure C: Ruthenium-Catalyzed C−H Oxygenation 
[RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), arylacetamide or phenylacetyl ester 132 or 134 (0.50 
mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and DCE (2.0 mL) were placed into a 25 mL Schlenk tube 
equipped with a septum under N2. The tube was then placed into an oil bath and the reaction mixture 
was stirred at 110 C for 16 h. At ambient temperature, the reaction mixture was diluted with H2O 
(15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layer was concentrated under 
reduced pressure. The crude products were purified by column chromatography (n-hexane/EtOAc) 
on silica gel to afford the desired products 135. 
5.2.4 General Procedure D: Cobalt-Catalyzed C−H Arylation 
A suspension of benzamide 9 (0.25 mmol, 1.0 equiv), arylsilane 136 (0.5 mmol, 2.0 equiv), Co(OAc)2 
(8.9 mg, 20.0 mol %), CsF (0.75 mmol, 3.0 equiv), CuF2 (0.5 mmol, 2.0 equiv) in NMP (1.0 mL) was 
stirred at 100 °C for 20 h under N2 atmosphere. At ambient temperature, the reaction mixture was 
diluted with water (30 mL) and extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were 
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dried over Na2SO4. After filtration and evaporation of the solvents in vacuo, the remaining residue was 
purified by column chromatography on silica gel (n-hexane/acetone). 
5.2.5 General Procedure E: Cobalt-Catalyzed C−H Arylation in GVL 
A suspension of benzamide 9 (0.25 mmol, 1.0 equiv), arylsilane 136 (0.5 mmol, 2.0 equiv), Co(OAc)2 
(8.9 mg, 20.0 mol %), CsF (0.375 mmol, 1.5 equiv), CuF2 (0.5 mmol, 2.0 equiv) in GVL (1.0 mL) was 
stirred at 120 °C for 20 h under N2 atmosphere. At ambient temperature, the reaction mixture was 
diluted with CH2Cl2 (15 mL) and washed with NaOH (2 M, 10 mL) and H2O (2 x 20 mL). The 
combined organic layers were dried over Na2SO4. After filtration and evaporation of the solvents in 
vacuo, the remaining residue was purified by column chromatography on silica gel 
(n-hexane/acetone). 
5.2.6 General Procedure F: Cobalt(III)-Catalyzed C−H/C−C Functionalization 
A suspension of indole 95 or heteroarene 152 (0.50 mmol, 1.0 equiv), vinylcyclopropanes 138 
(0.60 mmol, 1.2 equiv), [Cp*Co(CO)I2] (23.8 mg, 50.0 µmol, 10 mol %), AgSbF6 (34.4 mg, 
100 µmol, 20 mol %) and NaOPiv (12.4 mg, 100 µmol, 20 mol %) in DCE (1.0 mL, 0.50 M) was 
stirred at 50 °C for 20 h. At ambient temperature, the solvent was removed in vacuo and the 
remaining residue was purified by column chromatography on silica gel to afford the desired 
products 146 or 148. 
 
5.2.7 General Procedure G: Rhodium(III)-Catalyzed C−H/C−C Functionalization 
A suspension of indole 95 or heteroarene 147 (0.25 mmol, 1.0 equiv), vinylcyclopropane 133 
(0.30 mmol, 1.2 equiv), [Cp*Rh(CH3CN)3](SbF6)2 (19.7 mg, 25.0 µmol, 10 mol %) and NaOPiv 
(6.2 mg, 50.0 µmol, 20 mol %) in DCE (1.0 mL, 0.25 M) was stirred at 50 °C for 20 h. At ambient 
temperature, the solvent was removed in vacuo and the remaining residue was purified by column 
chromatography on silica gel to afford the desired products 151 or 153. 
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5.3 Experimental Procedures and Analytical Data 
5.3.1 Ruthenium-Catalyzed Oxidative C−H Alkenylations of Arylactamides 
 
 
 
(E)-n-Butyl 3-[2-(2-amino-2-oxoethyl)phenyl]acrylate (133aa): 
The general procedure A was followed using 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol) and 
n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography (n-hexane/acetone: 
3/1) yielded 133aa (84 mg, 64%) as a white solid.  
M. p. = 118–119 °C.  
1
H NMR (400 MHz, CDCl3): δ = 7.91 (d, J = 15.8 Hz, 1H), 7.63–7.60 (m, 1H), 7.39–7.28 (m, 3H), 
6.38 (d, J = 15.8 Hz, 1H), 5.74 (sbr, 1H), 5.46 (sbr, 1H), 4.19 (t, J = 6.7 Hz, 2H), 3.72 (s, 2H), 1.68 (dt, 
J = 14.6, 6.8 Hz, 2H), 1.42 (dd, J = 14.6, 7.5 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H).  
13
C NMR (100 MHz, CDCl3): δ = 172.3 (Cq), 166.6 (Cq), 141.0 (CH), 134.2 (Cq), 134.1 (Cq), 131.3 
(CH), 130.4 (CH), 128.1 (CH), 127.2 (CH), 121.1 (CH), 64.6 (CH2), 40.6 (CH2), 30.7 (CH2), 19.2 
(CH2), 13.7 (CH3).  
IR (ATR): 2959, 1710, 1660, 1626, 1310, 1165, 766 cm
-1
.  
MS (ESI) m/z (relative intensity): 545 (100) [2M+Na]
+
, 284 (45) [M+Na]
+
, 262 (27) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C15H20NO3 [M+H]
+
: 262.1438, found: 262.1435. 
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(E)-n-Butyl 3-[2-(2-amino-2-oxoethyl)-5-bromophenyl]acrylate (133ba): 
The general procedure A was followed using 2-(4-bromophenyl)acetamide (132b) (106 mg, 0.50 
mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/acetone: 3/1) yielded 133ba (104 mg, 61%) as a white solid.  
M. p. = 165–166 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.79 (d, J = 15.8 Hz, 1H), 7.72 (d, J = 2.1 Hz, 1H), 7.46 (dd, J = 8.2, 
2.1 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 6.36 (d, J = 15.8 Hz, 1H), 5.58 (sbr, 1H), 5.44 (sbr, 1H), 4.18 (t, J 
= 6.7 Hz, 2H), 3.64 (s, 2H), 1.74–1.60 (m, 2H), 1.48–1.33 (m, 2H), 0.94 (t, J = 7.5 Hz, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 170.6 (Cq), 165.4 (Cq), 138.8 (CH), 135.3 (Cq), 132.3 (CH), 132.1 
(Cq), 131.9 (CH), 129.2 (CH), 121.5 (CH), 121.2 (Cq), 64.0 (CH2), 39.2 (CH2), 30.0 (CH2), 18.4 (CH2), 
13.1 (CH3).  
IR (ATR): 2957, 1712, 1657, 1312, 1173, 975, 806 cm
-1
.  
MS (ESI) m/z (relative intensity): 362 (100) ([M+Na]
+
, 
79
Br), 342 (23) ([M+H]
+
, 
81
Br).  
HR-MS (ESI) m/z calcd for C15H19
79
BrNO3 [M+H]
+
: 340.0543, found: 340.0540. 
 
 
(E)-n-Butyl 3-[2-(2-amino-2-oxoethyl)-5-chlorophenyl]acrylate (133ca): 
The general procedure A was followed using 2-(4-chlorophenyl)acetamide (132c) (84.5 mg, 0.50 
mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/acetone: 3/1) yielded 133ca (97 mg, 66%) as a white solid.  
M. p. = 153–154 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.80 (d, J = 15.8 Hz, 1H), 7.57 (d, J = 2.2 Hz, 1H), 7.32 (dd, J = 7.6, 
2.2 Hz, 1H), 7.22 (d, J = 7.6 Hz, 1H), 6.37 (d, J = 15.8 Hz, 1H), 5.50 (sbr, 1H), 5.42 (sbr, 1H), 4.18 (t, J 
= 6.7 Hz, 2H), 3.66 (s, 2H), 1.70–1.61 (m, 2H), 1.46–1.35 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H).  
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13
C NMR (75 MHz, CDCl3): δ = 171.5 (Cq), 166.2 (Cq), 139.7 (CH), 135.7 (Cq), 134.1 (Cq), 132.6 
(CH), 132.4 (Cq), 130.2 (CH), 127.0 (CH), 122.3 (CH), 64.8 (CH2), 39.8 (CH2), 30.7 (CH2), 19.0 
(CH2), 13.6 (CH3).  
IR (ATR): 2958, 1711, 1657, 1635, 1313, 1171, 976 cm
-1
.  
MS (ESI) m/z (relative intensity): 613 (100) [2M+Na]
+
, 318 (75) [M+Na]
+
, 296 (20) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C15H19ClNO3 [M+H]
+
: 296.1048, found: 296.1045. 
 
 
(E)-n-Butyl 3-[2-(2-amino-2-oxoethyl)-5-fluorophenyl]acrylate (133da): 
The general procedure A was followed using 2-(4-fluorophenyl)acetamide (132d) (76.5 mg, 0.50 
mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/acetone: 3/1) yielded 133da (76.7 mg, 55%) as a white solid.  
M. p. = 127–128 °C.  
1
H NMR (400 MHz, CDCl3): δ = 7.81 (d, J = 15.8, 1H), 7.30–7.25 (m, 2H), 7.06 (td, J = 8.2, 2.7 Hz, 
1H), 6.35 (d, J = 15.8 Hz, 1H), 5.62 (sbr, 1H), 5.44 (sbr, 1H), 4.18 (t, J = 6.7 Hz, 2H), 3.66 (s, 2H), 1.70–
1.62 (m, 2H), 1.45–1.35 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H).  
13
C NMR (100 MHz, CDCl3): δ = 171.9 (Cq), 166.3 (Cq), 162.2 (Cq, 
1
JC–F = 247.3 Hz), 139.9 (CH, 
4
JC–
F = 2.3 Hz), 136.0 (Cq, 
3
JC–F = 7.6 Hz), 133.0 (CH, 
3
JC–F = 8.2 Hz), 130.0 (Cq, 
4
JC–F = 3.2 Hz), 122.2 
(CH), 117.3 (CH, 
2
JC–F = 21.5 Hz), 113.7 (CH, 
2
JC–F = 22.4 Hz), 64.7 (CH2), 39.7 (CH2), 30.7 (CH2), 
19.1 (CH2), 13.7 (CH3).  
19
F NMR (376 Hz, CDCl3): δ = –113.8.  
IR (ATR): 2956, 1703, 1674, 1492, 1268, 1175, 730 cm
-1
.  
MS (ESI) m/z (relative intensity): 581 (100) [2M+Na]
+
, 302 (40) [M+Na]
+
, 280 (25) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C15H19FNO3 [M+H]
+
: 280.1343, found: 280.1341. 
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(E)-n-Butyl 3-[2-(2-amino-2-oxoethyl)-4-methylphenyl]acrylate (133ea): 
The general procedure A was followed using 2-(m-tolyl)acetamide (132e) (74.5 mg, 0.50 mmol) and 
n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography (n-hexane/acetone: 
3/1) yielded 133ea (78 mg, 58%) as a white solid.  
M. p. = 133–134 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 15.7 Hz, 1H), 7.51 (d, J = 7.9 Hz, 1H), 7.15–7.06 (m, 2H), 
6.34 (d, J = 15.7 Hz, 1H), 5.47 (sbr, 1H), 5.35 (sbr, 1H), 4.18 (t, J = 6.7 Hz, 2H), 3.68 (s, 2H), 2.34 (s , 
3H), 1.71–1.61 (m, 2H), 1.47–1.34 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 171.3 (Cq), 165.9 (Cq), 140.1 (Cq), 139.9 (CH), 133.3 (Cq), 131.2 
(CH), 130.3 (Cq), 128.2 (CH), 126.4 (CH), 119.3 (CH), 63.8 (CH2), 39.9 (CH2), 30.1 (CH2), 20.6 
(CH3), 18.5 (CH2), 13.1 (CH3).  
IR (ATR): 2959, 1700, 1666, 1313, 1176, 906, 729 cm
-1
.  
MS (ESI) m/z (relative intensity): 573 (100) [2M+Na]
+
, 298 (23) [M+Na]
+
, 276 (17) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C16H22NO3 [M+H]
+
: 276.1594, found: 276.1592. 
 
 
(E)-n-Butyl 3-[2-(2-amino-2-oxoethyl)-4-methoxyphenyl]acrylate (133fa):  
The general procedure A was followed using 2-(3-methoxyphenyl)acetamide (132f) (82.5 mg, 0.50 
mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/acetone: 3/1) yielded 133fa (74 mg, 51%) as a white solid.  
M. p. = 123–124 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.84 (d, J = 15.7 Hz, 1H), 7.60 (d, J = 8.7 Hz, 1H), 6.89–6.80 (m, 2H), 
6.30 (d, J = 15.7 Hz, 1H), 5.50 (sbr, 1H), 5.45 (sbr, 1H), 4.19 (t, J = 6.7 Hz, 2H), 3.83 (s, 3H), 3.71 (s, 
2H), 1.73–1.63 (m, 2H), 1.47–1.43 (m, 2H), 0.96 (t, J = 8.3 Hz, 3H).  
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13
C NMR (125 MHz, CDCl3): δ = 171.1 (Cq), 166.1 (Cq), 160.4 (Cq), 139.5 (CH), 135.2 (Cq), 127.9 
(CH), 125.5 (Cq), 117.7 (CH), 115.5 (CH), 113.2 (CH), 63.7 (CH2), 54.7 (CH3), 40.1 (CH2), 30.1 
(CH2), 18.5 (CH2), 13.1 (CH3).  
MS (ESI) m/z (relative intensity): 314 (100) [M+Na]
+
, 292 (15) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C16H22NO4 [M+H]
+
: 292.1543, found: 292.1541. 
 
 
 
(E)-Butyl 3-(2-(2-amino-2-oxoethyl)-3-methylphenyl)acrylate (133ga):  
The general procedure A was followed using 2-(3-methoxyphenyl)acetamide (132g) (82.5 mg, 0.50 
mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/acetone: 3/1) yielded 133ga (74 mg, 51%) as a white solid.  
M. p. = 120–121 °C. 
1
H NMR (300 MHz, CDCl3): δ = 7.93 (d, J = 15.7 Hz, 1H), 7.43 (dd, J = 6.7, 2.4 Hz, 1H), 7.25–7.18 
(m, 2H), 6.33 (d, J = 15.7 Hz, 1H), 4.18 (t, J = 6.7 Hz, 2H), 3.73 (s, 2H), 2.34 (s, 3H), 1.72–1.62 (m, 
2H), 1.48–1.34 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 171.8 (Cq), 166.4 (Cq), 141.7 (CH), 138.2 (Cq), 134.6 (Cq), 132.6 
(Cq), 132.2 (CH), 127.8 (CH), 125.2 (CH), 121.6 (CH), 64.6 (CH2), 36.9 (CH2), 30.8 (CH2), 20.3 
(CH3), 19.3 (CH2), 13.8 (CH3).  
IR (ATR): 2960, 1709, 1656, 1276, 1180, 909, 731 cm
-1
.  
MS (ESI) m/z (relative intensity): 573 (100) [2M+Na]
+
,298 (50) [M+Na]
+
, 276 (20) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C16H22NO3[M+H]+: 276.1594, found: 276.1592. 
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(E)-Methyl 3-[2-(2-amino-2-oxoethyl)-5-chlorophenyl]acrylate (133cc): 
The general procedure A was followed using 2-(4-chlorophenyl)acetamide (132c) (84.5 mg, 0.50 
mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/acetone: 3/1) yielded 133cc (66 mg, 52%) as a white solid.  
M. p. = 133–134 °C.  
1
H NMR (500 MHz, CDCl3): δ = 7.81 (d, J = 15.8 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.33 (dd, J = 8.2, 
2.2 Hz, 1H), 7.23 (d, J = 8.3 Hz, 1H), 6.36 (d, J = 15.8 Hz, 1H), 5.51 (sbr, 1H), 5.40 (sbr, 1H), 3.79 (s, 
3H), 3.66 (s, 2H).  
13
C NMR (125 MHz, CDCl3): δ = 171.0 (Cq), 166.0 (Cq), 139.4 (CH), 135.1 (Cq), 133.5 (Cq), 132.0 
(CH), 131.9 (Cq), 129.7 (CH), 126.5 (CH), 121.3 (CH), 51.4 (CH3), 39.3 (CH2).  
IR (ATR): 2953, 1712, 1669, 1312, 1169, 973, 697 cm
-1
.  
MS (ESI) m/z (relative intensity): 529 (100) [2M+Na]
+
,276 (50) [M+Na]
+
, 254 (20) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C12H13ClNO3 [M+H]
+
: 254.0516, found: 254.0519. 
 
 
 
(E)-Benzyl 3-[2-(2-amino-2-oxoethyl)-5-chlorophenyl]acrylate (133cd): 
The general procedure A was followed using 2-(4-chlorophenyl)acetamide (132c) (84.5 mg, 0.50 
mmol) and benzyl acrylate (5d) (162 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/acetone: 3/1) yielded 133cd (105 mg, 64%) as a white solid.  
M. p. = 165–166 °C.  
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1
H NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 15.8 Hz, 1H), 7.56 (d, J = 2.2 Hz, 1H), 7.40–7.35 (m, 3H), 
7.35–7.30 (m, 2H), 7.24–7.20 (m, 2H), 6.41 (d, J = 15.8 Hz, 1H), 5.46 (sbr, 1H), 5.40 (sbr, 1H), 5.23 (s, 
2H), 3.65 (s, 2H).  
13
C NMR (125 MHz, CDCl3): δ = 171.3 (Cq), 165.9 (Cq), 140.2 (CH), 135.7 (Cq), 135.5 (Cq), 134.0 
(Cq), 132.5 (CH), 132.4 (Cq), 130.2 (CH), 128.5 (CH), 128.3 (CH), 128.2 (CH), 127.0 (CH), 121.8 
(CH), 66.7 (CH2), 39.8 (CH2).  
IR (ATR): 2940, 1710, 1669, 1635, 1312, 1168, 697 cm
-1
.  
MS (ESI) m/z (relative intensity): 352 (100) [M+Na]
+
, 330 (20) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C18H17ClNO3 [M+H]
+
: 330.0891, found: 330.0888. 
 
 
 
(E)-Ethyl 3-[2-(2-amino-2-oxoethyl)phenyl]acrylate (133ab): 
The general procedure A was followed using 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol) and 
ethyl acrylate (5b) (100 mg, 1.00 mmol). Isolation by column chromatography (n-hexane/acetone: 3/1) 
yielded 133ab (83 mg, 71%) as a white solid.  
M. p. = 101–103 °C.  
1
H NMR (400 MHz, CDCl3): δ = 7.91 (d, J = 15.7 Hz, 1H), 7.62 (dd, J = 7.5, 1.6 Hz, 1H), 7.40–7.28 
(m, 3H), 6.38 (d, J = 15.7 Hz, 1H), 5.53 (sbr, 1H), 5.40 (sbr, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.73 (s, 2H), 
1.33 (t, J = 7.1 Hz, 3H).  
13
C NMR (100 MHz, CDCl3): δ = 171.2 (Cq), 165.6 (Cq), 139.9 (CH), 133.1 (Cq), 133.1 (Cq), 130.3 
(CH), 129.5 (CH), 127.2 (CH), 126.3 (CH), 120.2 (CH), 59.7 (CH2), 39.6 (CH2), 13.3 (CH3).  
IR (ATR): 2934, 1714, 1667, 1633, 1315, 1179, 766 cm
-1
.  
MS (ESI) m/z (relative intensity): 489 (100) [2M+Na]
+
,256 (65) [M+Na]
+
, 234 (25) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C13H16NO3 [M+H]
+
: 234.1125, found: 234.1123. 
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(E)-Phenyl 3-[2-(2-amino-2-oxoethyl)phenyl]acrylate (133ae): 
The general procedure A was followed using 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol) and 
phenyl acrylate (5e) (128 mg, 1.00 mmol). Isolation by column chromatography (n-hexane/acetone: 
3/1) yielded 133ae (79 mg, 56%) as a white solid.  
M. p. = 153–154 °C.  
1
H NMR (300 MHz, CDCl3): δ = 8.09 (d, J = 15.7 Hz, 1H), 7.68 (dd, J = 7.3, 1.8 Hz, 1H), 7.44–7.29 
(m, 5H), 7.24–7.20 (m, 1H), 7.18–7.12 (m, 2H), 6.57 (d, J = 15.7 Hz, 1H), 5.56 (sbr, 1H), 5.44 (sbr, 1H), 
3.74 (s, 2H).  
13
C NMR (125 MHz, CDCl3): δ = 171.9 (Cq), 164.8 (Cq), 150.6 (Cq), 142.8 (CH), 134.4 (Cq), 133.7 
(Cq), 131.3 (CH), 130.8 (CH), 129.3 (CH), 128.4 (CH), 127.3 (CH), 125.8 (CH), 121.5 (CH), 120.0 
(CH), 40.6 (CH2).  
IR (ATR): 3182, 1722, 1661, 1631, 1483, 1142, 975 cm
-1
.  
MS (ESI) m/z (relative intensity): 585 (100) [2M+Na]
+
, 304 (55) [M+Na]
+
, 282 (4) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C17H16NO3 [M+H]
+
: 282.1125, found: 282.1123. 
 
(E)-naphthalen-2-yl 3-(2-(2-amino-2-oxoethyl)phenyl)acrylate (133af): 
The general procedure A was followed using 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol) and 
phenyl acrylate (5f) (128 mg, 1.00 mmol). Isolation by column chromatography (n-hexane/acetone: 
3/1) yielded 133af (79 mg, 56%) as a white solid.  
M. p. = 158–159 °C.  
1
H NMR (300 MHz, CDCl3): δ = 8.13 (d, J = 15.7 Hz, 1H), 7.89–7.78 (m, 3H), 7.73–7.68 (m, 1H), 
7.63 (d, J = 2.3 Hz, 1H), 7.52–7.44 (m, 2H), 7.44–7.36 (m, 2H), 7.34–7.27 (m, 2H), 6.62 (d, J = 15.7 
Hz, 1H), 3.75 (s, 2H).  
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13
C NMR (125 MHz, CDCl3): δ = 170.8 (Cq), 164.0 (Cq), 147.3 (Cq), 142.0 (CH), 133.4 (Cq), 132.7 
(Cq), 132.7 (Cq), 130.4 (Cq), 130.3 (CH), 129.8 (CH), 128.3 (CH), 127.2 (CH), 126.7 (CH), 126.6 (CH), 
126.3 (CH), 125.5 (CH), 124.6 (CH), 120.1 (CH), 119.0 (CH), 117.5 (CH), 39.7 (CH2).  
IR (ATR): 2924, 1724, 1667, 1598, 1214, 1142, 760 cm
-1
.  
MS (ESI) m/z (relative intensity): 685 (100) [2M+Na]
+
,354 (52) [M+Na]
+
, 332 (6) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C21H18NO3[M+H]
+
: 332.1281, found: 332.1278. 
 
 
 
(E)-n-Butyl 3-[1-(2-amino-2-oxoethyl)naphthalen-2-yl]acrylate (133ha): 
The general procedure A was followed using 2-(naphthalen-1-yl)acetamide (132h) (92.5 mg, 0.50 
mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/aceton: 3/1) yielded 133ha (110 mg, 71%) as a white solid.  
M. p. = 156–157 °C. 1H NMR (400 MHz, CDCl3): δ = 8.19 (d, J = 15.7 Hz, 1H), 8.08 (d, J = 8.3 Hz, 
1H), 7.85 (t, J = 8.8 Hz, 2H), 7.70 (d, J = 8.7 Hz, 1H), 7.65–7.50 (m, 2H), 6.52 (d, J = 15.7 Hz, 1H), 
5.42 (sbr, 1H), 5.24 (sbr, 1H), 4.27–4.22 (m, 4H), 1.76–1.66 (m, 2H), 1.44 (dt, J = 13.6, 6.8 Hz, 2H), 
0.98 (t, J = 7.3 Hz, 3H).
  
13
C NMR (100 MHz, CDCl3): δ = 171.0 (Cq), 165.6 (Cq), 140.2 (CH), 133.3 (Cq), 131.5 (Cq), 130.7 
(Cq), 129.8 (Cq), 127.9 (CH), 127.8 (CH), 126.7 (CH), 126.2 (CH), 123.5 (CH), 122.9 (CH), 121.2 
(CH), 63.8 (CH2), 35.3 (CH2), 29.7 (CH2), 18.2 (CH2), 12.7 (CH3).   
IR (ATR): 2957, 1644, 1626, 1380, 1259, 1175, 1164, 792 cm
-1
. MS (ESI) m/z (relative intensity): 645 
(68) [2M+Na]
+
, 334 (100) [M+Na]
+
, 312 (24) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C19H22NO3 [M+H]
+
: 312.1594, found: 312.1590. 
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(E)-2-{2-[2-(Phenylsulfonyl)vinyl]phenyl}acetamide (133ag): 
The general procedure A was followed using 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol) and 
(vinylsulfonyl)benzene (5g) (168 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/acetone: 3/1) yielded 133ag (95 mg, 61%) as a yellow solid.  
M. p. = 135–136 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.96–7.87 (m, 3H), 7.63–7.47 (m, 4H), 7.42–7.26 (m, 3H), 6.80 (d, J 
= 15.2 Hz, 1H), 5.44 (sbr, 2H), 3.72 (s, 2H).  
13
C NMR (125 MHz, CDCl3): δ = 171.4 (Cq), 140.3 (Cq), 139.3 (CH), 134.6 (Cq), 133.4 (CH), 132.0 
(Cq), 131.4 (CH), 131.2 (CH), 129.7 (CH), 129.3 (CH), 128.2 (CH), 127.7 (CH), 127.5 (CH), 40.6 
(CH2).  
IR (ATR): 1670, 1303, 1144, 1084, 752, 687, 541 cm
-1
.  
MS (ESI) m/z (relative intensity): 625 (100) [2M+Na]
+
, 324 (73) [M+Na]
+
, 302 (13) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C16H16NO3S [M+H]
+
: 302.0845, found: 302.0841. 
 
 
 
(E)-Cholesteryl [2-(2-amino-2-oxoethyl)phenyl]acrylate (133ah):  
The general procedure A was followed using 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol) and 
cholesteryl acrylate (5h) (440 mg, 1.00 mmol) in 1,4-dioxane (1.8 mL) and PhMe (0.2 mL) at 120 °C. 
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Isolation by column chromatography (n-hexane/acetone: 3/1) yielded 133ah (163 mg, 57%) as a white 
solid.  
M. p. = 127–128 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.88 (d, J = 15.8 Hz, 1H), 7.59 (dd, J = 7.6, 1.4 Hz, 1H), 7.38–7.25 
(m, 3H), 6.35 (d, J = 15.8 Hz, 1H), 5.64 (sbr, 1H), 5.45 (sbr, 1H), 5.40–5.34 (m, 1H), 4.78–4.64 (m, 1H), 
3.69 (s, 2H), 2.37 (d, J = 7.8 Hz, 2H), 2.08–0.94 (m, 29H), 0.90 (d, J = 6.5 Hz, 3H), 0.85 (dd, J = 6.6, 
1.3 Hz, 6H), 0.67 (s, 3H).  
13
C NMR (100 MHz, CDCl3): δ = 172.5 (Cq), 166.0 (Cq), 140.9 (CH), 139.6 (Cq), 134.2 (Cq), 134.1 
(Cq), 131.3 (CH), 130.4 (CH), 128.1 (CH), 127.2 (CH), 122.7 (CH), 121.4 (CH), 74.3 (CH), 56.7 (CH), 
56.1 (CH), 50.0 (CH), 42.3 (Cq), 40.5 (CH2), 39.7 (CH2), 39.5 (CH2), 38.2 (CH2), 37.0 (CH2), 36.6 (Cq), 
36.2 (CH2), 35.8 (CH), 31.9 (CH2), 31.8 (CH), 28.2 (CH2), 28.0 (CH), 27.8 (CH2), 24.3 (CH2), 23.8 
(CH2), 22.8 (CH3), 22.5 (CH3), 21.0 (CH2), 19.3 (CH3), 18.7 (CH3), 11.8 (CH3).  
IR (ATR): 2936, 1667, 1320, 1171, 907, 765, 731, 593 cm
-1
. MS (ESI) m/z (relative intensity): 1169 
(100) [2M+Na]
+
, 596 (70) [M+Na]
+
, 574 (12) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C38H56NO3 [M+H]
+
: 574.4255, found: 574.4249.  
 
 
 
(E)-n-Butyl 3-{2-[2-(tert-butylamino)-2-oxoethyl]phenyl}acrylate (133ia): 
The general procedure A was followed using N-(tert-butyl)-2-phenylacetamide (132i) (95.5 mg, 0.50 
mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133ia (133 mg, 84%) as a white solid.  
M. p. = 142–143 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.86 (d, J = 15.8 Hz, 1H), 7.58 (dd, J = 7.4, 1.7 Hz, 1H), 7.37–7.23 
(m, 3H), 6.35 (d, J = 15.8 Hz, 1H), 5.15 (sbr, 1H), 4.19 (t, J = 6.7 Hz, 2H), 3.60 (s, 2H), 1.71–1.61 (m, 
2H), 1.47–1.36 (m, 2H), 1.25 (s, 9H), 0.94 (t, J = 8.4 Hz, 3H).  
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13
C NMR (125 MHz, CDCl3): δ = 168.8 (Cq), 166.4 (Cq), 141.2 (CH), 134.7 (Cq), 133.9 (Cq), 131.2 
(CH), 130.3 (CH), 127.8 (CH), 127.0 (CH), 120.8 (CH), 64.5 (CH2), 51.4 (Cq), 42.4 (CH2), 30.8 (CH2), 
28.7 (CH2), 19.3 (CH3), 13.8 (CH3).  
IR (ATR): 2961, 1710, 1636, 1547, 1358, 1167, 762 cm
-1
. MS (ESI) m/z (relative intensity): 340 (60) 
[M+Na]
+
, 318 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C19H28NO3 [M+H]
+
: 318.2064, found: 318.2063. 
 
 
 
(E)-Methyl 3-{2[2-(tert-butylamino)-2-oxoethyl]phenyl}acrylate (133ic): 
The general procedure A was followed using N-(tert-butyl)-2-phenylacetamide (132i) (95.5 mg, 0.50 
mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133ic (118 mg, 86%) as a white solid.  
M. p. = 135–136 °C.  
1
H NMR (400 MHz, CDCl3): δ = 7.88 (d, J = 15.8 Hz, 1H), 7.58 (dd, J = 7.6, 1.5 Hz, 1H), 7.37–7.24 
(m, 3H), 6.35 (d, J = 15.8 Hz, 1H), 5.17 (sbr, 1H), 3.78 (s, 3H), 3.60 (s, 2H), 1.25 (s, 9H).  
13
C NMR (100 MHz, CDCl3): δ = 168.1 (Cq), 166.0 (Cq), 140.6 (CH), 133.8 (Cq), 132.9 (Cq), 130.3 
(CH), 129.4 (CH), 126.9 (CH), 126.1 (CH), 119.3 (CH), 50.8 (CH3), 50.5 (Cq), 41.4 (CH2), 27.6 (CH3).  
IR (ATR): 2925, 1711, 1646, 1545, 1318, 1170, 765 cm
-1
.  
MS (ESI) m/z (relative intensity): 298 (100) [M+Na]
+
, 276 (30) [M+H]
+
, 244 (20).  
HR-MS (ESI) m/z calcd for C16H22NO3 [M+H]
+
: 276.1594, found: 276.1596. 
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(E)-Methyl 3-{2-[2-(n-butylamino)-2-oxoethyl]phenyl}acrylate (133jc): 
The general procedure A was followed using N-n-butyl-2-phenylacetamide (132j) (95.5 mg, 0.50 
mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133jc (118 mg, 86%) as a white solid.  
M. p. = 142–143 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.87 (d, J = 15.8 Hz, 1H), 7.59 (dd, J = 7.4, 1.8 Hz, 1H), 7.38–7.23 
(m, 3H), 6.35 (d, J = 15.8 Hz, 1H), 5.32 (sbr, 1H), 3.77 (s, 3H), 3.67 (s, 2H), 3.21–3.12 (m, 2H), 1.42–
1.28 (m, 2H), 1.27–1.13 (m, 2H), 0.83 (t, J = 7.2 Hz, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 169.5 (Cq), 166.7 (Cq), 141.2 (CH), 134.3 (Cq), 133.9 (Cq), 31.3 
(CH), 130.4 (CH), 128.0 (CH), 127.1 (CH), 120.5 (CH), 51.8 (CH3), 41.3 (CH2), 39.5 (CH2), 31.6 
(CH2), 20.0 (CH2), 13.7 (CH3).  
IR (ATR): 2955, 1713, 1637, 1546, 1315, 1167, 762 cm
-1
.  
MS (ESI) m/z (relative intensity): 298 (100) [M+Na]
+
, 276 (45) [M+H]
+
, 244 (70).  
HR-MS (ESI) m/z calcd for C16H21NO3 [M+H]
+
: 276.1594,  found: 276.1596.
 
 
 
 
(E)-n-Butyl 3-[2-(2-morpholino-2-oxoethyl)phenyl]acrylate (133ka): 
The general procedure A was followed using 1-morpholino-2-phenylethanone (132k) (103 mg, 0.50 
mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133ka (89 mg, 54%) as colorless oil.  
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1
H NMR (300 MHz, CDCl3): δ = 7.82 (d, J = 15.8 Hz, 1H), 7.57 (dd, J = 7.4, 1.6 Hz, 1H), 7.35–7.25 
(m, 2H), 7.20 (dd, J = 7.4, 1.5 Hz, 1H), 6.34 (d, J = 15.8 Hz, 1H), 4.18 (t, J = 6.7 Hz, 2H), 3.79 (s, 2H), 
3.66–3.56 (m, 6H), 3.47–3.41 (m, 2H), 1.71–1.61 (m, 2H), 1.49–1.32 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H).  
13
C NMR (75 MHz, CDCl3): δ = 169.0 (Cq), 166.8 (Cq), 141.3 (CH), 134.5 (Cq), 133.6 (Cq), 130.2 
(CH), 130.1 (CH), 127.6 (CH), 127.0 (CH), 120.5 (CH), 66.8 (CH2), 66.5 (CH2), 64.5 (CH2), 46.4 
(CH2), 42.3 (CH2), 37.5 (CH2), 30.8 (CH2), 19.2 (CH2), 13.7 (CH3).  
IR (ATR): 2958, 1708, 1633, 1433, 1169, 1113, 763 cm
-1
. MS (ESI) m/z (relative intensity): 354 (100) 
[M+Na]
+
, 332 (70) [M+H]
+
, 258 (40).  
HR-MS (ESI) m/z calcd for C19H26NO4 [M+H]
+
: 332.1856, found: 332.1854. 
 
 
 
(E)-n-Butyl 3-{2-[2-oxo-2-(pyrrolidin-1-yl)ethyl]phenyl}acrylate (133la): 
The general procedure A was followed using 2-phenyl-1-(pyrrolidin-1-yl)ethanone (132l) (94.5 mg, 
0.50 mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133la (139 mg, 88%) as a white oil.  
1
H NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 15.5, 1H), 7.55 (dd, J = 7.8, 1.4 Hz, 1H), 7.33–7.19 (m, 
3H), 6.33 (d, J = 15.5 Hz, 1H), 4.16 (dd, J = 8.4, 4.9 Hz, 2H), 3.73 (s, 2H), 3.43–3.49 (m, 4H), 1.98–
1.89 (m, 2H), 1.87–1.80 (m, 2H), 1.70–1.58 (m, 2H), 1.47–1.34 (m, 2H), 0.93 (t, J = 8.6 Hz, 3H).  
13
C NMR (100 MHz, CDCl3): δ = 167.6 (Cq), 165.9 (Cq), 140.8 (CH), 133.8 (Cq), 132.8 (Cq), 129.4 
(CH), 129.0 (CH), 126.3 (CH), 125.7 (CH), 119.1 (CH), 63.3 (CH2), 45.8 (CH2), 44.9 (CH2), 38.1 
(CH2), 29.7 (CH2), 25.1 (CH2), 23.3 (CH2), 18.1 (CH2), 12.7 (CH3).  
IR (ATR): 2958, 1707, 1632, 1431, 1311, 1216, 730 cm
-1
.  
MS (ESI) m/z (relative intensity): 338 (65) [M+Na]
+
, 316 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C19H26NO3 [M+H]
+
: 316.1907, found: 316.1912. 
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(E)-Methyl 3-{2-[2-(diisopropylamino)-2-oxoethyl]phenyl}xacrylate (133mc): 
The general procedure A was followed using N,N-diisopropyl-2-phenylacetamide (132m) (110 mg, 
0.50 mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133ma (91 mg, 60%) as a white solid.  
M. p. = 136–137 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.81 (d, J = 15.8 Hz, 1H), 7.55 (dd, J = 7.5, 1.5 Hz, 1H), 7.34–7.18 
(m, 3H), 6.32 (d, J = 15.8 Hz, 1H), 3.93 (dt, J = 13.3, 6.7 Hz, 1H), 3.76 (s, 3H), 3.75 (s, 2H), 3.43 (dt, 
J = 13.0, 6.3 Hz, 1H), 1.38 (d, J = 6.8 Hz, 6H), 1.15 (d, J = 6.7 Hz, 6H).  
13
C NMR (125 MHz, CDCl3): δ = 168.8 (Cq), 167.0 (Cq), 141.9 (CH), 135.5 (Cq), 133.4 (Cq), 130.2 
(CH), 130.0 (CH), 127.1 (CH), 126.7 (CH), 119.6 (CH), 51.6 (CH3), 49.2 (CH), 46.0 (CH), 40.1 (CH2), 
20.8 (CH3), 20.5 (CH3).  
IR (ATR): 2964, 1712, 1631, 1435, 1336, 1169, 729 cm
-1
.  
MS (ESI) m/z (relative intensity): 326 (33) [M+Na]
+
, 304 (100) [M+H]
+
, 272 (45).  
HR-MS (ESI) m/z calcd for C18H26NO3 [M+H]
+
: 304.1907, found: 304.1913. 
 
 
 
(E)-n-Butyl 3-{2-{2-oxo-2-[((R)-1-phenylethyl)amino]ethyl}phenyl}acrylate (133na): 
The general procedure A was followed using 2-phenyl-N-{(R)-1-phenylethyl}acetamide (132n) (120 
mg, 0.50 mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133na (141 mg, 77%) as a white solid.  
M. p. = 77–78 °C.  
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1
H NMR (400 MHz, CDCl3): δ = 7.88 (d, J = 15.8 Hz, 1H), 7.58 (dd, J = 7.5, 1.7 Hz, 1H), 7.36–7.29 
(m, 2H), 7.26-7.23 (m, 3H), 7.22–7.19 (m, 1H), 7.18–7.15 (m, 2H), 6.34 (d, J = 15.8 Hz, 1H), 
5.06-5.11 (m, 1H), 5.62 (sbr, 1H), 4.21–4.15 (m, 2H), 3.68 (s, 2H), 1.66 (dq, J = 12.3, 6.9 Hz, 2H), 
1.47–1.38 (m, 2H), 1.37 (d, J = 7.0 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H).  
13
C NMR (100 MHz, CDCl3): δ = 168.9 (Cq), 166.5 (Cq), 142.8 (Cq), 141.0 (CH), 131.3 (Cq), 130.4 
(Cq), 129.3 (CH), 129.0 (CH), 128.5 (CH), 128.1 (CH), 127.2 (CH), 127.1 (CH), 126.0 (CH), 121.0 
(CH), 64.5 (CH2), 48.8 (CH), 41.3 (CH2), 30.7 (CH2), 21.4 (CH3), 19.1 (CH2), 13.6 (CH3).  
IR (ATR): 2960, 1712, 1641, 1541, 1312, 1171, 699 cm
-1
. MS (ESI) m/z (relative intensity): 388 (100) 
[M+Na]
+
, 366 (57) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C23H28NO3 [M+H]
+
: 366.2064, found: 366.2064.  
HPLC (n-hexane/iPrOH: 70/30): t = 5.20 min. 
 
 
 
 
 
 
(E)-n-Butyl 3-{2-{2-[(3-acetoxypropyl)amino]-2-oxoethyl}phenyl}acrylate (133oa): 
The general procedure A was followed using 3-(2-phenylacetamido)propyl acetate (132o) (118 mg, 
0.50 mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133oa (110 mg, 61%) as a colorless oil.  
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1
H NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 15.8 Hz, 1H), 7.57 (dd, J = 7.3, 1.7 Hz, 1H), 7.35–7.22 
(m, 3H), 6.34 (d, J = 15.8 Hz, 1H), 5.81 (sbr, 1H), 4.15 (t, J = 6.7 Hz, 2H), 3.98 (t, J  = 6.0, 2H), 3.65 (s, 
2H), 3.22 (dd, J = 12.8, 6.7 Hz, 2H), 1.94 (s, 3H), 1.77–1.68 (m, 2H), 1.67–1.59 (m, 2H), 1.34–1.32 (m, 
2H), 0.92 (t, J = 7.3 Hz, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 170.9 (Cq), 169.8 (Cq), 166.4 (Cq), 140.9 (CH), 134.1 (Cq), 133.9 
(Cq), 131.1 (CH), 130.2 (CH), 127.9 (CH), 127.0 (CH), 120.7 (CH), 64.4 (CH2), 61.7 (CH2), 41.1 
(CH2), 36.5 (CH2), 30.7 (CH2), 28.6 (CH2), 20.8 (CH3), 19.2 (CH2), 13.7 (CH3).  
IR (ATR): 2961, 1710, 1649, 1239, 1174, 907, 726 cm
-1
.  
MS (ESI) m/z (relative intensity): 384 (100) [M+Na]
+
, 362 (70) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C20H28NO5 [M+H]
+
: 362.1962, found: 362.1961. 
 
 
 
(E)-Methyl 3-{2-[2-(tert-butylamino)-2-oxoethyl]-5-fluorophenyl}acrylate (133pc): 
The general procedure A was followed using N-(tert-butyl)-2-(4-fluorophenyl)acetamide (132p) (105 
mg, 0.50 mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133pc (119 mg, 81%) as a white solid.  
M. p. = 147–148 °C.  
1
H NMR (400 MHz, CDCl3): δ = 7.80 (dd, J = 15.8, 1.5 Hz, 1H), 7.26–7.19 (m, 2H), 7.02 (td, J = 8.2, 
2.7 Hz, 1H), 6.32 (d, J = 15.8 Hz, 1H), 5.28 (sbr, 1H), 3.77 (s, 3H), 3.53 (s, 2H), 1.26 (s, 9H).  
13
C NMR (100 MHz, CDCl3): δ = 168.9 (Cq), 166.6 (Cq), 162.0 (Cq, 
1
JC–F = 246.7 Hz), 140.6 (CH, 
4
JC–
F = 2.3 Hz), 135.7 (Cq, 
3
JC–F = 7.7 Hz), 132.9 (CH, 
3
JC–F = 8.2 Hz), 130.7 (Cq, 
4
JC–F = 3.2 Hz), 121.2 
(CH), 117.2 (CH, 
2
JC–F = 21.4 Hz), 113.4 (CH, 
2
JC–F = 22.4 Hz), 51.8 (CH3), 51.5 (Cq), 41.4 (CH2), 
28.6 (CH3).  
19
F NMR (376 Hz, CDCl3): δ = –114.3.  
IR (ATR): 2967, 1718, 1645, 1491, 1266, 1171, 977 cm
-1
.  
MS (ESI) m/z (relative intensity): 316 (90) [M+Na]
+
, 294 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C16H21FNO3 [M+H]
+
: 294.1500, found: 294.1502. 
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(E)-Methyl 3-{2-[2-(tert-butylamino)-2-oxoethyl]-5-methoxyphenyl}acrylate (133qc): 
The general procedure A was followed using N-(tert-butyl)-2-(4-methoxyphenyl)acetamide (132q) 
(111 mg, 0.50 mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 133qc (111 mg, 73%) as a white solid.  
M. p. = 142–143 °C.  
1
H NMR (500 MHz, CDCl3): δ = 7.84 (d, J = 15.7 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 7.10 (d, J = 2.1 Hz, 
1H), 6.95–6.89 (m, 1H), 6.35 (d, J = 15.7 Hz, 1H), 5.16 (sbr, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 3.55 (s, 2H), 
1.26 (s, 9H).  
13
C NMR (125 MHz, CDCl3): δ = 207.0 (Cq), 166.9 (Cq), 159.0 (Cq), 141.6 (CH), 134.9 (Cq), 132.5 
(CH), 127.1 (Cq), 120.3 (CH), 116.4 (CH), 111.9 (CH), 55.4 (CH3), 51.8 (CH3), 51.3 (Cq), 41.6 (CH2), 
28.6 (CH3). IR (ATR): 2965, 1715, 1645, 1496, 1228, 1194, 978 cm
-1
. MS (ESI) m/z (relative 
intensity): 328 (33) [M+Na]
+
, 306 (40) [M+H]
+
, 274 (20).  
HR-MS (ESI) m/z calcd for C17H24NO4 [M+H]
+
: 306.1700, found: 306.1703. 
 
 
 
 
(E)-Methyl 3-{5-acetoxy-2-[2-(tert-butylamino)-2-oxoethyl]phenyl}acrylate (133rc): 
The general procedure A was followed using 4-[2-(tert-butylamino)-2-oxoethyl]phenyl acetate (132r) 
(125 mg, 0.50 mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 133rc (117 mg, 70%) as a white solid.  
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M. p. = 128–129 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.77 (d, J = 15.8 Hz, 1H), 7.25 (d, J = 2.1 Hz, 1H), 7.22 (d, J = 8.3 Hz, 
1H), 7.06–7.01 (m, 1H), 6.28 (d, J = 15.8 Hz, 1H), 5.16 (sbr, 1H), 3.73 (s, 3H), 3.51 (s, 2H), 2.24 (s, 3H), 
1.22 (s, 9H).
  
13
C NMR (125 MHz, CDCl3): δ = 169.0 (Cq), 168.6 (Cq), 166.6 (Cq), 150.0 (Cq), 140.7 (CH), 135.1 
(Cq), 132.3 (Cq), 132.2 (CH), 123.4 (CH), 121.0 (CH), 119.8 (CH), 51.8 (CH3), 51.6 (Cq), 41.7 (CH2), 
28.7 (CH3), 21.2 (CH3).  
IR (ATR): 2967, 1762, 1716, 1648, 1203, 1171, 731 cm
-1
.  
MS (ESI) m/z (relative intensity): 356 (50) [M+Na]
+
, 334 (100) [M+H]
+
, 302 (45).  
HR-MS (ESI) m/z calcd for C18H24NO5 [M+H]
+
: 334.1649, found: 334.1646. 
 
 
 
(E)-Methyl 3-{2-[2-(tert-butylamino)-2-oxoethyl]-5-(4-methylphenylsulfonamido)-phenyl}acry-
late (133sc): 
The general procedure A was followed using N-(tert-butyl)-2-[4-(4-methylphenylsulfonamido)-
phenyl]acetamide (132s) (180 mg, 0.50 mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 5/1) yielded 133sc (147 mg, 66%) as a white solid.  
M. p. = 152–153 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.74 (d, J = 15.8 Hz, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.43 (sbr, 1H), 
7.20 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 2.2 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H), 6.97 (dd, J = 8.2, 2.2 Hz, 1H), 
6.17 (d, J = 15.8 Hz, 1H), 5.30 (sbr, 1H), 3.79 (s, 3H), 3.51 (s, 2H), 2.36 (s, 3H), 1.30 (s, 9H).  
13
C NMR (125 MHz, CDCl3): δ = 168.4 (Cq), 165.9 (Cq), 142.9 (Cq), 140.0 (CH), 135.5 (Cq), 135.2 
(Cq), 133.6 (Cq), 131.3 (CH), 130.4 (Cq), 128.6 (CH), 126.2 (CH), 122.5 (CH), 119.8 (CH), 118.7 (CH), 
50.8 (CH3), 50.7 (Cq), 40.5 (CH2), 27.5 (CH3), 20.5 (CH3).  
IR (ATR): 2966, 1718, 1649, 1321, 1159, 1092, 543 cm
-1
.  
MS (ESI) m/z (relative intensity): 467 (100) [M+Na]
+
, 445 (70) [M+H]
+
, 413 (20).  
HR-MS (ESI) m/z calcd for C23H29N2O5S [M+H]
+
: 445.1792, found: 445.1791. 
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(E)-Methyl 3-{4-bromo-2-[2-(tert-butylamino)-2-oxoethyl]phenyl}acrylate (133tc): 
The general procedure A was followed using 2-(3-bromophenyl)-N-(tert-butyl)acetamide (132t) (135 
mg, 0.50 mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133tc (150 mg, 85%) as a white solid. 
Gram-scale reaction: The general procedure A was followed using 2-(3-bromophenyl)-
N-(tert-butyl)acetamide (132t) (1.08 g, 4.00 mmol) and methyl acrylate (5c) (0.69 g, 8.00 mmol) in 
THF (16 mL). Recrystallization from PhMe yielded 133tc (1.17 g, 83%) as a white solid.  
M. p. = 143–144 °C.  
1
H NMR (400 MHz, CDCl3): δ = 7.81 (d, J = 15.8 Hz, 1H), 7.47–7.45 (m, 2H), 7.45–7.44 (m, 1H), 
6.36 (d, J = 15.8 Hz, 1H), 5.30 (sbr, 1H), 3.80 (s, 3H), 3.56 (s, 2H), 1.30 (s, 9H).  
13
C NMR (100 MHz, CDCl3): δ = 168.3 (Cq), 166.8 (Cq), 140.6 (CH), 136.7 (Cq), 134.2 (CH), 132.9 
(Cq), 131.0 (CH), 128.4 (CH), 124.4 (Cq), 120.6 (CH), 51.8 (CH3), 51.7 (Cq), 41.9 (CH2), 28.6 (CH3).  
IR (ATR): 2970, 1713, 1644, 1586, 1315, 1172, 821 cm
-1
.  
MS (ESI) m/z (relative intensity): 376 (95) ([M+Na]
+
, 
79
Br), 356 (100) ([M+H]
+
, 
81
Br).  
HR-MS (ESI) m/z calcd for C16H21
79
BrNO3 [M+H]
+
: 354.0699, found: 354.0699. 
 
 
(E)-Methyl 3-{3-[2-(tert-butylamino)-2-oxoethyl]-[1,1'-biphenyl]-4-yl}acrylate (133uc): 
The general procedure A was followed using 2-([1,1'-biphenyl]-3-yl)-N-(tert-butyl)acetamide (132u) 
(134 mg, 0.50 mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 133uc (158 mg, 90%) as a white solid.  
M. p. = 182–183 °C.  
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1
H NMR (300 MHz, CDCl3): δ = 7.93 (d, J = 15.8 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.61–7.57 (m, 2H), 
7.56 (dd, J = 8.1, 1.5 Hz, 1H), 7.51 (d, J = 1.7 Hz, 1H), 7.48–7.43 (m, 2H), 7.40–7.35 (m, 1H), 6.42 (d, 
J = 15.8 Hz, 1H), 5.25 (sbr, 1H), 3.81 (s, 3H), 3.69 (s, 2H), 1.30 (s, 9H).  
13
C NMR (100 MHz, CDCl3): δ = 169.0 (Cq), 167.0 (Cq), 143.2 (Cq), 141.2 (CH), 139.8 (Cq), 135.4 
(Cq), 132.7 (Cq), 129.9 (CH), 128.9 (CH), 128.0 (CH), 127.5 (CH), 127.0 (CH), 126.5 (CH), 119.9 
(CH), 51.8 (Cq), 51.5 (CH2), 42.6 (CH3), 28.6 (CH3).  
IR (ATR): 2966, 1716, 1645, 1543, 1167, 763, 697 cm
-1
.  
MS (ESI) m/z (relative intensity): 374 (50) [M+Na]
+
, 352 (100) [M+H]
+
, 320 (45).  
HR-MS (ESI) m/z calcd for C22H26NO3 [M+H]
+
: 352.1907, found: 352.1905. 
 
 
(E)-Methyl 3-{2-[2-(tert-butylamino)-2-oxoethyl]-4-methylphenyl}acrylate (133vc): 
The general procedure A was followed using N-(tert-butyl)-2-(m-tolyl)acetamide (132v) (103 mg, 
0.50 mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133vc (132 mg, 91%) as a white solid.  
M. p. = 140–141 °C.  
1
H NMR (400 MHz, CDCl3): δ = 7.86 (d, J = 15.8 Hz, 1H), 7.51 (d, J = 7.9 Hz, 1H), 7.12 (d, J = 7.9 Hz, 
1H), 7.08 (s, 1H), 6.34 (d, J = 15.8 Hz, 1H), 5.10 (sbr, 1H), 3.79 (s, 3H), 3.58 (s, 2H), 2.36 (s, 3H), 1.27 
(s, 9H).  
13
C NMR (100 MHz, CDCl3): δ = 169.2 (Cq), 167.2 (Cq), 141.5 (CH), 140.9 (Cq), 134.8 (Cq), 132.1 
(CH), 131.0 (Cq), 128.8 (CH), 127.0 (CH), 119.1 (CH), 51.7 (CH3), 51.4 (Cq), 42.4 (CH2), 28.6 (CH3), 
21.3 (CH3).  
IR (ATR): 2967, 1717, 1646, 1543, 1173, 1159, 816 cm
-1
.  
MS (ESI) m/z (relative intensity): 312 (100) [M+Na]
+
, 290 (60) [M+H]
+
, 258 (40).  
HR-MS (ESI) m/z calcd for C17H24NO3 [M+H]
+
: 290.1751, found: 290.1754. 
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(E)-n-Butyl 3-{2-[2-(tert-butylamino)-2-oxoethyl]-5-nitrophenyl}acrylate (133wa): 
The general procedure A was followed using N-(tert-butyl)-2-(4-nitrophenyl)acetamide (132w) (118 
mg, 0.50 mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133wa (104 mg, 65%) as a white solid.  
M. p. = 159–160 °C.  
1
H NMR (300 MHz, CDCl3): δ = 8.42 (d, J = 2.3 Hz, 1H), 8.17 (dd, J = 8.4, 2.3 Hz, 1H), 7.86 (d, J = 
15.8 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 6.50 (d, J = 15.8 Hz, 1H), 5.37 (sbr, 1H), 4.22 (t, J = 6.7 Hz, 2H), 
3.67 (s, 2H), 1.71–1.65 (m, 2H), 1.48–1.40 (m, 2H), 1.32 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 166.4 (Cq), 165.1 (Cq), 146.4 (Cq), 140.6 (Cq), 138.3 (CH), 134.6 
(Cq), 131.3 (CH), 123.2 (CH), 122.4 (CH), 120.8 (CH), 63.9 (CH2), 50.9 (Cq), 40.8 (CH2), 29.7 (CH2), 
27.6 (CH3), 18.1 (CH2), 12.7 (CH3).  
IR (ATR): 2962, 1714, 1648, 1547, 1176, 821, 739 cm
-1
.  
MS (ESI) m/z (relative intensity): 385 (100) [M+Na]
+
, 363 (55) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C29H27N2O5 [M+H]
+
: 363.1914, found: 363.1911. 
 
 
(E)-n-Butyl 3-{1-[2-oxo-2-(pyrrolidin-1-yl)ethyl]naphthalen-2-yl}acrylate (133xa): 
The general procedure A was followed using 2-(naphthalen-1-yl)-1-(pyrrolidin-1-yl)ethanone (132x) 
(120 mg, 0.50 mmol) and n-butyl acrylate (5a) (128 mg, 1.00 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 133xa (110 mg, 60%) as a white solid.  
M. p. = 149–150 °C.  
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1
H NMR (300 MHz, CDCl3): δ = 8.14 (d, J = 15.7 Hz, 1H), 7.98–7.94 (m, 1H), 7.84–7.74 (m, 2H), 
7.66 (d, J = 8.7 Hz, 1H), 7.56–7.45 (m, 2H), 6.47 (d, J = 15.7 Hz, 1H), 4.22 (m, 4H), 3.68 (t, J = 6.8 Hz, 
2H), 3.52 (t, J = 6.9 Hz, 2H), 2.15–2.00 (m, 2H), 1.91 (m, 2H), 1.71 (ddd, J = 14.5, 9.6, 6.6 Hz, 2H), 
1.46 (tdd, J = 14.4, 8.4, 6.4 Hz, 2H), 0.98 (t, J = 7.3 Hz, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 168.0 (Cq), 166.9 (Cq), 142.4 (CH), 134.2 (Cq), 132.9 (Cq), 132.1 
(Cq), 131.4 (Cq), 128.5 (CH), 127.8 (CH), 126.8 (CH), 126.4 (CH), 124.7 (CH), 123.6 (CH), 120.7 
(CH), 64.3 (CH2), 46.9 (CH2), 46.1 (CH2), 34.5 (CH2), 30.8 (CH2), 26.4 (CH2), 24.4 (CH2), 19.3 (CH2), 
13.8 (CH3).  
IR (ATR): 2957, 1705, 1628, 1418, 1172, 912, 727 cm
-1
.  
MS (ESI) m/z (relative intensity): 388 (30) [M+Na]
+
, 366 (100) [M+H]
+
, 292 (25).  
HR-MS (ESI) m/z calcd for C23H28NO3 [M+H]
+
: 366.2064, found: 366.2065. 
 
 
(E)-Methyl 3-{3-methyl-2-[2-(methylamino)-2-oxoethyl]phenyl}acrylate (133yc): 
The general procedure A was followed using N-methyl-2-(o-tolyl)acetamide (132y) (81.5 mg, 0.50 
mmol) and methyl acrylate (5c) (86 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133yc (65 mg, 53%) as a white solid.  
M. p. = 112–113 °C.  
1
H NMR (300 MHz, CDCl3): δ = 7.90 (d, J = 15.7 Hz, 1H), 7.43 (dd, J = 6.3, 2.9 Hz, 1H), 7.25–7.22 
(m, 2H), 6.32 (d, J = 15.7 Hz, 1H), 5.20 (sbr, 1H), 3.78 (s, 3H), 3.72 (s, 2H), 2.72 (d, J = 4.8 Hz, 3H), 
2.30 (s, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 170.0 (Cq), 166.7 (Cq), 141.9 (CH), 138.4 (Cq), 134.7 (Cq), 132.5 
(Cq), 132.3 (CH), 127.8 (CH), 125.2 (CH), 121.1 (CH), 51.8 (CH3), 37.3 (CH2), 26.6 (CH3), 20.3 
(CH3).  
IR (ATR): 2950, 1718, 1644, 1599, 1316, 1164, 790 cm
-1
.  
MS (ESI) m/z (relative intensity): 270 (100) [M+Na]
+
, 248 (15) [M+H]
+
, 216 (20).  
HR-MS (ESI) m/z calcd for C14H18NO3 [M+H]
+
: 248.1281, found: 248.1280. 
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(E)-N-(tert-butyl)-2-[2-(1,2-diphenylvinyl)phenyl]acetamide (133'ic): 
The general procedure B was followed using N-(tert-butyl)-2-phenylacetamide (132i) (95.5 mg, 0.50 
mmol) and 1,2-diphenylethyne (51b) (106 mg, 1.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 133'ic (105 mg, 57%) as a white solid.  
M. p. = 135–136 oC. 1H NMR (400 MHz, CDCl3): δ = 7.34–7.28 (m, 4H), 7.20 (ddd, J = 5.8, 2.4, 1.2 
Hz, 3H), 7.17–7.12 (m, 5H), 7.10–7.07 (m, 2H), 6.59 (s, 1H), 4.85 (sbr, 1H), 3.35 (s, 2H), 1.16 (s, 9H).  
13
C NMR (100 MHz, CDCl3): δ = 170.1 (Cq), 144.1 (Cq), 142.0 (Cq), 139.9 (Cq), 136.9 (Cq), 133.7 (Cq), 
131.1 (CH), 130.9 (CH), 130.9 (CH), 129.7 (CH), 129.4 (CH), 128.5 (CH), 128.1 (CH), 128.1 (CH), 
127.6 (CH), 127.1 (CH), 127.0 (CH), 51.0 (CH2), 42.3 (Cq), 28.56 (CH3).  
IR (ATR): 2914, 1694, 1656, 1444, 1221, 747, 696 cm
-1
.  
MS (EI) m/z (relative intensity): 369 (70) [M]
+
, 278 (75), 222 (55).  
HR-MS (ESI) m/z calcd for C26H28NO [M+H]
+
: 370.2145, found: 370.2141.  
 
 
 
(E)-2-{2-[1,2-Bis(4-fluorophenyl)vinyl]-5-bromophenyl}-N-(tert-butyl)acetamide (133'td):  
The general procedure B was followed using 2-(3-bromophenyl)-N-(tert-butyl)acetamide (132t) 
(134.5 mg, 0.50 mmol) and 1,2-bis(4-fluorophenyl)ethyne (51d) (128 mg, 1.00 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 5/1) yielded 133'td (148 mg, 61%) as a white solid.  
M. p. = 135–136 °C.  
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1
H NMR (300 MHz, CDCl3): δ = 7.46 (d, J = 2.0 Hz, 1H), 7.40 (dd, J = 8.3, 2.1 Hz, 1H), 7.12 (d, J 
= 8.0 Hz, 1H), 7.10–7.01 (m, 4H), 6.94–6.83 (m, 4H), 6.53 (s, 1H), 4.85 (sbr, 1H), 3.25 (s, 2H), 1.19 
(s, 9H).
  
13
C NMR (125 MHz, CDC3): δ = 168.7 (Cq), 162.1 (Cq, 
1
JC–F = 248.8 Hz), 161.7 (Cq, 
1
JC–F = 247.6 
Hz), 142.4 (Cq), 139.6 (Cq,), 135.6 (Cq), 135.1 (Cq, 
4
JC–F = 3.8 Hz), 133.8 (CH), 132.4 (Cq, 
4
JC–F = 
3.8 Hz), 132.2 (CH), 131.4 (CH, 
3
JC–F = 8.2 Hz), 130.8 (CH, 
3
JC–F = 8.2 Hz), 130.3 (CH), 130.2 (CH), 
121.9 (Cq), 115.7 (CH, 
2
JC–F = 21.5 Hz), 115.2 (CH, 
2
JC–F = 21.5 Hz), 51.3 (CH2), 41.9 (Cq), 28.7 
(CH3).  
19
F NMR (282 Hz, CDCl3): δ = –113.81, –113.7.  
IR (ATR): 1639, 1544, 1506, 1228, 823, 548  cm
-1
. 
MS (EI) m/z (relative intensity): 485 (25) [M, 
81
Br]
+
, 374 (20), 304 (30).  
HR-MS (ESI) m/z calcd for C26H25
81
BrF2NO [M+H]
+
: 485.1013, found: 485.1010. 
 
 
 
 
(E)-2-[2-(1,2-diphenylvinyl)phenyl]acetamide (133'ac): 
The general procedure B was followed using 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol), 
1,2-diphenylethyne (51b) (106 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (30.6 mg, 10.0 mol %) in 
1,4-dioxane (2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 133'ab 
(103 mg, 66%) as a white solid.  
M. p. = 123–124 oC. 
1
H NMR (400 MHz, CDCl3): δ = 7.38–7.34 (m, 1H), 7.33-7.29 (m, 3H), 7.22–7.18 (m, 3H), 7.18–7.13 
(m, 5H), 7.12-7.08 (m, 2H), 6.63 (s, 1H), 4.91 (sbr, 1H), 3.46 (s, 2H).
  
13
C NMR (100 MHz, CDCl3): δ = 173.1 (Cq), 144.3 (Cq), 141.8 (Cq), 140.0 (Cq), 136.8 (Cq), 133.1 (Cq), 
131.3 (CH), 131.1 (CH), 130.9 (CH), 129.9 (CH), 129.4 (CH), 128.6 (CH), 128.2 (CH), 128.1 (CH), 
127.6 (CH), 127.5 (CH), 127.1 (CH), 40.6 (CH2).  
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IR (ATR): 1666, 1606, 1490, 1441, 1373, 769, 698 cm
-1
.  
MS (EI) m/z (relative intensity): 313 (50) [M]
+
, 268 (30), 222 (65).  
HR-MS (ESI) m/z calcd for C22H20NO [M+H]
+
: 313.1462, found: 313.1465.  
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Sythesis of [D5]-132i 
 
 
 
A solution of the [D]5-PhMgBr in THF (30 mL) was prepared from bromobenzene-d5 (1.62 g, 10 
mmol) and magnesium (0.25 g, 10 mmol). Then, the reaction mixture was cooled to 0 °C and at –
78 °C cold ethylene oxide (approx. 15 mmol) was added. The resulting mixture was allowed to warm 
to 25 °C and then stirred for an additional 6 h. The reaction was stopped by the addition of aq. HCl 
(2N, 10 mL), the solution was extracted with Et2O (3 x 20 mL) and washed with brine (20 mL). The 
combined organic extracts were dried over NaSO4 and concentrated. Purification of the crude 
product by flash chromatography on silica gel (n-hexane/EtOAc 10/1→0/1) yielded 
2-phenylethanol-d5 (0.43 g, 34%).
[136]
 
H5IO6 (1.37 g, 6 mmol) was dissolved in MeCN (20 mL) and the mixture was stirred vigorously at 
25 °C for 15 min and 2-phenylethanol-d5 (0.38g, 3.0 mmol) was added. A solution of PCC (13 mg, 2 
mol %) in MeCN (6 mL) was then added in two portions at 0 °C and the reaction mixture was stirred 
at 25 °C for 3 h. The reaction mixture was then diluted with EtOAc (30 mL) and washed with a 
mixture of brine and water (1:1, 30 mL), sat. aq. NaHSO3 solution (30 mL) and brine (30 mL). The 
solution was dried over Na2SO4 and concentrated to give 2-phenyl acetic acid-d5 (80%). 
2-Phenyl acetic acid-d5 was converted to [D5]-132i following previously reported procedures.
[137] 
1
H NMR (400 MHz, CDCl3): δ = 5.18 (sbr, 1H), 3.46 (s, 2H), 1.26 (s, 9H). 
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Intermolecular competition experiment between amide and ketone 
 
 
 
A suspension of 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol), 2,2-dimethyl-1phenylpro-
pan-1-one (58a) (81.0 mg, 0.50 mmol), n-butyl acrylate (5a) (64 mg, 0.50 mmol), [RuCl2(p-
cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (35.5 mg, 20 mol %) and Cu(OAc)2·H2O (200 mg, 1.00 
mmol) in 1,4-dioxane (2.0 mL) was stirred at 110 °C for 24 h under N2 atomsphere. Afterwards, the 
solvent was removed in vacuo and purification of the remaining residue by column chromatography 
(n-hexane/EtOAc) yieled 133aa (35 mg, 27%) and 141 (76 mg, 53%). 
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1
H NMR (300 MHz, CDCl3): δ = 7.66–7.61 (m, 1H), 7.49 (d, J = 15.9 Hz, 1H), 7.40–7.32 (m, 2H), 
7.20–7.15 (m, 1H), 6.35 (d, J = 15.9 Hz, 1H), 4.19–4.10 (m, 2H), 1.71–1.56 (m, 2H), 1.45–1.34 (m, 
2H), 1.23–1.20 (m, 9H), 0.92 (t, J = 7.4 Hz, 3H).  
13
C NMR (75 MHz, CDCl3): δ = 214.1 (Cq), 166.3 (Cq), 142.0 (Cq), 141.5 (CH), 131.1 (Cq), 129.1 
(CH), 129.0 (CH), 126.6 (CH), 125.3 (CH), 120.5 (CH), 64.5 (CH2), 45.2 (CH2), 30.7 (CH2), 27.2 
(CH3), 19.1 (CH2), 13.7 (CH3).  
IR (ATR): 2961, 1710, 1688, 1463, 1307, 1267, 1177, 962, 758 cm
-1
.  
MS (EI) m/z (relative intensity): 288 (45) [M]
+
, 231 (50), 174 (25).  
HR-MS (ESI) m/z calcd for C18H25O3 [M+H]
+
: 289.1324, found: 289.1327. 
 
Intermolecular competition experiment between arylacetamide and benzamide 
 
 
 
A suspension of 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol), benzamide (9a) (60.5 mg, 0.50 
mmol), n-butyl acrylate (5a) (64 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), 
AgSbF6 (35.5 mg, 20 mol %) and Cu(OAc)2·H2O (200 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL) was 
stirred at 110 °C for 24 h under N2 atomsphere. Afterwards, the solvent was removed in vacuo and 
purification of the remaining residue by column chromatography (n-hexane/EtOAc) yieled 142 (48 
mg, 39%). 
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1
H NMR (400 MHz, CDCl3): δ = 8.08 (d, J = 16.0 Hz, 1H), 7.64–7.61 (m, 1H), 7.58–7.54 (m, 1H), 
7.48–7.43 (m, 1H), 7.40 (td, J = 7.5, 1.4 Hz, 1H), 6.39 (d, J = 16.0 Hz, 1H), 5.89 (sbr, 1H), 5.80 (sbr, 
1H), 4.18 (t, J = 6.7 Hz, 2H), 1.66 (dq, J = 12.2, 6.9 Hz, 2H), 1.46–1.35 (m, 2H), 0.94 (t, J = 7.4 Hz, 
3H).  
13
C NMR (100 MHz, CDCl3): δ = 170.3 (Cq), 166.5 (Cq), 141.8 (CH), 135.8 (Cq), 133.1 (Cq), 130.8 
(CH), 129.8 (CH), 127.8 (CH), 127.3 (CH), 121.1 (CH), 64.6 (CH2), 30.7 (CH2), 19.2 (CH2), 13.7 
(CH3). 
The analytical data are in accordance with previously reported data.
[138]
 
 
 
Intermolecular competition experiment between primary and secondary amide 
 
 
 
A suspension of 2-phenylacetamide (132a) (67.5 mg, 0.50 mmol), N-(tert-butyl)-2-phenylacetamide 
(132i) (95.5 mg, 0.50 mmol), n-butyl acrylate (5a) (64 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (15.3 
mg, 5.0 mol %), AgSbF6 (35.5 mg, 20 mol %) and Cu(OAc)2·H2O (200 mg, 1.00 mmol) in 
1,4-dioxane (2.0 mL) was stirred at 110 °C for 24 h under N2 atomsphere. Afterwards, the solvent 
was removed in vacuo and purification of the remaining residue by column chromatography 
(n-hexane/EtOAc) yieled 133aa (31 mg, 24%) and 133ia (76 mg, 48%). 
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Intermolecular competition experiment between electron-rich and electron-deficient amide 
 
 
A suspension of 2-(4-fluorophenyl)acetamide (132d) (76.5 mg, 0.50 mmol), 
2-(4-methoxyphenyl)acetamide (132i) (82.5 mg, 0.50 mmol), n-butyl acrylate (5a) (64 mg, 0.50 
mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (35.5 mg, 20 mol %) and Cu(OAc)2·H2O 
(200 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL) was stirred at 110 °C for 24 h under N2 atomsphere. 
Afterwards, the solvent was removed in vacuo and purification of the remaining residue by column 
chromatography (n-hexane/EtOAc) yieled 133da (24 mg, 17%) and 133ia (64 mg, 44%). 
 
 
M. p. = 129–130 °C.   
1
H NMR (300 MHz, CDCl3): δ = 7.82 (d, J = 15.7 Hz, 1H), 7.16 (t, J = 8.0 Hz, 1H), 7.07 (d, J = 2.6 Hz, 
1H), 6.88 (dd, J = 8.4, 2.5 Hz, 1H), 6.37 – 6.28 (m, 1H), 5.96 (d, J = 15.9 Hz, 1H), 5.57 (s, 1H), 4.16 (t, 
J = 6.7 Hz, 2H), 3.79 (s, 3H), 3.61 (s, 2H), 1.65 (dt, J = 14.7, 6.8 Hz, 2H), 1.39 (dq, J = 14.4, 7.3 Hz, 
2H), 0.98 – 0.88 (m, 3H).  
13
C NMR (125 MHz, CDCl3): δ = 172.8 (Cq), 166.5 (Cq), 159.0 (Cq), 141.1 (CH), 134.9 (Cq), 132.3 
(CH), 126.5 (Cq), 121.0 (CH), 116.4 (CH), 111.8 (CH), 64.6 (CH2), 55.4 (CH3) , 34.0 (CH2), 30.8 
(CH2), 19.2 (CH2), 13.8 (CH3).  
IR (ATR): 2965, 1705, 1654, 1312, 1264, 1176, 728 cm
-1
.  
MS (ESI) m/z (relative intensity): 314 (100) [M+Na]
+
, 292 (20) [M+H]
+
.  
HR-MS (ESI) m/z calcd for C16H22NO4 [M+H]
+
: 292.1545, found: 292.1542.  
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H/D Exchange Experiments 
 
 
 
 
 
The representative procedure B was followed using 132q (111 mg, 0.50 mmol), 5c (86 mg, 1.0 
mmol), [RuCl2(p-cymene)] (15.3 mg, 5.0 mol %), AgSbF6 (35.5 mg, 20 mol %) and Cu(OAc)2·H2O 
(200 mg, 1.0 mmol) in 1,4-dioxane (1.8 mL) and CD3OD (0.2 mL). Purification by column 
chromatography (n-hexane/EtOAc: 10/1→5/1) yielded [D]n-133qc (91.5 mg, 60%) as a colorless 
solid and reisolated starting material [D]n-132q (38.9 mg, 35%). The deuterium content was 
determinded by NMR spectroscopy. 
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Kinetic Isotope Effect (KIE) Studies 
Under an atmosphere of nitrogen 132i (143 mg, 0.75 mmol) or [D]5-132i (147 mg, 0.75 mmol), 5a 
(192 mg, 1.50 mmol), [RuCl2(p-cymene)]2 (23 mg, 5.0 mol %), AgSbF6 (52 mg, 20 mol %) and 
Cu(OAc)2∙H2O (299 mg, 1.50 mmol) were dissolved in 1,4-dioxane (3.0 mL) and stirred at 100 °C. 
For the first 2 h an in situ IR spectrum was acquired every 30 s, for the following 4 h one spectrum 
was acquired every 1 min and for the remaining 16 h one spectrum was acquired every 2 min. 
The KIE was determined by measuring initial rates from the increase of the peak at 1726 cm
-1
, which 
corresponds to a C=O vibration of product 133ia. The absolute peak area was measured from 1744 to 
1701 cm
-1
 with a one-point baseline at 871 cm
-1
. A linear fit was employed to derive the initial rates. 
 
 
 
 
 
Figure xx. Plot of peak area at 1726 cm
–1
 vs reaction time for 132i (left) and [D]5-132i (right). 
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5.3.2 Ruthenium-Catalyzed C−H Oxygenation 
Analytical Data 
 
 
 
N-(tert-butyl)-2-(2-hydroxyphenyl)acetamide (135ia): 
The general procedure C was followed using N-(tert-butyl)-2-phenylacetamide (132i) (95.5 mg, 0.50 
mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) in DCE (2.0 
mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 135ia (64.2 mg, 62%) as a 
white solid. 
M.p. = 125–126 oC. 
1
H NMR (300 MHz, CDCl3): δ = 10.25 (sbr, 1H), 7.20 (m, 1H), 7.03–6.97 (m, 2H), 6.84 (t, J = 7.4 Hz, 
1H), 5.89 (sbr, 1H), 3.51 (s, 2H), 1.37 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 173.1 (Cq), 156.6 (Cq), 130.4 (CH), 129.0 (CH), 121.9 (Cq), 120.1 
(CH), 118.1 (CH), 52.2 (Cq), 42.4 (CH2), 28.6 (CH3). 
IR (ATR): 1632, 1555, 1492, 1355, 1057, 942, 797 cm
–1
. 
MS (EI) m/z (relative intensity): 207 (40) [M]
+
, 134 (65), 108 (70).  
HR-MS (EI) m/z calcd for C12H17NO2
+
 [M]
+
: 207.1259, found: 207.1261. 
 
 
 
n-Butyl-2-(2-hydroxyphenyl)acetamide (135ja): 
The general procedure C was followed using n-butyl-2-phenylacetamide (132j) (95.5 mg, 0.50 
mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) in DCE (2.0 
mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 135ja (73.5 mg, 71%) as a 
white solid. 
M.p. = 130–131 oC. 
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1
H NMR (300 MHz, CDCl3): δ = 9.98 (sbr, 1H), 7.19 (td, J = 7.9, 1.7 Hz, 1H), 7.05–6.97 (m, 2H), 6.84 
(td, J = 7.4, 1.2 Hz, 1H), 6.24 (sbr, 1H), 3.58 (s, 2H), 3.26 (td, J = 7.1, 5.9 Hz, 2H), 1.57–1.44 (m, 2H), 
1.41–1.26 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 173.4 (Cq), 156.2 (Cq), 130.5 (CH), 129.1 (CH), 121.6 (Cq), 120.3 
(CH), 117.9 (CH), 41.1 (CH2), 39.9 (CH2), 31.3 (CH2), 20.0 (CH2), 13.7 (CH3). 
IR (ATR): 1630, 1542, 1488, 1299, 1057, 966 cm
–1
. 
MS (EI) m/z (relative intensity): 207 (70) [M]
+
, 134 (50), 108 (100).  
HR-MS (EI) m/z calcd for C12H17NO2
+
 [M]
+
: 207.1259, found: 207.1258. 
 
 
 
 
(R)-2-(2-hydroxyphenyl)-N-(1-phenylethyl)acetamide (135na): 
The general procedure C was followed using (R)-2-phenyl-N-(1-phenylethyl)acetamide (132n) 
(119.5 mg, 0.50 mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %) in DCE (2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 
135na (80.3 mg, 63%) as a white solid. 
M.p. = 140–141 oC. 
1
H NMR (400 MHz, CDCl3): δ = 9.77 (sbr, 1H), 7.31 (m, 2H), 7.28–7.24 (m, 3H), 7.20–7.11 (m, 1H), 
6.96 (m, 2H), 6.83–6.77 (m, 1H), 6.27 (sbr, 1H), 5.06 (m, 1H), 3.61–3.46 (m, 2H), 1.47 (d, J = 6.9 Hz, 
3H). 
13
C NMR (100 MHz, CDCl3): δ = 172.5 (Cq), 156.2 (Cq), 142.2 (Cq), 130.4 (CH), 129.2 (CH), 128.8 
(CH), 127.7 (CH), 126.1 (CH), 121.4 (Cq), 120.2 (CH), 118.1 (CH), 49.5 (CH), 41.2 (CH2), 21.4 
(CH3). 
IR (ATR): 1635, 1521, 1438, 1219, 1059, 734 cm
–1
. 
MS (EI) m/z (relative intensity): 255 (30) [M]
+
, 178 (45), 108 (70).  
HR-MS (EI) m/z calcd for C16H17NO2
+
 [M]
+
: 255.1259, found: 255.1257. 
HPLC (n-hexane/EtOAc: 80/20): t = 14.39 min. 
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3-{2-(2-hydroxyphenyl)acetamido}propyl acetate (135oa): 
The general procedure C was followed using 3-(2-phenylacetamido)propyl acetate (132o) (117.5 mg, 
0.50 mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) in DCE 
(2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 135oa (80.3 mg, 64%) 
as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 9.66 (sbr, 1H), 7.18–7.12 (m, 1H), 7.02–6.91 (m, 2H), 6.83–6.77 (m, 
1H), 5.66 (sbr, 1H), 4.13–4.06 (m, 2H), 3.53 (s, 2H), 3.31–3.24 (m, 2H), 2.06–2.01 (m, 2H), 1.84–1.76 
(m, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 173.2 (Cq), 171.3 (Cq), 156.0 (Cq), 130.3 (CH), 129.1 (CH), 121.4 
(Cq), 120.2 (CH), 117.9 (CH), 61.7 (CH2), 41.1 (CH2), 36.7 (CH2), 28.4 (CH2), 21.0 (CH3). 
IR (ATR): 1637, 1541, 1366, 1236, 1041, 754 cm
–1
. 
MS (EI) m/z (relative intensity): 251 (30) [M]
+
, 191 (25), 134 (40).  
HR-MS (EI) m/z calcd for C13H17NO4
+
 [M]
+
: 251.1158, found: 251.1158. 
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N-(tert-butyl)-2-(2-hydroxy-4-methylphenyl)acetamide (135za): 
The general procedure C was followed using N-(tert-butyl)-2-(p-tolyl)acetamide (132z) (102.5 mg, 
0.50 mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) in DCE 
(2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 135za (56.4 mg, 51%) 
as a white solid. 
M.p. = 118–119 oC. 
1
H NMR (300 MHz, CDCl3): δ = 10.04 (sbr, 1H), 6.83 (d, J = 7.6 Hz, 1H), 6.78 (d, J = 0.8 Hz, 1H), 
6.61 (ddd, J = 7.6, 1.7, 0.8 Hz, 1H), 5.64 (sbr, 1H), 3.41 (s, 2H), 2.26 (s, 3H), 1.33 (s, 9H). 
13
C NMR (125 MHz, CDCl3): δ = 173.0 (Cq), 156.3 (Cq), 139.0 (Cq), 129.9 (CH), 120.6 (CH), 118.8 
(CH), 118.6 (Cq), 52.2 (Cq), 42.3 (CH2), 28.6 (CH3), 21.2 (CH3). 
IR (ATR): 1641, 1548, 1364, 1222, 909, 733 cm
–1
. 
MS (EI) m/z (relative intensity): 221 (25) [M]
+
, 148 (50), 120 (70).  
HR-MS (EI) m/z calcd for C13H19NO2
+
 [M]
+
: 221.1416, found: 221.1413. 
 
 
 
 
N-(tert-Butyl)-2-(4-hydroxy-[1,1'-biphenyl]-3-yl)acetamide (135ua): 
The general procedure C was followed using 2-([1,1'-biphenyl]-3-yl)-N-(tert-butyl)acetamide (132u) 
(133.5 mg, 0.50 mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %) in DCE (2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 
135ua (75 mg, 53%) as a white solid. 
M.p. = 145–146 oC. 
1
H NMR (300 MHz, CDCl3): δ = 10.45 (sbr, 1H), 7.55 (d, J = 1.6 Hz, 1H), 7.53 (dd, J = 3.0, 1.6 Hz, 
1H), 7.44 (m, 3H), 7.34–7.27 (m, 1H), 7.25 (d, J = 2.6 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 5.92 (sbr, H), 
3.58 (s, 2H), 1.39 (s, 9H). 
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13
C NMR (75 MHz, CDCl3): δ = 173.0 (Cq), 156.2 (Cq), 140.8 (Cq), 133.2 (Cq), 129.2 (CH), 128.7 
(CH), 127.7 (CH), 126.7 (CH), 126.6 (CH), 122.1 (Cq), 118.5 (CH), 52.2 (Cq), 42.7 (CH2), 28.6 (CH3). 
IR (ATR): 1643, 1556, 1483, 1357, 1054, 964, 826 cm
–1
. 
MS (EI) m/z (relative intensity): 283 (20) [M]
+
, 210 (100), 182 (70).  
HR-MS (EI) m/z calcd for C18H21NO2
+
 [M]
+
: 283.1572, found: 283.1569. 
 
 
 
N-(tert-Butyl)-2-(4-fluoro-2-hydroxyphenyl)acetamide (135pa): 
The general procedure C was followed using N-(tert-butyl)-2-(4-fluorophenyl)acetamide (132p) 
(104.5 mg, 0.50 mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %) in DCE (2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 
135pa (70.9 mg, 63%) as a white solid. 
M.p. = 115–116 oC. 
1
H NMR (300 MHz, CDCl3): δ = 10.71 (sbr, 1H), 6.93 (t, J = 8.3, 1H), 6.70 (dd, J = 10.4, 2.6 Hz, 1H), 
6.53 (td, J = 8.3, 2.6 Hz, 1H), 5.83 (sbr, 1H), 3.46 (s, 2H), 1.38 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 172.9 (Cq), 164.8 (Cq, 
1
JC–F = 245.2 Hz), 158.0 (Cq, 
3
JC–F = 12.4 
Hz), 130.8 (CH, 
3
JC–F = 10.5 Hz), 117.6 (Cq, 
4
JC–F = 2.8 Hz), 106.5 (CH, 
2
JC–F = 21.4 Hz), 105.4 (CH, 
2
JC–F = 24.1 Hz), 52.2 (Cq), 41.6 (CH2), 28.4 (CH3).  
IR (ATR): 1643, 1604, 1517, 1264, 906, 729, 650 cm
–1
. 
MS (EI) m/z (relative intensity): 225 (30) [M]
+
, 152 (40), 126 (60).  
HR-MS (EI) m/z calcd for C12H16FNO2
+
 [M]
+
: 225.1165, found: 225.1161. 
 
 
 
2-(5-Bromo-2-hydroxyphenyl)-N-(tert-butyl)acetamide (135ta): 
The general procedure C was followed using 2-(3-bromophenyl)-N-(tert-butyl)acetamide (132t) (135 
mg, 0.50 mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) in 
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DCE (2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 135ta (108.7 
mg, 76%) as a white solid. 
M.p. = 132–133 oC. 
1
H NMR (300 MHz, CDCl3): δ = 10.40 (sbr, 1H), 7.25–7.20 (m, 1H), 7.08 (d, J = 2.4 Hz, 1H), 6.83 (d, 
J = 8.6 Hz, 1H), 5.77 (sbr, 1H), 3.41 (s, 2H), 1.33 (s, 9H). 
13
C NMR (125 MHz, CDCl3): δ = 172.3 (Cq), 155.9 (Cq), 132.6 (CH), 131.7 (CH), 123.8 (Cq), 120.0 
(CH), 111.5 (Cq), 52.5 (Cq), 42.2 (CH2), 28.6 (CH3). 
IR (ATR): 1634, 1566, 1412, 1268, 1151, 817, 628 cm
–1
. 
MS (EI) m/z (relative intensity): 285 (15) [M, 
79
Br]
+
, 211 (45), 186 (40).  
HR-MS (EI) m/z calcd for C12H16
79
BrNO2
+
 [M]
+
: 285.0364, found: 285.0363. 
 
 
 
4-(2-(tert-Butylamino)-2-oxoethyl)-3-hydroxyphenyl acetate (135ra): 
The general procedure C was followed using 4-(2-(tert-butylamino)-2-oxoethyl)phenyl acetate (132r) 
(124.5 mg, 0.50 mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %) in DCE (2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 
135ra (63.6 mg, 48%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 10.57 (sbr, 1H), 6.92 (d, J = 8.2 Hz, 1H), 6.66 (d, J = 2.4 Hz, 1H), 
6.54 (dd, J = 8.2, 2.4 Hz, 1H), 5.71 (sbr, 1H), 3.42 (s, 2H), 2.25 (s, 3H), 1.32 (s, 9H). 
13
C NMR (125 MHz, CDCl3): δ = 172.7 (Cq), 169.3 (Cq), 157.6 (Cq), 151.0 (Cq), 130.5 (CH), 121.9 
(Cq), 112.9 (CH), 111.6 (CH), 52.4 (Cq), 42.2 (CH2), 28.6 (CH3), 21.2 (CH3). 
IR (ATR): 1640, 1552, 1392, 1205, 1145, 731 cm
–1
. 
MS (EI) m/z (relative intensity): 265 (20) [M]
+
, 193 (30), 165 (60).  
HR-MS (EI) m/z calcd for C14H19NO4
+
 [M]
+
: 265.1314, found: 265.1312. 
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N-(tert-butyl)-2-(2-hydroxy-4-nitrophenyl)acetamide (135wa): 
The general procedure C was followed using N-(tert-butyl)-2-(4-nitrophenyl)acetamide (132w) (118 
mg, 0.50 mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) in 
DCE (2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 135wa (81.9 mg, 
65%) as a white solid. 
M.p. = 128–129 oC. 
1
H NMR (300 MHz, CDCl3): δ = 11.06 (sbr, 1H), 7.81 (d, J = 2.3 Hz, 1H), 7.69 (dd, J = 8.3, 2.3 Hz, 
1H), 7.14 (d, J = 8.3 Hz, 1H), 5.81 (sbr, 1H), 3.60 (s, 2H), 1.39 (s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 170.1 (Cq), 157.7 (Cq), 148. 7 (Cq), 130.0 (CH), 127.7 (Cq), 114.6 
(CH), 113.2 (CH), 51.7 (Cq), 42.1 (CH2), 27.8 (CH3). 
IR (ATR): 1643, 1520, 1426, 1318, 899, 730 cm
–1
. 
MS (EI) m/z (relative intensity): 252 (20) [M]
+
, 179 (50), 153 (90).  
HR-MS (EI) m/z calcd for C12H16N2O4
+
 [M]
+
: 252.1110, found: 252.1109. 
 
 
 
 
2-(2-Bromo-6-hydroxyphenyl)-n-butylacetamide (135'aa) : 
The general procedure C was followed using 2-(2-bromophenyl)-n-butylacetamide (132'a) (134.5 
mg, 0.50 mmol), PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) in 
DCE (2.0 mL). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 135'aa (82.6 mg, 
58%) as a white solid. 
M.p. = 133–134 oC. 
1
H NMR (300 MHz, CDCl3): δ = 9.99 (sbr, 1H), 7.13 (dd, J = 7.8, 1.4 Hz, 1H), 7.04 (dd, J = 8.0, 7.8 Hz, 
1H), 6.96 (dd, J = 8.0, 1.4 Hz, 1H), 5.99 (sbr, 1H), 3.83 (s, 2H), 3.29 (m, 2H), 1.59–1.47 (m, 2H), 1.42–
1.30 (m, 2H), 0.93 (t, J = 9.1, 3H). 
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13
C NMR (75 MHz, CDCl3): δ = 172.5 (Cq), 157.3 (Cq), 129.6 (CH), 124.3 (CH), 124.2 (Cq), 122.1 
(Cq), 117.7 (CH), 39.9 (CH2), 39.7 (CH2), 31.2 (CH2), 19.9 (CH2), 13.6 (CH3). 
IR (ATR): 1643, 1538, 1484, 1361, 1063, 963, 866 cm
–1
. 
MS (EI) m/z (relative intensity): 285 (40) [M, 
79
Br]
+
, 206 (90), 186 (70).  
HR-MS (EI) m/z calcd for C12H16
79
BrNO2
+
 [M]
+
: 285.0364, found: 285.0360. 
 
 
 
 
Methyl 2-(2-hydroxyphenyl)acetate (135aa): 
The general procedure C was followed using methyl 2-phenylacetate (134a) (75 mg, 0.50 mmol), 
PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) in DCE (2.0 mL). 
Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 135aa (41.5 mg, 50%) as a 
colorless liquid. 
1
H NMR (400 MHz, CDCl3): δ = 7.30 (sbr, 1H), 7.21–7.15 (m, 1H), 7.10–7.06 (m, 1H), 6.93 (dd, J = 
8.1, 0.9 Hz, 1H), 6.87 (td, J = 7.4, 1.2 Hz, 1H), 3.74 (s, 3H), 3.67 (s, 2H). 
13
C NMR (100 MHz, CDCl3): δ = 174.3 (Cq), 155.2 (Cq), 131.0 (CH), 129.3 (CH), 121.0 (CH), 120.5 
(Cq), 117.7 (CH), 52.8 (CH3), 37.8 (CH2). 
IR (ATR): 1642, 1535, 1412, 1228, 1058, 914, 730 cm
–1
. 
MS (EI) m/z (relative intensity): 166 (20) [M]
+
, 134 (90), 106 (80).  
HR-MS (EI) m/z calcd for C9H10O3
+
 [M]
+
: 166.0630, found: 166.0627. 
 
 
 
Ethyl 2-(2-hydroxyphenyl)acetate (135ba): 
The general procedure C was followed using ethyl 2-phenylacetate (134b) (82 mg, 0.50 mmol), 
PhI(TFA)2 (430 mg, 1.00 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) in DCE (2.0 mL). 
Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 135ba (45 mg, 50%) as a 
colorless liquid. 
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1
H NMR (300 MHz, CDCl3): δ = 7.63 (sbr, 1H), 7.26–7.19 (m, 1H), 7.12 (d, J = 6.3 Hz, 1H), 7.00–6.87 
(m, 2H), 4.23 (q, J = 7.2 Hz, 2H), 3.70 (s, 2H), 1.31 (t, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 166.7 (Cq), 144.4 (Cq), 131.0 (CH), 129.2 (CH), 120.9 (CH), 117.9 
(Cq), 100.0 (CH), 62.0 (CH2), 38.2 (CH2), 14.0 (CH3). 
IR (ATR): 1703, 1642, 1422, 1359, 1110, 964, 732 cm
–1
. 
MS (EI) m/z (relative intensity): 180 (20) [M]
+
, 134 (90), 106 (85).  
HR-MS (EI) m/z calcd for C10H12O3
+
 [M]
+
: 180.0786, found: 180.0789. 
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5.3.3 Cobalt-Catalyzed C−H Arylation 
Analytical Data 
 
 
 
N-(Quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137ba):  
The general procedure D was followed using N-(quinolin-8-yl)benzamide 9b (62 mg, 0.25 mmol) 
and trimethoxy(phenyl)silane 136a (99 mg, 0.50 mmol). Isolation by column chromatography 
(n-hexane/acetone: 10/1) yielded 137ba (56.7 mg, 70%) as a white solid. 
M. p. = 125–126 °C. 
1
H NMR (300 MHz, CDCl3): δ = 9.77 (sbr, 1H), 8.80 (dd, J = 7.4, 1.5 Hz, 1H), 8.51 (dd, J = 4.2, 1.7 Hz, 
1H), 8.05 (dd, J = 8.3, 1.7 Hz, 1H), 7.90 (dd, J = 3.1, 1.9 Hz, 1H), 7.60–7.39 (m, 7H), 7.36–7.24 (m, 
3H), 7.18–7.11 (m, 1H).  
13
C NMR (125 MHz, CDCl3): δ = 167.6 (Cq), 147.6 (CH), 140.2 (Cq), 139.9 (Cq), 138.3 (Cq), 136.0 
(Cq), 135.9 (CH), 134.5 (Cq), 130.6 (CH), 130.4 (CH), 129.1 (CH), 128.9 (CH), 128.3 (Cq), 127.6 (CH), 
127.5 (CH), 127.5 (CH), 127.2 (CH), 121.4 (CH), 121.3 (CH), 116.2 (CH).  
IR (ATR): 1669, 1523, 1483, 1326, 826, 765 cm
–1
.  
MS (EI) m/z (relative intensity): 324 (40) [M]
+
, 181 (100), 152 (55).  
HR-MS (EI) m/z calcd for C22H16N2O
+
 [M]
+
: 380.1263, found: 324.1257. 
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3-Methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137aa):  
The general procedure D was followed using 2-methyl-N-(quinolin-8-yl)benzamide 9a (65.5 mg, 
0.25 mmol) and trimethoxy(phenyl)silane 136a (99 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137aa (60.8 mg, 72%) as a pale yellow solid. 
M. p. = 120–121 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.61 (sbr, 1H), 8.75 (dd, J = 7.4, 1.6 Hz, 1H), 8.59 (dd, J = 4.2, 1.7 
Hz, 1H), 8.06 (dd, J = 8.3, 1.7 Hz, 1H), 7.51 (dd, J = 3.4, 1.3 Hz, 1H), 7.50–7.49 (m, 1H), 7.48 (d, J 
= 7.4 Hz, 1H), 7.45–7.41 (m, 1H), 7.40–7.37 (m, 1H), 7.34 (dd, J = 8.3, 4.2 Hz, 1H), 7.30 (dd, J = 
1.6, 0.6 Hz, 1H), 7.28 (ddd, J = 2.0, 1.3, 0.7 Hz, 1H), 7.22–7.17 (m, 2H), 7.10–7.05 (m, 1H), 2.52 (s, 
3H).  
13
C NMR (100 MHz, CDCl3): δ = 168.3 (Cq), 148.0 (CH), 140.4 (Cq), 139.7 (Cq), 138.4 (Cq), 136.9 
(Cq), 136.1 (CH), 135.8 (Cq), 134.4 (Cq), 129.5 (CH), 129.2 (CH), 128.6 (CH), 128.1 (CH), 127.8 
(Cq), 127.6 (CH), 127.2 (CH), 127.2 (CH), 121.6 (CH), 121.4 (CH), 116.4 (CH), 19.8 (CH3).  
IR (ATR): 1671, 1483, 1424, 1328, 791, 698 cm
–1
.  
MS (EI) m/z (relative intensity): 338 (25) [M]
+
, 195 (30).  
HR-MS (ESI) m/z calcd for C23H18N2O
+
 [M]
+
: 338.1419, found: 338.1419. 
 
 
 
4-Methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137ca):  
The general procedure D was followed using 3-methyl-N-(quinolin-8-yl)benzamide 9c (65.5 mg, 
0.25 mmol) and trimethoxy(phenyl)silane 136a (98 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137ca (51.5 mg, 61%) as a white solid.  
M. p. = 136–137 °C. 
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1
H NMR (400 MHz, CDCl3): δ = 9.72 (sbr, 1H), 8.79 (dd, J = 7.6, 1.3 Hz, 1H), 8.49 (dd, J = 4.2, 1.7 
Hz, 1H), 8.05 (dd, J = 8.3, 1.7 Hz, 1H), 7.71 (d, J = 0.8 Hz, 1H), 7.49 (dd, J = 8.4, 7.4 Hz, 3H), 7.43 
(dd, J = 8.3, 1.4 Hz, 1H), 7.36 (d, J = 0.9 Hz, 2H), 7.32 (dd, J = 8.3, 4.2 Hz, 1H), 7.27–7.23 (m, 2H), 
7.12 (ddd, J = 8.7, 2.5, 1.3 Hz, 1H), 2.46 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 168.0 (Cq), 147.7 (CH), 134.0 (Cq), 138.4 (Cq), 137.5 (Cq), 137.4 
(Cq), 136.0 (Cq), 135.9 (CH), 134.6 (Cq), 131.2 (CH), 130.6 (CH), 129.8 (CH), 129.0 (CH), 128.3 
(CH), 127.7 (Cq), 127.4 (CH), 127.3 (CH), 121.4 (CH), 121.3 (CH), 116.2 (CH), 21.0 (CH3).  
IR (ATR): 1659, 1519, 1482, 1279, 766, 665 cm
–1
.  
MS (EI) m/z (relative intensity): 338 (35) [M]
+
, 195 (100), 152 (30).  
HR-MS (EI) m/z calcd for C23H18N2O
+
 [M]
+
: 338.1419, found: 338.1420. 
 
 
 
 
5-Methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137da):  
The general procedure D was followed using 4-methyl-N-(quinolin-8-yl)benzamide 9d (65.5 mg, 
0.25 mmol) and trimethoxy(phenyl)silane 136a (99 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137da (49 mg, 58%) as a white solid. 
M. p. = 118–119 °C. 
1
H NMR (300 MHz, CDCl3): δ = 9.74 (Sbr, 1H), 8.79 (dd, J = 7.5, 1.4 Hz, 1H), 8.49 (dd, J = 4.2, 1.7 Hz, 
1H), 8.04 (dd, J = 8.3, 1.7 Hz, 1H), 7.82 (d, J = 7.5 Hz, 1H), 7.50 (dd, J = 3.5, 2.1 Hz, 1H), 7.49–7.46 
(m, 2H), 7.44–7.40 (m, 1H), 7.34–7.29 (m, 2H), 7.29–7.25 (m, 3H), 7.17–7.11 (m, 1H), 2.45 (s, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 167.6 (Cq), 147.5 (CH), 140.6 (Cq), 140.2 (Cq), 140.1 (Cq), 138.3 
(Cq), 135.8 (CH), 134.6 (Cq), 133.3 (Cq), 131.3 (CH), 129.3 (CH), 128.9 (CH), 128.2 (CH), 128.2 
(CH), 127.6 (Cq), 127.4 (CH), 127.2 (CH), 121.2 (CH), 121.2 (CH), 116.1 (CH), 21.5 (CH3).  
IR (ATR): 1661, 1520, 1482, 1263, 853, 765 cm
–1
.  
MS (EI) m/z (relative intensity): 338 (30) [M]
+
, 195 (90), 165 (30).  
HR-MS (EI) m/z calcd for C23H18N2O
+
 [M]
+
: 338.1419, found: 338.1423. 
 
  Experimental Section  
127 
 
 
 
2,6-Dimethyl-N-(quinolin-8-yl)-[1,1':3',1''-terphenyl]-2'-carboxamide (137eb): 
The general procedure D was followed using N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide 9e (81 
mg, 0.25 mmol) and (2,6-dimethylphenyl)trimethoxysilane 136b (113 mg, 0.50 mmol). Isolation by 
column chromatography (n-hexane/acetone: 10/1) yielded 137eb (70 mg, 68%) as a white solid. 
M. p. = 210–211 °C. 
1
H NMR (300 MHz, CDCl3): δ = 9.48 (sbr, 1H), 8.59 (dd, J = 4.2, 1.7 Hz, 1H), 8.39 (dd, J = 6.1, 2.9 Hz, 
1H), 8.03–7.99 (m, 1H), 7.59–7.54 (m, 3H), 7.50–7.47 (m, 1H), 7.37–7.28 (m, 4H), 7.23–7.17 (m, 3H), 
7.15–7.08 (m, 1H), 6.95 (d, J = 1.7 Hz, 2H), 2.20 (s, 6H). 
13
C NMR (125 MHz, CDCl3): δ = 166.8 (Cq), 147.5 (CH), 140.4 (Cq), 140.3 (Cq), 139.5 (Cq), 139.4 
(Cq), 138.1 (Cq), 136.3 (Cq), 136.3 (Cq), 135.8 (CH), 134.2 (Cq), 129.4 (CH), 129.0 (CH), 128.8 (CH), 
128.7 (CH), 128.1 (CH), 127.5 (Cq), 127.2 (CH), 127.2 (CH), 127.1 (CH), 127.0 (CH), 121.2 (CH), 
121.0 (CH), 116.1 (CH), 21.0 (CH3).  
IR (ATR): 1673, 1517, 1480, 1324, 824, 698 cm
–1
. 
MS (EI) m/z (relative intensity): 428 (30) [M]
+
, 285 (100), 241 (30), 144 (80).  
HR-MS (EI) m/z calcd for C30H24N2O
+
 [M]
+
: 428.1889, found: 428.1888. 
 
 
 
3-Fluoro-2',6'-dimethyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137fb):  
The general procedure D was followed using 2-fluoro-N-(quinolin-8-yl)benzamide 9f (66.5 mg, 0.25 
mmol) and (2,6-dimethylphenyl)trimethoxysilane 136b (113 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137fb (48 mg, 52%) as a white solid. 
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M. p. = 160–161 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.87 (sbr, 1H), 8.72 (dd, J = 4.2, 1.7 Hz, 1H), 8.66 (dd, J = 6.2, 2.9 Hz, 
1H), 8.09 (dd, J = 8.4, 1.7 Hz, 1H), 7.53–7.46 (m, 1H), 7.44–7.37 (m, 3H), 7.21 (ddd, J = 9.4, 8.4, 1.1 
Hz, 1H), 7.02–6.99 (m, 1H), 6.99–6.94 (m, 3H), 2.16 (s, 6H). 
13
C NMR (100 MHz, CDCl3): δ = 162.5 (Cq), 159.9 (Cq, 
1
JC-F = 250.1 Hz), 147.9 (CH), 141.6 (Cq, 
3
JC-F = 11.0 Hz), 138.3 (Cq), 138.2 (Cq, 
4
JC-F = 2.0 Hz), 136.1 (Cq), 134.2 (Cq), 131.2 (CH, 
3
JC-F = 9.0 
Hz), 128.4 (CH), 127.8 (Cq), 127.6 (CH), 127.3 (CH), 125.9 (CH, 
4
JC-F = 3.2 Hz), 125.4 (Cq, 
2
JC-F = 
16.3 Hz), 121.7 (CH), 121.5 (CH), 116.6 (CH), 114.9 (CH), 114.8 (CH, 
2
JC-F = 22.0 Hz), 20.7 (CH3).  
19
F NMR (376 MHz, CDCl3): δ = –114.6. 
IR (ATR): 1677, 1520, 1483, 1423, 905, 757 cm
–1
. 
MS (EI) m/z (relative intensity): 370 (20) [M]
+
, 227 (20), 183 (35), 144 (100).  
HR-MS (EI) m/z calcd for C24H19FN2O
+
 [M]
+
: 370.1481, found: 370.1484. 
 
 
 
 
2',6'-Dimethyl-N-(quinolin-8-yl)-3-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide (137gb): 
The general procedure D was followed using N-(quinolin-8-yl)-2-(trifluoromethyl)benzamide 9g 
(65.5 mg, 0.25 mmol) and (2,6-dimethylphenyl)trimethoxysilane 136b (113 mg, 0.50 mmol). 
Isolation by column chromatography (n-hexane/acetone: 10/1) yielded 137gb (53 mg, 50%) as a 
white solid. 
M. p. = 145–146 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.73 (sbr, 1H), 8.69 (dd, J = 4.2, 1.7 Hz, 1H), 8.56 (dd, J = 6.6, 2.4 Hz, 
1H), 8.08 (dd, J = 8.3, 1.7 Hz, 1H), 7.79 (dd, J = 7.8, 0.6 Hz, 1H), 7.64 (td, J = 7.8, 0.8 Hz, 1H), 7.44–
7.36 (m, 4H), 6.95 (dd, J = 9.0, 5.5 Hz, 1H), 6.92–6.88 (m, 2H), 2.15 (s, 6H). 
13
C NMR (100 MHz, CDCl3): δ = 164.5 (Cq), 147.9 (CH), 140.4 (Cq), 138.2 (Cq), 137.7 (Cq), 136.3 
(Cq), 136.1 (CH), 135.3 (Cq, 
3
JC-F= 2.0 Hz), 134.0 (Cq), 133.7 (CH), 129.6 (CH), 128.1 (Cq, 
2
JC-F= 
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31.0 Hz), 127.9 (CH), 127.7 (Cq), 127.3 (CH), 127.3 (CH), 125.3 (CH, 
3
J = 4.9 Hz), 123.8 (Cq, 
1
J = 
272.0 Hz), 121.7 (CH), 121.5 (CH), 116.5 (CH), 20.8 (CH3).  
19
F NMR (376 Hz, CDCl3): δ = –58.9.
  
IR (ATR): 1680, 1526, 1322, 1127, 822, 789 cm
–1
. 
MS (EI) m/z (relative intensity): 420 (20) [M]
+
, 276 (80), 248 (30).  
HR-MS (EI) m/z calcd for C25H19F3N2O
+
 [M]
+
: 420.1443, found: 420.1446. 
 
 
 
2',4',6'-Trimethyl-N-(quinolin-8-yl)-3-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide (137gc): 
The general procedure D was followed using N-(quinolin-8-yl)-2-(trifluoromethyl)benzamide 9g 
(65.5 mg, 0.25 mmol) and mesityltrimethoxysilane 136c (120 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137gc (51 mg, 47%) as a white solid. 
M. p. = 158–159 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.74 (sbr, 1H), 8.69 (dd, J = 4.2, 1.7 Hz, 1H), 8.58 (dd, J = 6.1, 2.9 
Hz, 1H), 8.08 (dd, J = 8.3, 1.7 Hz, 1H), 7.79–7.76 (m, 1H), 7.62 (td, J = 7.8, 0.8 Hz, 1H), 7.44–7.37 
(m, 4H), 6.73 (d, J = 0.6 Hz, 2H), 2.10 (s, 9H).  
13
C NMR (100 MHz, CDCl3): δ = 164.7 (Cq), 147.9 (CH), 140.6 (Cq), 138.2 (Cq), 137.3 (Cq), 136.1 
(CH), 135.5 (CH, 
3
JC–F = 5.0 Hz), 134.9 (Cq), 134.1 (Cq), 134.0 (Cq), 129.5 (CH), 128.0 (Cq, 
2
JC–F = 
31.3 Hz), 128.1 (CH), 127.7 (Cq), 127.3 (CH), 125.2 (CH, 
3
JC–F = 11.2 Hz), 121.9 (Cq, 
3
JC–F = 5.3 Hz), 
121.7 (CH), 121.5 (CH), 118.3 (Cq, 
1
JC–F = 279.3 Hz), 116.5 (CH), 20.9 (CH3), 20.7 (CH3).  
19
F NMR (376 MHz, CDCl3): δ = –58.9. 
IR (ATR): 1682, 1528, 1485, 1117, 822, 693 cm
–1
.  
MS (EI) m/z (relative intensity): 434 (30) [M]
+
, 291 (20), 144 (100).  
HR-MS (EI) m/z calcd for C26H24N2O
+
 [M]
+
: 434.1606, found: 434.1606. 
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3-Phenyl-N-(quinolin-8-yl)-2-naphthamide (137ha): 
The general procedure D was followed using N-(quinolin-8-yl)-2-naphthamide 9h (74.5 mg, 0.25 
mmol) and trimethoxy(phenyl)silane 136a (99 mg, 0.50 mmol). Isolation by column chromatography 
(n-hexane/acetone: 10/1) yielded 137ha (56 mg, 60%) as a white solid. 
M. p. = 200–201 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.80 (sbr, 1H), 8.90 (dd, J = 7.6, 1.3 Hz, 1H), 8.52 (dd, J = 4.2, 1.7 
Hz, 1H), 8.24–8.19 (m, 1H), 8.06 (dd, J = 8.3, 1.7 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.92 (td, J = 5.6, 
2.6 Hz, 1H), 7.65–7.62 (m, 2H), 7.60 (d, J = 8.5 Hz, 1H), 7.56–7.51 (m, 3H), 7.47 (dd, J = 8.3, 1.4 
Hz, 1H), 7.32 (dd, J = 8.3, 4.2 Hz, 1H), 7.26 (dd, J = 8.5, 2.9 Hz, 2H), 7.14–7.09 (m, 1H). 
13
C NMR (100 MHz, CDCl3): δ = 167.8 (Cq), 148.0 (CH), 140.3 (Cq), 138.4 (Cq), 137.0 (Cq), 136.0 
(CH), 134.5 (Cq), 134.2 (Cq), 133.8 (Cq), 132.6 (Cq), 130.5 (Cq), 129.7 (CH), 128.9 (CH), 128.3 (CH), 
128.0 (CH), 127.8 (CH), 127.5 (CH), 127.4 (CH), 127.3 (CH), 126.4 (CH), 125.7 (CH), 121.8 (CH), 
121.4 (CH), 116.6 (CH). 
IR (ATR): 1667, 1518, 1482, 1325, 825, 790 cm
–1
.  
MS (EI) m/z (relative intensity): 374 (10) [M]
+
, 231 (60), 202 (30).  
HR-MS (EI) m/z calcd for C26H18N2O
+
 [M]
+
: 374.1419, found: 374.1417. 
 
 
 
 
3,5-Dimethyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137ia): 
The general procedure D was followed using 2,4-dimethyl-N-(quinolin-8-yl)benzamide 9i (69 g, 0.25 
mmol) and trimethoxy(phenyl)silane 136a (99 mg, 0.50 mmol). Isolation by column chromatography 
(n-hexane/Actone: 10/1) yielded 137ia (60 mg, 68%) as a white solid.  
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M. p. = 123–124 °C. 
1
H NMR (300 MHz, CDCl3): δ = 9.59 (sbr, 1H), 8.74 (dd, J = 7.3, 1.7 Hz, 1H), 8.57 (dd, J = 4.2, 1.7 Hz, 
1H), 8.05 (dd, J = 8.3, 1.7 Hz, 1H), 7.50 (t, J = 1.7 Hz, 1H), 7.49–7.45 (m, 2H), 7.42 (dd, J = 8.3, 1.7 
Hz, 1H), 7.33 (dd, J = 8.3, 4.2 Hz, 1H), 7.22–7.14 (m, 2H), 7.10 (s, 2H), 7.08–7.02 (m, 1H), 2.48 (s, 
3H), 2.40 (s, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 168.3 (Cq), 147.8 (CH), 140.4 (Cq), 139.6 (Cq), 138.92 (Cq), 138.3 
(Cq), 135.9 (CH), 135.8 (Cq), 134.4 (Cq), 134.1 (Cq), 130.1 (CH), 128.5 (CH), 128.2 (CH), 128.0 (CH), 
127.7 (Cq), 127.2 (CH), 127.1 (CH), 121.4 (CH), 121.3 (CH), 116.3 (CH), 21.3 (CH3), 19.8 (CH3).  
IR (ATR): 1671, 1519, 1482, 1325, 826, 700 cm
–1
. 
MS (EI) m/z (relative intensity): 352 (25) [M]
+
, 209 (100), 165 (35).  
HR-MS (EI) m/z calcd for C24H20N2O
+
 [M]
+
: 352.1576, found: 352.1569. 
 
 
 
 
2',3,5,6'-Tetramethyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137ib):  
The general procedure D was followed using 2,4-dimethyl-N-(quinolin-8-yl)benzamide 9i (69 g, 0.25 
mmol) and (2,6-dimethylphenyl)trimethoxysilane 136b (113 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137ib (66.5, 70%) as a white solid. 
M. p. = 137–138 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.62 (sbr, 1H), 8.69 (dd, J = 4.2, 1.7 Hz, 1H), 8.65 (dd, J = 6.2, 2.8 Hz, 
1H), 8.06 (dd, J = 8.3, 1.7 Hz, 1H), 7.42–7.39 (m, 2H), 7.37 (dd, J = 8.3, 4.2 Hz, 1H), 7.12–7.09 (m, 
1H), 6.90 (s, 3H), 6.84 (dd, J = 1.0, 0.6 Hz, 1H), 2.47 (s, 3H), 2.39 (s, 3H), 2.19 (s, 6H). 
13
C NMR (100 MHz, CDCl3): δ = 168.0 (Cq), 147.7 (CH), 139.5 (Cq), 139.0 (Cq), 138.4 (Cq), 138.3 
(Cq), 136.2 (Cq), 136.1 (CH), 135.6 (Cq), 134.7 (Cq), 134.4 (Cq), 130.0 (CH), 127.7 (Cq), 127.6 (CH), 
127.3 (CH), 127.1 (CH), 127.1 (CH), 121.4 (CH), 121.3 (CH), 116.2 (CH), 21.3 (CH3), 20.8 (CH3), 
19.8 (CH3).  
IR (ATR): 1671, 1518, 1482, 1325, 858, 770 cm
–1
. 
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MS (EI) m/z (relative intensity): 380 (20) [M]
+
, 237 (80), 179 (35), 144 (40).  
HR-MS (EI) m/z calcd for C26H24N2O
+
 [M]
+
: 380.1889, found: 380.1894. 
 
 
 
 
2',3-Dimethyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137ad):  
The general procedure D was followed using 2-methyl-N-(quinolin-8-yl)benzamide 9a (65.5 mg, 
0.25 mmol) and trimethoxy(o-tolyl)silane 136d (106 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137ad (70.4 mg, 80%) as a white solid. 
M. p. = 115–116 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.61 (sbr, 1H), 8.67 (dt, J = 2.9, 1.4 Hz, 1H), 8.65 (dd, J = 6.3, 2.7 Hz, 
1H), 8.07 (dd, J = 8.3, 1.7 Hz, 1H), 7.43–7.41 (m, 2H), 7.40–7.34 (m, 2H), 7.30–7.28 (m, 1H), 7.28–
7.25 (m, 1H), 7.14 (ddd, J = 7.6, 1.2, 0.6 Hz, 1H), 7.06–7.02 (m, 1H), 6.99–6.95 (m, 2H), 2.52 (s, 3H), 
2.28 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 167.8 (Cq), 147.8 (CH), 139.7 (Cq), 139.3 (Cq), 138.3 (Cq), 137.5 
(Cq), 136.1 (CH), 135.9 (Cq), 135.6 (Cq), 134.3 (Cq), 129.9 (CH), 129.6 (CH), 129.3 (CH), 128.7 (CH), 
127.7 (Cq), 127.6 (CH), 127.4 (CH), 127.3 (CH), 125.2 (CH), 121.4 (CH), 121.4 (CH), 116.2 (CH), 
20.3 (CH3), 19.8 (CH3).  
IR (ATR): 1673, 1519, 1482, 1325, 899, 790 cm
–1
. 
MS (EI) m/z (relative intensity): 352 (15) [M]
+
, 209 (100), 165 (55), 144 (70).  
HR-MS (EI) m/z calcd for C24H20N2O
+
 [M]
+
: 353.1576, found: 352.1586. 
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3'-Methoxy-3-methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137ae):  
The general procedure D was followed using 2-methyl-N-(quinolin-8-yl)benzamide 9a (65.5 mg, 
0.25 mmol) and trimethoxy(3-methoxyphenyl)silane 136e (114 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137ae (61 mg, 66%) as a white solid. 
M. p. = 102–103 °C. 
1
H NMR (300 MHz, CDCl3): δ = 9.66 (sbr, 1H), 8.80–8.76 (m, 1H), 8.59 (dd, J = 4.2, 1.7 Hz, 1H), 8.05 
(dd, J = 8.3, 1.7 Hz, 1H), 7.52–7.45 (m, 2H), 7.41 (dd, J = 6.1, 3.1 Hz, 1H), 7.38–7.34 (m, 1H), 7.32 (t, 
J = 3.1 Hz, 1H), 7.31–7.26 (m, 1H), 7.11–7.06 (m, 3H), 6.62 (ddd, J = 5.1, 4.0, 2.1 Hz, 1H), 3.63 (s, 
3H), 2.52 (s, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 168.2 (Cq), 159.2 (Cq), 147.8 (CH), 141.6 (Cq), 139.5 (Cq), 138.3 
(Cq), 136.7 (Cq), 136.0 (CH), 135.8 (Cq), 134.3 (Cq), 129.5 (CH), 129.1 (CH), 129.1 (CH), 127.7 (Cq), 
127.4 (CH), 127.1 (CH), 121.6 (CH), 121.3 (CH), 121.1 (CH), 116.3 (CH), 113.6 (CH), 107.8 (CH), 
55.1 (CH3), 19.8 (CH3).  
IR (ATR): 1671, 1520, 1482, 1264, 730, 700 cm
–1
. 
MS (EI) m/z (relative intensity): 368 (40) [M]
+
, 225 (100), 144 (60).  
HR-MS (EI) m/z calcd for C24H20N2O2
+
 [M]
+
: 368.1525, found: 368.1526. 
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3,4'-Dimethyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137af):  
The general procedure D was followed using 2-methyl-N-(quinolin-8-yl)benzamide 9a (65.5 mg, 
0.25 mmol) and trimethoxy(p-tolyl)silane 136f (106 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137af (55 mg, 62%) as a white solid. 
M. p. = 118–119 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.62 (sbr, 1H), 8.78 (dd, J = 7.4, 1.5 Hz, 1H), 8.60 (dd, J = 4.2, 1.7 Hz, 
1H), 8.07 (dd, J = 8.3, 1.7 Hz, 1H), 7.52–7.47 (m, 1H), 7.46–7.43 (m, 3H), 7.39–7.32 (m, 2H), 7.29–
7.24 (m, 2H), 6.75–6.72 (m, 2H), 3.61 (s, 3H), 2.51 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 168.5 (Cq), 158.9 (Cq), 148.0 (CH), 139.3 (Cq), 138.4 (Cq), 136.8 
(Cq), 136.1 (CH), 135.8 (Cq), 134.5 (Cq), 132.8 (Cq), 129.8 (CH), 129.1 (CH), 129.1 (CH), 127.8 (Cq), 
127.6 (CH), 127.2 (CH), 121.6 (CH), 121.4 (CH), 116.5 (CH), 113.7 (CH), 55.1 (CH3), 19.8 (CH3).  
IR (ATR): 1666, 1514, 1244, 1176, 786, 569 cm
–1
. 
MS (EI) m/z (relative intensity): 352 (20) [M]
+
, 208 (80), 180 (40).  
HR-MS (ESI) m/z calcd for C24H20N2O
+
 [M]
+
: 352.1576, found: 352.1574. 
 
 
 
 
4'-Methoxy-3-methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137ag): 
The general procedure D was followed using 2-methyl-N-(quinolin-8-yl)benzamide 9a (65.5 mg, 
0.25 mmol) and trimethoxy(4-methoxyphenyl)silane 136g (114 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137ag (58 mg, 63%) as a white solid. 
M. p. = 150–151 °C. 
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1
H NMR (400 MHz, CDCl3): δ = 9.63 (sbr, 1H), 8.78 (dd, J = 7.4, 1.5 Hz, 1H), 8.60 (dd, J = 4.2, 1.7 Hz, 
1H), 8.06 (dd, J = 8.3, 1.7 Hz, 1H), 7.52–7.47 (m, 1H), 7.46–7.42 (m, 3H), 7.39–7.32 (m, 2H), 7.28–
7.25 (m, 2H), 6.76–6.74 (m, 1H), 6.73–6.72 (m, 1H), 3.61 (s, 3H), 2.51 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 168.5 (Cq), 158.9 (Cq), 148.0 (CH), 139.2 (Cq), 138.4 (Cq), 136.8 
(Cq), 136.1 (CH), 135.7 (Cq), 134.4 (Cq), 132.8 (Cq), 129.8 (CH), 129.12 (CH), 129.13 (CH), 127.8 
(Cq), 127.6 (CH), 127.2 (CH), 121.6 (CH), 121.4 (CH), 116.5 (CH), 113.7 (CH), 55.1 (CH3), 19.8 
(CH3).  
IR (ATR): 1673, 1519, 1482, 1245, 791, 665 cm
–1
. 
MS (EI) m/z (relative intensity): 368 (30) [M]
+
, 225 (100).  
HR-MS (EI) m/z calcd for C24H20N2O2
+
 [M]
+
: 368.1525, found: 368.1528. 
 
 
 
 
3-Methyl-N-(quinolin-8-yl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide (132ah): 
The general procedure D was followed using 2-methyl-N-(quinolin-8-yl)benzamide 9a (65.5 mg, 
0.25 mmol) and trimethoxy(4-(trifluoromethyl)phenyl)silane 136h (133 mg, 0.50 mmol). Isolation 
by column chromatography (n-hexane/Actone: 10/1) yielded 137ah (89 mg, 88%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ = 9.62 (sbr, 1H), 8.72 (dd, J = 6.7, 2.3 Hz, 1H), 8.58 (dd, J = 4.2, 1.7 Hz, 
1H), 8.10–8.06 (m, 1H), 7.62 (dd, J = 8.7, 0.7 Hz, 2H), 7.49 (dd, J = 4.5, 3.4 Hz, 2H), 7.43 (m, 3H), 
7.38 (dd, J = 8.5, 3.8 Hz, 1H), 7.34 (dd, J = 2.5, 1.7 Hz, 1H), 7.30–7.26 (m, 1H), 2.54 (s, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 167.8 (Cq), 148.0 (CH), 144.0 (Cq), 138.2 (Cq), 136.7 (Cq), 136.3 
(Cq), 136.1 (CH), 134.0 (Cq), 130.3 (CH), 129.4 (CH), 129.2 (Cq, 
2
JC–F = 32.5 Hz), 129.0 (CH), 127.8 
(Cq), 127.5 (CH), 127.2 (CH), 125.1 (CH, 
3
JC–F = 7.9 Hz), 123.9 (Cq, 
1
JC–F = 270.3 Hz), 122.9 (Cq), 
122.0 (CH), 121.5 (CH), 116.8 (CH), 19.8 (CH3).  
19
F NMR (282 MHz, CDCl3): δ = –62.7. 
IR (ATR): 1671, 1518, 1481, 1321, 1061, 825, 606 cm
–1
. 
MS (EI) m/z (relative intensity): 406 (30) [M]
+
, 263 (70), 165 (20).  
HR-MS (EI) m/z calcd for C24H17F3N2O
+
 [M]
+
: 406.1293, found: 406.1294. 
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4'-Methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137bi):  
The general procedure D was followed using N-(quinolin-8-yl)benzamide 9b (62 mg, 0.25 mmol) 
and trimethoxy(p-tolyl)silane 136i (100 μL, 0.50 mmol). Isolation by column chromatography 
(n-hexane/acetone: 10/1) yielded 137bi (46 mg, 54%) as a white solid. 
M. p. = 115–116 °C. 
1
H NMR (300 MHz, CDCl3): δ = 9.79 (sbr, 1H), 8.80 (dd, J = 7.4, 1.5 Hz, 1H), 8.51 (dd, J = 4.2, 1.7 Hz, 
1H), 8.07 (dd, J = 8.3, 1.7 Hz, 1H), 7.90–7.85 (m, 1H), 7.53 (m, 2H), 7.49–7.43 (m, 4H), 7.42–7.40 (m, 
1H), 7.34 (dd, J = 8.3, 4.2 Hz, 1H), 6.83–6.77 (m, 2H), 3.64 (s, 3H). 
13
C NMR (125 MHz, CDCl3): δ = 168.1 (Cq), 159.3 (Cq), 147.7 (CH), 139.9 (Cq), 138.5 (Cq), 136.0 
(CH), 135.9 (Cq), 134.6 (Cq), 132.4 (Cq), 130.6 (CH), 130.5 (CH), 130.1 (CH), 129.3 (CH), 127.7 
(Cq), 127.3 (CH), 127.2 (CH), 121.5 (CH), 121.4 (CH), 116.3 (CH), 113.9 (CH), 55.1 (CH3).  
IR (ATR): 1663, 1517, 1481, 1245, 826, 762 cm
–1
. 
MS (EI) m/z (relative intensity): 338 (30) [M]
+
, 195 (80), 165 (30).  
HR-MS (EI) m/z calcd for C23H18N2O
+
 [M]
+
: 338.1419, found: 338.1416. 
 
 
 
 
2',3,6'-Trimethyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137ab): 
The general procedure D was followed using 2-methyl-N-(quinolin-8-yl)benzamide 9a (65.5 mg, 
0.25 mmol) and (2,6-dimethylphenyl)trimethoxysilane 136b (113 mg, 0.50 mmol). Isolation by 
column chromatography (n-hexane/acetone: 10/1) yielded 137ab (57 mg, 62%) as a white solid. 
M. p. = 128–129 °C. 
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1
H NMR (300 MHz, CDCl3): δ = 9.63 (sbr, 1H), 8.69 (dd, J = 4.2, 1.7 Hz, 1H), 8.66–8.62 (m, 1H), 8.08 
(dd, J = 8.3, 1.7 Hz, 1H), 7.43 (d, J = 0.9 Hz, 1H), 7.41 (s, 1H), 7.41–7.36 (m, 2H), 7.28 (dd, J = 7.7, 
1.2 Hz, 1H), 7.05–7.01 (m, 1H), 6.90 (s, 3H), 2.50 (s, 3H), 2.17 (s, 6H). 
13
C NMR (125 MHz, CDCl3): δ = 167.6 (Cq), 147.5 (CH), 139.3 (Cq), 138.3 (Cq), 138.2 (Cq), 137.3 
(Cq), 136.2 (Cq), 136.0 (CH), 135.5 (Cq), 134.3 (Cq), 129.2 (CH), 129.1 (CH), 127.7 (Cq), 127.2 (CH), 
127.2 (CH), 127.1 (CH), 127.0 (CH), 121.4 (CH), 121.3 (CH), 116.2 (CH), 20.9 (CH3), 19.9 (CH3). 
IR (ATR): 1665, 1523, 1481, 1384, 825, 762 cm
–1
. 
MS (EI) m/z (relative intensity): 366 (35) [M]
+
, 223 (100), 165 (50).  
HR-MS (EI) m/z calcd for C25H22N2O
+
 [M]
+
: 366.1732, found: 366.1737. 
 
 
 
 
 
 
1 
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2',3,4',6'-Tetramethyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (137ac): 
The general procedure D was followed using 2-methyl-N-(quinolin-8-yl)benzamide 9a (65.5 mg, 
0.25 mmol) and mesityltrimethoxysilane 136c (120 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 137ac (60 mg, 63%) as a white solid.  
M. p. = 156–157 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.65 (sbr, 1H), 8.69 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (dd, J = 5.7, 3.3 
Hz, 1H), 8.09 (dd, J = 8.3, 1.7 Hz, 1H), 7.44–7.42 (m, 2H), 7.41–7.36 (m, 2H), 7.27 (ddd, J = 7.6, 
1.2, 0.7 Hz, 1H), 7.01 (dd, J = 7.6, 1.2, 0.6 Hz, 1H), 6.72 (d, J = 0.6 Hz, 2H), 2.49 (s, 3H), 2.13 (s, 
6H), 2.09 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 167.9 (Cq), 147.8 (CH), 138.5 (Cq), 138.3 (Cq), 137.7 (Cq), 136.6 
(Cq), 136.5 (Cq), 136.12 (Cq), 136.11 (CH), 135.5 (Cq), 134.4 (Cq), 129.2 (CH), 129.1 (CH), 127.9 
(CH), 127.8 (Cq), 127.5 (CH), 127.3 (CH), 121.5 (CH), 121.4 (CH), 116.3 (CH), 20.9 (CH3), 20.7 
(CH3), 19.8 (CH3).  
IR (ATR): 1672, 1518, 1481, 1325, 790, 729 cm
–1
. 
MS (EI) m/z (relative intensity): 380 (30) [M]
+
, 237 (90), 179 (45), 144 (100).  
HR-MS (ESI) m/z calcd for C26H24N2O
+
 [M]
+
: 380.1883, found: 380.1875. 
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2-Methyl-6-(naphthalen-1-yl)-N-(quinolin-8-yl)benzamide (137aj):  
The general procedure D was followed using 2-methyl-N-(quinolin-8-yl)benzamide 9a (65.5 mg, 
0.25 mmol) and trimethoxy(naphthalen-1-yl)silane 131j (124 mg, 0.50 mmol). Isolation by column 
chromatography (n-hexane/acetone: 10/1) yielded 132aj (78 mg, 80%) as a white solid. 
M. p. = 215–216 °C. 
1
H NMR (400 MHz, CDCl3): δ = 9.52 (sbr, 1H), 8.51 (dd, J = 6.8, 2.1 Hz, 1H), 8.29 (dd, J = 4.2, 1.6 Hz, 
1H), 7.93 (dd, J = 8.3, 1.6 Hz, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.64 (d, J = 8.3 Hz, 1H), 7.53 (d, J = 8.3 Hz, 
1H), 7.50 (d, J = 7.1 Hz, 1H), 7.47–7.45 (m, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.40–7.32 (m, 3H), 7.31 (d, 
J = 1.9 Hz, 2H), 7.29–7.26 (m, 1H), 7.22 (dd, J = 8.3, 4.2 Hz, 1H), 2.57 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 167.6 (Cq), 147.5 (CH), 138.2 (Cq), 138.0 (Cq), 137.8 (Cq), 137.7 
(Cq), 136.2 (Cq), 135.8 (CH), 134.1 (Cq), 133.5 (Cq), 132.2 (Cq), 129.8 (CH), 128.8 (CH), 128.6 (CH), 
128.0 (CH), 127.7 (CH), 127.5 (Cq), 127.1 (CH), 127.0 (CH), 126.3 (CH), 126.0 (CH), 125.6 (CH), 
124.9 (CH), 121.3 (CH), 121.1 (CH), 116.0 (CH), 19.9 (CH3).  
IR (ATR): 1674, 1521, 1479, 1261, 798, 609 cm
–1
. 
MS (EI) m/z (relative intensity): 388 (35) [M]
+
, 245 (100), 202 (35).  
HR-MS (EI) m/z calcd for C27H20N2O
+
 [M]
+
: 388.1576, found: 388.1579. 
  
  Experimental Section  
140 
 
H/D-Exchange Experiment 
 
 
 
 
The representative procedure D was followed using 9d (65.5 mg, 0.25 mmol, 1.0 equiv), 136a (37.1 
mg, 0.375 mmol, 1.5 equiv), Co(OAc)2 (8.9 mg, 20 mol %), CsF (114 mg, 0.75 mmol, 3.0 equiv) and 
CuF2 (51.0 mg, 0.5 mmol, 2.0 equiv) in NMP (0.9 mL) and D2O (0.1 mL). At ambient temperature, the 
reaction mixture was diluted with CH2Cl2 (15 mL) and washed with NaOH (2 M, 10 mL) and H2O (2 x 
20 mL). The combined organic layers were dried over Na2SO4. After filtration and evaporation of the 
solvents in vacuo, the remaining residue was purified by column chromatography on silica gel 
(n-hexane/Aceton) to yield [D]n-9d (25.1 mg, 38 %, ) and [D]n-137da (36.6 mg, 43 %) as white solids. 
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5.3.4 Cobalt-Catalyzed C−H/C-C Functionalizations 
 
Analytical Data 
 
 
 
(Z)-Dimethyl 2-{4-[1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate [(Z)-151aa]:  
The general procedure F was followed using 1-(pyridin-2-yl)-1H-indole (95a) (97.1 mg, 0.50 mmol) 
and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (110 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-151aa (176 mg, 93%, E/Z = 1:11) as a 
yellow oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.86 (ddd, J = 8.0, 7.6, 1.9 Hz, 
1H), 7.59‒7.53 (m, 1H), 7.46‒7.41 (m, 1H), 7.36–7.27 (m, 2H), 7.15–7.09 (m, 2H), 6.43 (d, J = 
0.7 Hz, 1H), 5.64 (dtt, J = 10.8, 7.2, 1.0 Hz, 1H), 5.40 (dtt, J = 10.8, 7.6, 1.0 Hz, 1H), 3.69 (s, 6H), 
3.65 (d, J = 7.2 Hz, 2H), 3.35 (t, J = 7.7 Hz, 1H), 2.62 (ddd, J = 7.7, 7.6, 1.0 Hz, 1.83H, Z), 2.54 (ddd, 
J = 7.7, 7.6, 1.0 Hz, 0.17H, E).  
13
C-NMR (125 MHz, CDCl3): δ  = 169.0 (Cq), 151.1 (Cq), 149.5 (CH), 139.2 (Cq), 138.1 (CH), 
137.2 (Cq), 128.8 (CH), 128.4 (Cq), 126.2 (CH), 121.9 (CH), 121.7 (CH), 120.8 (CH), 120.5 (CH), 
119.9 (CH), 109.9 (CH), 102.7 (CH), 52.5 (CH3), 51.5 (CH), 31.7 (CH2, E), 30.9 (CH2, E), 26.7 (CH2, 
Z), 25.9 (CH2, Z).  
IR (ATR): 1732, 1586, 1469, 1436, 1150, 745 cm
–1
.  
MS (EI) m/z (relative intensity): 378 (30) [M]
+
, 247 (100), 219 (90), 206 (70).  
HR-MS (EI): m/z calcd. for [C22H22N2O4]
+
 [M]
+  
378.1574, found 378.1578.  
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(E)-Dimethyl 2-{4-[1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate [(E)-151aa']: 
The general procedure G was followed using 1-(pyridin-2-yl)-1H-indole (95a) (48.5 mg, 0.25 mmol) 
and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 0.30 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 3/1) yielded (E)-151aa' (72.8 mg, 77%, E/Z = 2:1) as a 
yellow oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.65–8.60 (m, 1H), 7.85 (ddd, J = 8.0, 7.6, 2.0 Hz, 1H), 7.55 (dd, J 
= 5.9, 3.2 Hz, 1H), 7.46–7.38 (m, 1H), 7.35–7.26 (m, 2H), 7.14–7.08 (m, 2H), 6.41 (d, J = 0.7 Hz, 
1H), 5.69–5.56 (m, 1H), 5.40 (dtt, J = 10.8, 7.6, 1.0 Hz, 0.33H, Z), 5.32 (dtt, J = 15.7, 7.6, 1.0 Hz, 
0.67H, E), 3.69 (s, 6H), 3.55 (d, J = 6.6 Hz, 2H), 3.33 (t, J = 7.7 Hz, 1H), 2.62 (ddd, J = 7.7, 7.6, 
1.4 Hz, 0.73H, Z), 2.53 (ddd, J = 7.7, 7.6, 1.4 Hz, 1.27H, E).  
13
C-NMR (125 MHz, CDCl3): δ = 169.0 (Cq), 151.1 (Cq), 149.3 (CH), 139.1 (Cq), 138.0 (CH), 137.1 
(Cq), 129.6 (CH), 127.5 (Cq), 126.2 (CH), 121.8 (CH), 121.7 (CH), 120.8 (CH), 120.5 (CH), 119.9 
(CH), 110.0 (CH), 102.9 (CH), 52.4 (CH3), 51.6 (CH), 31.7 (CH2, E), 30.9 (CH2, E), 26.7 (CH2, Z), 
25.9 (CH2, Z).  
IR (ATR): 1732, 1586, 1469, 1436, 1150, 745 cm
–1
.  
MS (EI) m/z (relative intensity): 378 (30) [M]
+
, 247 (100), 219 (90), 206 (70).  
HR-MS (EI): m/z calcd. for [C22H22N2O4]
+
 [M]
+  
378.1574, found 378.1578. 
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(Z)-Dimethyl 2-{4-[5-fluoro-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate [(Z)-151ba]:  
The general procedure F was followed using 5-fluoro-1-(pyridin-2-yl)-1H-indole (95b) (106 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-151ba (182 mg, 92%, E/Z = 
1:10) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.90 (ddd, J = 8.0, 7.5, 2.0 Hz, 
1H), 7.42 (dt, J = 8.0, 2.0 Hz, 1H), 7.36–7.30 (m, 1H), 7.23–7.15 (m, 2H), 6.85 (td, J = 9.1, 2.6 Hz, 
1H), 6.38 (d, J = 0.8 Hz, 1H), 5.60 (dtt, J = 10.8, 7.4, 1.4 Hz, 1H), 5.39 (dtt, J = 10.8, 7.6, 1.0 Hz, 
1H), 3.68 (s, 6H), 3.61 (d, J = 7.4 Hz, 2H), 3.36 (t, J = 7.6, 1H), 2.59 (ddd, J = 7.6, 7.6, 1.4 Hz, 
1.82H, Z), 2.53 (ddd, J = 7.6, 7.6, 1.4 Hz, 0.18H, E).  
13
C-NMR (125 MHz, CDCl3): δ = 169.1 (Cq), 158.3 (Cq, 
1
JC−F = 234.0 Hz), 151.0 (Cq), 149.6 (CH), 
140.8 (Cq), 138.3 (CH), 133.8 (Cq), 128.8 (Cq, 
3
JC−F = 10.3 Hz), 128.5 (CH), 126.5 (CH), 122.1 (CH), 
120.8 (CH), 110.7 (CH, 
3
JC−F = 9.7 Hz), 109.7 (CH, 
2
JC−F = 25.9 Hz), 104.9 (CH, 
2
JC−F = 23.6 Hz), 
102.6 (CH, 
4
JC−F = 4.5 Hz), 52.5 (CH3), 51.5 (CH), 31.7 (CH2, E), 31.0 (CH2, E), 26.7 (CH2, Z), 26.0 
(CH2, Z).  
19
F-NMR (282 MHz, CDCl3): δ = ‒123.9 (E), ‒124.0 (Z).  
IR (ATR): 1732, 1585, 1470, 1436, 1265, 1230, 1151, 730, 701 cm
–1
.  
MS (ESI) m/z (relative intensity): 419 (80) [M+Na]
+
, 397 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C22H22FN2O4
+ 
[M+H]
+
 397.1558, found 397.1557. 
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(Z)-Dimethyl 2-{4-[6-(methoxycarbonyl)-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate 
[(Z)-151ca]:  
The general procedure F was followed using 3-methoxycabonyl-1-(pyridin-2-yl)-1H-indole (95c) 
(126 mg, 0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (110 mg, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-151ca (153 mg, 
70%, E/Z = 1:25) as a yellow oil.
  
1
H-NMR (500 MHz, CDCl3): δ = 8.71–8.66 (m, 1H), 8.18–8.14 (m, 1H), 7.92 (td, J = 7.7, 2.0 Hz, 1H), 
7.44–7.36 (m, 2H), 7.24 (ddd, J = 8.0, 6.2, 2.0 Hz, 1H). 7.19–7.11 (m, 2H), 5.40 (dtt, J = 10.8, 7.6, 
0.8 Hz, 1H), 5.16 (dtt, J = 10.8, 7.5, 1.2 Hz, 1H), 4.06 (dd, J = 6.8, 1.4 Hz, 2H), 3.94 (s, 3H), 3.69 (s, 
5.78H, Z), 3.61 (s, 0.22H, E), 3.24 (t, J = 7.6 Hz, 1H), 2.37 (ddd, J = 7.6, 7.5, 0.8 Hz, 2H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.0 (Cq), 165.8 (Cq), 150.0 (Cq), 149.9 (CH), 146.5 (CH), 138.6 
(Cq), 136.7 (CH), 128.7 (CH), 128.5 (Cq), 126.4 (CH), 125.7 (Cq), 123.4 (CH), 122.9 (CH), 122.3 (CH), 
121.6 (Cq), 110.2 (CH), 105.8 (CH), 52.4 (CH), 51.2 (CH3), 50.9 (CH3), 26.6 (CH2), 24.6 (CH2).  
IR (ATR): 1735, 1698, 1588, 1538, 1469, 1436, 1194, 788, 749 cm
–1
.  
MS (ESI) m/z (relative intensity): 459 (100) [M+Na]
+
, 437 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C24H25N2O6
+ 
[M+H]
+
 437.1707, found 437.1709. 
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(E,Z)-Dimethyl 2-{4-[6-(methoxycarbonyl)-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}-malo-
nate [(E,Z)-151ca']:  
The general procedure G was followed using 3-methoxycabonyl-1-(pyridin-2-yl)-1H-indole (95c) 
(63.0 mg, 0.25 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 
0.30 mmol). Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded (E,Z)-151ca' 
(104 mg, 95%, E/Z = 1:1) as a yellow oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.72–8.67 (m, 1H), 8.19–8.13 (m, 1H), 7.96–7.89 (m, 1H), 7.43–
7.37 (m, 2H), 7.27–7.22 (m, 1H), 7.19–7.12 (m, 2H), 5.53 (dtt, J = 15.4, 7.5, 1.4 Hz, 0.50H, E), 5.40 
(dtt, J = 10.7, 7.5, 1.4 Hz, 0.50H, Z), 5.19 (dtt, J = 10.7, 7.5, 1.1 Hz, 0.50H, Z), 5.09 (dtt, J = 15.4, 7.5, 
1.1 Hz, 0.50H, E), 4.06 (d, J = 7.0 Hz, 0.96H, E), 3.95 (s, 3H), 3.93 (d, J = 7.0 Hz, 1.04H, Z), 3.69 (s, 
3.17H, Z), 3.62 (s, 2.83H, E), 3.23–3.21 (m, 1H), 2.42 (d, J = 7.6, 7.5, 1.4 Hz, 0.94H, E), 2.37 (ddd, J 
= 7.6, 7.5, 1.4 Hz, 1.06H, Z).  
13
C-NMR (125 MHz, CDCl3): δ = 169.3 (Cq), 166.1 (Cq), 150.2 (Cq), 146.7 (Cq), 138.8 (CH), 136.8 
(Cq), 129.3 (CH), 128.7 (CH), 127.2 (CH), 126.6 (Cq), 125.8 (CH), 123.6 (CH), 123.1 (CH), 122.5 
(CH), 121.7 (CH), 110.4 (CH), 106.0 (Cq), 52.6 (CH3), 51.3 (CH), 51.0 (CH3), 31.6 (CH2, E), 29.1 
(CH2, E), 26.6 (CH2, Z), 24.6 (CH2, Z).  
IR (ATR): 1732, 1695, 1587, 1468, 1434, 1190, 1152, 1077, 788, 732 cm
–1
.  
MS (ESI) m/z (relative intensity): 459 (100) [M+Na]
+
, 437 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C24H24N2NaO6
+ 
[M+Na
+
] 459.1527, found 459.1527. 
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(Z)-2-{4-[1-(Pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonitrile [(Z)-151ab]:  
The general procedure F was followed using 1-(pyridin-2-yl)-1H-indole (95a) (97.1 mg, 0.50 mmol) 
and 2-vinylcyclopropane-1,1-dicarbonitrile (138b) (70.9 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-151ab (105 mg, 67%, E/Z = 1:3) as a pale 
yellow oil.  
1
H-NMR (600 MHz, CDCl3): δ = 8.66–8.63 (m, 1H), 7.90 (ddd, J = 7.9, 4.9, 2.0 Hz, 1H), 7.58–7.54 
(m, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.36–7.30 (m, 2H), 7.16–7.11 (m, 2H), 6.44 (d, J = 0.7 Hz, 1H), 
5.98–5.88 (m, 1H), 5.50 (dtt, J = 10.4, 7.5, 1.1 Hz, 0.77H, Z), 5.37 (dtt, J = 15.4, 7.5, 1.0 Hz, 0.23H, 
E), 3.70 (d, J = 7.5 Hz, 2H), 3.60 (t, J = 7.2 Hz, 0.77H, Z), 3.60 (t, J = 7.2 Hz, 0.23H, E), 2.71 (ddd, J 
= 7.3, 7.2, 1.1 Hz, 2H). 
13
C-NMR (125 MHz, CDCl3): δ = 151.1 (Cq), 149.6 (CH), 138.4 (CH), 137.9 (Cq), 137.2 (Cq), 135.0 
(CH), 133.2 (CH), 128.3 (Cq), 122.6 (CH), 122.1 (CH), 122.0 (CH), 120.9 (CH), 120.2 (CH), 112.1 
(Cq), 110.0 (CH), 103.2 (CH), 33.8 (CH2, E), 30.9 (CH2, E), 28.6 (CH2, Z), 26.3 (CH2, Z), 22.8 (CH).  
IR (ATR): 2257, 1586, 1469, 1456, 1437, 1211, 1149, 782, 745 cm
–1
.  
MS (ESI) m/z (relative intensity): 335 (100) [M+Na]
+
, 313 (80) [M+H]
+
,
 
197 (80).  
HR-MS (ESI) m/z calcd. for C20H17N4
+ 
[M+H]
+
 313.1448, found 313.1442. 
 
 
 
 
(E,Z)-2-{4-[1-(Pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonitrile [(E,Z)-151ab']:  
The general procedure G was followed using 1-(pyridin-2-yl)-1H-indole (95a) (48.5 mg, 0.25 mmol) 
and 2-vinylcyclopropane-1,1-dicarbonitrile (138b) (35.5 mg, 0.30 mmol). Isolation by column 
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chromatography (n-hexane/EtOAc: 3/1) yielded (E,Z)-151ab' (54.2 mg, 69%, E/Z = 1:1) as a pale 
yellow oil.
  
1
H-NMR (500 MHz, CDCl3): δ = 8.68–8.64 (m, 1H), 7.92 (ddd, J = 7.9, 4.9, 2.0 Hz, 1H), 7.58 (dd, J 
= 8.1, 3.9 Hz, 1H), 7.48 (dt, J = 8.0, 1.0 Hz, 1H), 7.37–7.32 (m, 2H), 7.18–7.14 (m, 2H), 6.49 (d, 0.7 
Hz, 0.47H, E), 6.46 (d, 0.7 Hz, 0.53H, Z), 5.98–5.88 (m, 1H), 5.50 (dtt, J = 10.4, 7.5, 1.1 Hz, 0.47H, 
Z), 5.37 (dtt, J = 15.4, 7.5, 1.0 Hz, 0.53H, E), 3.72 (d, J = 7.6 Hz, 2H), 3.67 (t, J = 7.5 Hz, 0.53H, Z), 
3.58 (t, J = 7.5 Hz, 0.47H, E), 2.73 (ddd, J = 7.5, 7.4, 1.1 Hz, 1.06H), 2.62 (ddd, J = 7.5, 7.4, 1.1 Hz, 
0.94H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.1 (Cq), 149.7 (CH), 138.5 (CH), 138.0 (Cq), 137.2 (Cq), 135.1 
(CH), 133.3 (CH), 128.3 (Cq), 122.6 (CH), 122.2 (CH), 120.9 (CH), 120.3 (CH), 112.2 (Cq), 110.0 
(CH), 103.5 (CH), 103.2 (CH), 33.7 (CH2, E), 30.9 (CH2, E), 28.5 (CH2, Z), 26.2 (CH2, Z), 23.7 (CH, 
E), 22.1 (CH, Z).  
IR (ATR): 2257, 1586, 1468, 1455, 1436, 1211, 908, 738, 737 cm
–1
.  
MS (ESI) m/z (relative intensity): 335 (100) [M+Na]
+
, 313 (80) [M+H]
+
,
 
197 (80).  
HR-MS (ESI) m/z calcd. for C20H16N4Na
+ 
[M+Na]
+
 335.1267, found 335.1270. 
 
 
 
 
(Z)-2-{4-[5-Fluoro-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonitrile [(Z)-151bb]:  
The general procedure F was followed using 5-fluoro-1-(pyridin-2-yl)-1H-indole (95b) (106 mg, 
0.50 mmol) and 2-vinylcyclopropane-1,1-dicarbonitrile (138b) (70.9 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-151bb (114 mg, 69%, E/Z = 1:4) as a 
yellow oil.
  
1
H-NMR (600 MHz, CDCl3): δ = 8.66–8.63 (m, 1H), 7.91 (ddd, J = 7.9, 5.0, 2.0 Hz, 1H), 7.43 (d, J 
= 7.5 Hz, 1H), 7.37–7.30 (m, 1H), 7.25–7.17 (m, 2H), 6.91–6.82 (m, 1H), 6.42 (s, 0.20H, E), 6.40 (s, 
0.80H, Z), 5.98–5.83 (m, 1H), 5.53 (dtt, J = 10.8, 7.5, 1.0 Hz, 0.80H, Z), 5.39 (dtt, J = 15.4, 7.5, 
1.0 Hz, 0.20H, E), 3.75–3.56 (m, 2H), 3.63 (t, J = 7.5 Hz, 0.80H, Z), 3.63 (t, J = 7.5 Hz, 0.20H, E), 
2.72 (ddd, J = 7.5, 7.4, 1.0 Hz, 1.60H, Z), 2.62 (ddd, J = 7.5, 7.4, 1.0 Hz, 0.40H, E).  
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13
C-NMR (125 MHz, CDCl3): δ = 158.4 (Cq, 
1
JC−F = 235.5 Hz), 150.8 (Cq), 149.6 (CH), 139.5 (Cq), 
138.6 (CH), 133.7 (Cq), 132.9 (CH), 128.7 (Cq, 
3
JC−F = 10.5 Hz), 122.4 (CH), 122.1 (CH), 120.8 
(CH), 112.1 (Cq), 110.7 (CH, 
3
JC−F = 9.7 Hz), 110.1 (CH, 
2
JC−F = 26.4 Hz), 105.1 (CH, 
2
JC−F = 
23.9 Hz), 103.1 (CH, 
4
JC−F = 4.6 Hz), 33.7 (CH2, E), 31.0 (CH2, E), 28.6 (CH2, Z), 26.3 (CH2, Z), 
23.2 (CH, E), 22.8 (CH, Z).
  
19
F-NMR (282 MHz, CDCl3): δ = ‒123.5.  
IR (ATR): 2255, 1617, 1470, 1438, 1385, 1175, 785, 735 cm
–1
.  
MS (ESI) m/z (relative intensity): 353 (100) [M+Na]
+
, 331 (80) [M+H]
+
,
 
215 (100).  
HR-MS (ESI) m/z calcd. for C20H16FN4
+ 
[M+H]
+
 331.1354, found 331.1342. 
 
 
 
 
(Z)-2-{4-[5-Methoxy-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonitrile [(Z)-151db]:  
The general procedure F was followed using 5-methoxy-1-(pyridin-2-yl)-1H-indole (95d) (112 mg, 
0.50 mmol) and 2-vinylcyclopropane-1,1-dicarbonitrile (138b) (70.9 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-151db (118 mg, 65%, E/Z = 1:3) as a 
pale yellow oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.63−8.60 (m, 1H), 7.87 (ddd, J = 7.9, 5.0, 2.0 Hz, 1H), 7.43 (d, J = 
7.9 Hz, 1H), 7.32–7.26 (m, 2H), 7.03 (d, J = 2.5 Hz, 1H), 6.78 (dd, J = 8.9, 2.5 Hz, 1H), 6.39 (s, 0.23H, 
Z), 6.37 (s, 0.77H, E), 5.91–5.84 (m, 1H), 5.49 (dtt, J = 10.8, 7.5, 1.1 Hz, 0.23H, Z), 5.34 (dtt, J = 15.4, 
7.5, 1.1 Hz, 0.77H, E), 3.83 (s, 3H), 3.72–3.68 (m, 2H), 3.63 (t, J = 7.5 Hz, 1H), 2.69 (ddd, J = 7.5, 
7.5, 1.1 Hz, 1.54H, Z), 2.57 (ddd, J = 7.5, 7.4, 1.1 Hz, 0.46H, E).  
13
C-NMR (125 MHz, CDCl3): δ = 154.8 (Cq), 151.1 (Cq), 149.5 (CH), 138.4 (Cq), 138.4 (CH), 134.9 
(CH), 133.2 (CH), 132.2 (Cq), 128.8 (Cq), 121.9 (CH), 120.5 (CH), 112.2 (Cq), 111.7 (CH), 110.8 
(CH), 103.0 (CH), 102.3 (CH), 55.8 (CH3), 33.6 (CH2, E), 31.0 (CH2, E), 28.6 (CH2, Z), 26.3 (CH2, Z), 
23.1 (CH, E), 22.7 (CH, Z).  
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IR (ATR): 2254, 1616, 1582, 1470, 1436, 1203, 1172, 729 cm
–1
.  
MS (ESI) m/z (relative intensity):  365 (100) [M+H]
+
,
 
343 (40), 227 (80).  
HR-MS (ESI) m/z calcd. for C21H19N4O
+ 
[M+H]
+
 365.1373, found 365.1365. 
 
 
 
 
(Z)-Diethyl 2-{4-[1-(Pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate [(Z)-151ac]:  
The general procedure F was followed using (pyridin-2-yl)-1H-indole (95a) (97.1 mg, 0.50 mmol) and 
diethyl 2-vinylcyclopropane-1,1-dicarboxylate (138c) (127 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-151ac (171 mg, 84%, E/Z =1:12) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.90–7.83 (m, 1H), 7.56–7.53 
(m, 1H), 7.42 (dt, J = 8.0, 8.0, 1.0 Hz, 1H), 7.33–7.25 (m, 2H), 7.13–7.08 (m, 2H), 6.44 (d, J = 0.9 Hz, 
1H), 5.62 (dtt, J = 10.8, 7.4, 1.4 Hz, 1H), 5.41 (dtt, J = 10.8, 7.6, 1.0 Hz, 1H), 4.15 (q, J = 7.2 Hz, 4H), 
3.64 (d, J = 7.4 Hz, 1.84H, Z), 3.55 (d, J = 7.4 Hz, 0.16H, E), 3.33 (t, J = 7.6 Hz, 1H), 2.60 (ddd, J = 7.6, 
7.6, 1.4 Hz, 2H), 1.23 (t, J = 7.2 Hz, 6H).  
13
C-NMR (75 MHz, CDCl3): δ = 168.7 (Cq), 151.1 (Cq), 149.5 (CH), 139.2 (Cq), 138.1 (CH), 137.1 
(Cq), 128.6 (CH), 128.4 (CH), 126.4 (Cq), 121.8 (CH), 121.6 (CH), 120.8 (CH), 120.5 (CH), 119.8 
(CH), 109.9 (CH), 102.6 (CH), 61.2 (CH2), 51.7 (CH), 31.4 (CH2, E), 30.7 (CH2, E), 26.4 (CH2, Z), 
25.8 (CH2, Z), 13.9 (CH3).  
IR (ATR): 1727, 1585, 1468, 1455, 1436, 1149, 1025, 783, 745 cm
–1
.  
MS (ESI) m/z (relative intensity): 429 (60) [M+Na]
+
, 407 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C24H27N2O4
+ 
[M+H]
+
 407.1965, found 407.1960. 
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(E)-Diethyl 2-{4-[1-(Pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate [(E)-151ac']:  
The general procedure G was followed using (pyridin-2-yl)-1H-indole (95a) (48.5 mg, 0.25 mmol) 
and diethyl 2-vinylcyclopropane-1,1-dicarboxylate (138c) (63.5 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 3/1) yielded (E)-151ac' (66.1 mg, 65%, E/Z =1.3:1) as a yellow 
oil.   
1
H-NMR (300 MHz, CDCl3): δ = 8.67–8.60 (m, 1H), 7.90–7.82 (m, 1H), 7.57–7.51 (m, 1H), 7.46–
7.38 (m, 1H), 7.34–7.26 (m, 2H), 7.14–7.07 (m, 2H), 6.41 (d, J = 0.8 Hz, 1H), 5.67–5.55 (m, 1H), 
5.41 (dtt, J = 10.8, 7.6, 1.0 Hz, 0.43H, Z), 5.32 (dtt, J = 15.3, 7.6, 1.0 Hz, 0.57H, E), 4.15 (q, J = 7.2 Hz, 
4H), 3.65 (d, J = 7.4 Hz, 0.86H, Z), 3.54 (d, J = 7.4 Hz, 1.14H, E), 3.29 (t, J = 7.6 Hz, 1H), 2.60 (ddd, 
J = 7.6, 7.6, 1.5 Hz, 0.86H, Z), 2.52 (ddd, J = 7.6, 7.6, 1.5 Hz, 1.14H, E), 1.23 (t, J = 7.2 Hz, 6H).
  
13
C-NMR (100 MHz, CDCl3): δ = 168.9 (Cq), 151.4 (Cq), 149.5 (CH), 139.3 (Cq), 138.2 (CH), 137.3 
(Cq), 129.6 (CH), 128.8 (CH), 128.5 (Cq), 127.8 (CH), 126.6 (CH), 121.8 (CH), 121.0 (CH), 120.0 
(CH), 110.1 (CH), 103.0 (CH), 61.3 (CH2), 51.9 (CH), 31.5 (CH2, E), 30.6 (CH2, E), 26.7 (CH2, Z), 
25.9 (CH2, Z), 14.0 (CH3).  
IR (ATR): 1728, 1585, 1469, 1436, 1149, 782, 746 cm
–1
.  
MS (ESI) m/z (relative intensity): 429 (100) [M+Na]
+
, 407 (20) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C24H27N2O4
+ 
[M+H]
+
 407.1965, found 407.1966. 
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(Z)-Diethyl 2-{4-[5-Fluoro-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate [(Z)-151bc]:  
The general procedure F was followed using 5-fluoro-1-(pyridin-2-yl)-1H-indole (95b) (106 mg, 
0.50 mmol) and diethyl 2-vinylcyclopropane-1,1-dicarboxylate (138c) (127 mg, 0.60 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-151bc (166 mg, 78%, E/Z = 1:11) as a 
yellow oil.
  
1
H-NMR (300 MHz, CDCl3): δ = 8.64–8.60 (m, 1H), 7.89–7.82 (m, 1H), 7.38 (d, J = 8.0 Hz, 1H), 
7.32–7.26 (m, 1H), 7.22–7.14 (m, 2H), 6.82 (td, J = 9.1, 2.6 Hz, 1H), 6.37 (s, 1H), 5.59 (dtt, J = 10.8, 
7.5, 1.4 Hz, 1H), 5.40 (dtt, J = 10.8, 7.6, 1.2 Hz, 1H), 4.13 (q, J =  7.2 Hz, 4H), 3.61 (d, J = 7.5 Hz, 
1.83H, Z), 3.50 (d, J = 7.5 Hz, 0.17H, E), 3.29 (t, J = 7.5 Hz, 1H), 2.58 (ddd, J = 7.6, 7.6, 1.4 Hz, 
2H), 1.21 (t, J = 7.2 Hz, 6H).  
13
C-NMR (75 MHz, CDCl3): δ = 168.8 (Cq), 158.3 (Cq, 
1
JC−F = 234.2 Hz), 151.0 (Cq), 149.6 (CH), 
140.9 (Cq), 138.4 (CH), 133.8 (Cq), 128.8 (Cq, 
3
JC−F = 9.7 Hz), 128.2 (CH), 126.8 (CH), 122.1 (CH), 
120.8 (CH), 110.7 (CH, 
3
JC−F = 9.6 Hz), 109.6 (CH, 
2
JC−F = 25.8 Hz), 104.3 (CH, 
2
JC−F = 25.5 Hz), 
102.6 (CH, 
4
JC−F = 4.2 Hz), 61.3 (CH2), 51.7 (CH), 31.5 (CH2, E), 30.9 (CH2, E), 26.5 (CH2, Z), 25.9 
(CH2, Z), 13.9 (CH3).  
19
F-NMR (282 MHz, CDCl3): δ = ‒124.0. IR (ATR): 1727, 1584, 1469, 1437, 1173, 1151, 1031, 855, 
785 cm
–1
.  
MS (ESI) m/z (relative intensity): 447 (90) [M+Na]
+
, 425 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C24H26FN2O4
+ 
[M+H]
+
 425.1871, found 425.1875.
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(Z)-Diethyl 2-{4-[5-Methoxy-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate [(Z)-151dc]:  
The general procedure F was followed using 5-methoxy-1-(pyridin-2-yl)-1H-indole (95d) (112 mg, 
0.50 mmol) and diethyl 2-vinylcyclopropane-1,1-dicarboxylate (138c) (127 mg, 0.60 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-151dc (142 mg, 65%, E/Z = 1:12) as a 
yellow oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.60 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.83 (ddd, J = 8.0, 7.5, 2.0 Hz, 
1H), 7.39 (dt, J = 8.0, 1.0 Hz, 1H), 7.25 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.24−7.21 (m, 1H), 7.01 (d, J = 
2.5 Hz, 1H), 6.75 (dd, J = 8.9, 2.5 Hz, 1H), 6.34 (d, J = 0.9 Hz, 1H), 5.60 (dtt, J = 10.8, 7.3, 1.2 Hz, 1H), 
5.39 (dtt, J = 10.8, 7.5, 1.2 Hz, 1H), 4.14 (q, J = 7.1 Hz, 4H), 3.81 (s, 3H), 3.63 (d, J = 7.3 Hz, 1.84H, 
Z), 3.53 (d, J = 7.3 Hz, 0.16H, E), 3.30 (t, J = 7.6 Hz, 1H), 2.59 (ddd, J = 7.6, 7.5, 1.2 Hz, 1.84H, Z), 
2.51 (ddd, J = 7.6, 7.5, 1.2 Hz, 0.16H, E), 1.20 (t, J = 7.2 Hz, 6H).  
13
C-NMR (100 MHz, CDCl3): δ = 168.8 (Cq), 154.7 (Cq), 151.3 (Cq), 149.5 (CH), 139.8 (Cq), 138.2 
(CH), 132.3 (Cq), 129.0 (Cq), 128.7 (CH), 126.4 (CH), 121.7 (CH), 120.6 (CH), 111.2 (CH), 110.8 
(CH), 102.6 (CH), 102.2 (CH), 61.3 (CH2), 55.7 (CH3), 51.8 (CH), 31.5 (CH2, E), 30.6 (CH2, E), 26.7 
(CH2, Z), 26.0 (CH2, Z), 14.0 (CH3).  
IR (ATR): 1727, 1581, 1470, 1436, 1203, 1171, 1151, 1031, 770, 712 cm
–1
.  
MS (ESI) m/z (relative intensity): 459 (100) [M+Na]
+
, 437 (90) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C25H29N2O5
+ 
[M+H]
+
 437.2071, found 437.2071. 
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(Z)-Dimethyl 2-{4-[4-methyl-2-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate [(Z)-153aa]:  
The general procedure F was followed using 2-(m-tolyl)pyridine (152a) (42.3 mg, 0.25 mmol) and 
dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-153aa (61.8 mg, 70%, E/Z = 1:3).  
1
H-NMR (500 MHz, CDCl3): δ = 8.67–8.65 (m, 1H), 7.73–7.67 (m, 1H), 7.37–7.32 (m, 1H), 7.17 (s, 
1H), 7.16–7.11 (m, 3H), 5.55 (dtt, J = 15.1, 7.6, 1.4 Hz, 0.25H, E), 5.49 (dtt, J = 10.8, 7.6, 1.4 Hz, 
0.75H, Z), 5.29–5.18 (m, 1H), 3.68 (s, 4.62H, Z), 3.66 (s, 1.38H, E), 3.45 (d, J = 7.2 Hz, 2H), 3.34–
3.29 (m, 1H), 2.55 (ddd, J = 7.7, 7.6, 1.3 Hz, 1.54H, Z), 2.51 (ddd, J = 7.7, 7.6, 1.3 Hz, 0.46H, E), 
2.33 (s, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.3 (Cq), 159.9 (Cq), 149.2 (CH), 140.1 (Cq), 136.1 (CH), 135.7 
(Cq), 135.1 (Cq), 132.1 (CH), 130.4 (CH), 129.6 (CH), 129.2 (CH), 124.7 (CH), 124.1 (CH), 121.6 
(CH), 52.5 (CH3, E), 52.4 (CH3, Z), 51.7 (CH, Z), 51.5 (CH, E), 35.7 (CH2, E), 31.8 (CH2, E), 30.5 
(CH2, Z), 26.6 (CH2, Z), 20.9 (CH3).  
IR (ATR): 1734, 1586, 1433, 1339, 1271, 1231, 1196, 1152, 749 cm
–1
.  
MS (ESI) m/z (relative intensity):  376 (70) [M+Na]
+
,
 
354 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C21H24NO4
+ 
[M+H]
+
 354.1700, found 354.1702. 
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(E)-Dimethyl 2-{4-[4-methyl-2-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate [(E)-153aa']:  
The general procedure G was followed using 2-(m-tolyl)pyridine (152a) (42.3 mg, 0.25 mmol) and 
dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 3/1) yielded (E)-153aa' (30.1 mg, 34%, E/Z = 2:1).  
1
H-NMR (500 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.73–7.68 (m, 1H), 7.37–7.32 
(m, 1H), 7.17 (s, 1H), 7.16–7.11 (m, 3H), 5.55 (dtt, J = 15.1, 7.6, 1.4 Hz, 0.67H, E), 5.49 (dtt, J = 
10.8, 7.6, 1.4 Hz, 0.33H, Z), 5.27–5.18 (m, 1H), 3.68 (s, 2.00H, Z), 3.66 (s, 4.00H, E), 3.46–3.29 (m, 
3H), 2.55 (ddd, J = 7.7, 7.6, 1.3 Hz, 0.66H, Z), 2.51 (ddd, J = 7.7, 7.6, 1.3 Hz, 1.34H, E), 2.33 (s, 
3H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.3 (Cq), 159.8 (Cq), 149.1 (CH), 140.1 (Cq), 136.0 (CH), 135.7 
(Cq), 134.7 (Cq), 132.9 (CH), 130.4 (CH), 129.8 (CH), 129.1 (CH), 126.2 (CH), 124.1 (CH), 121.6 
(CH), 52.5 (CH3), 52.4 (CH3), 51.7 (CH, Z), 51.5 (CH, E), 35.7 (CH2, E), 31.8 (CH2, E), 30.5 (CH2, 
Z), 26.6 (CH2, Z), 20.9 (CH3).  
IR (ATR): 1732, 1599, 1434, 1230, 1151, 829, 972, 773, 752 cm
–1
.  
MS (ESI) m/z (relative intensity): 376 (80) [M+Na]
+
,
 
354 (100) [M+H]
+
.   
HR-MS (ESI) m/z calcd. for C21H24NO4
+ 
[M+H]
+
 354.1700, found 354.1701. 
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(Z)-Dimethyl 2-{4-[4-methoxy-2-(pyridin-2-yl)phenyl]but-2-en-1-yl} malonate [(Z)-153ba]:  
The general procedure F was followed using 2-(3-methoxyphenyl)pyridine (152b) (46.3 mg, 
0.25 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 0.30 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-153ba (58.1 mg, 63%, E/Z 
= 1:5).  
1
H-NMR (300 MHz, CDCl3): δ = 8.68–8.64 (m, 1H), 7.72 (ddd, J = 6.7, 4.8, 1.8 Hz, 1H), 7.37–7.33 
(m, 1H), 7.24–7.20 (m, 1H), 7.19–7.14 (m, 1H), 6.89 (s, 1H), 6.87–6.85 (m, 1H), 5.56 (dtt, J = 15.3, 
7.6, 1.4 Hz, 0.17H, E), 5.47 (dtt, J = 10.8, 7.6, 1.4 Hz, 0.83H, Z), 5.30–5.14 (m, 1H), 3.79 (s, 3H), 
3.69 (s, 5.00H, Z), 3.67 (s, 1.00H, E), 3.41 (d, J = 7.2 Hz, 2H), 3.34–3.28 (m, 1H), 2.55 (ddd, J = 7.6, 
7.5, 1.3 Hz, 2H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 159.6 (Cq), 157.7 (Cq), 149.1 (CH), 141.1 (Cq), 136.1 
(CH), 132.1 (CH), 130.6 (CH), 130.3 (Cq), 124.6 (CH), 124.0 (CH), 121.7 (CH), 114.9 (CH), 114.4 
(CH), 55.4 (CH3), 52.5 (CH), 51.6 (CH3), 35.3 (CH2, E), 31.8 (CH2, E), 30.2 (CH2, Z), 26.7 (CH2, Z).  
IR (ATR): 1732, 1607, 1586, 1499, 1469, 1224, 1230, 1150, 750, 611 cm
–1
.  
MS (ESI) m/z (relative intensity):  392 (100) [M+Na]
+
,
 
369 (90) [M]
+
.  
HR-MS (ESI) m/z calcd. for C21H24NO5
+ 
[M+H]
+
 370.1649, found 370.1652. 
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(E,Z)-Dimethyl 2-{4-[4-methoxy-2-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate [(E,Z)-153ba] 
and (E,Z)Dimethyl 2{4-[2-methoxy-6-(pyridin-2-yl)phenyl}but-2-en-1-yl}malonate 
[(E,Z)-153ba']:  
The general procedure G was followed using 2-(3-methoxyphenyl)pyridine (152b) (46.3 mg, 
0.25 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 0.30 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 5/1->3/1->2/1) yielded (E,Z)-153ba and  
(E,Z)-ba' as inseparable mixture (22.2 mg, 24%, E/Z = 1:1) and (E,Z)-153ba'' (19.4 mg, 14%, E/Z = 
1:1).  
1
H-NMR (300 MHz, CDCl3): δ = 8.68–8.63 (m, 1H), 7.76–7.66 (m, 1H), 7.34 (ddd, J = 4.1, 2.0, 1.0 
Hz, 1H), 7.24–7.20 (m, 1H), 7.19–7.14 (m, 1H), 6.89 (s, 1H), 6.87–6.85 (m, 1H), 5.56 (dtt, J = 15.3, 
7.6, 1.4 Hz, 0.50H, E), 5.47 (dtt, J = 10.8, 7.6, 1.4 Hz, 0.50H, Z), 5.28–5.02 (m, 1H), 3.85–3.79 (s, 
3H), 3.70–3.62 (s, 6H), 3.47–3.22 (m, 3H), 2.57–2.51 (m, 2H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 159.5 (Cq), 157.7 (Cq), 149.1 (CH), 141.2 (Cq), 136.0 
(CH), 135.4 (CH), 132.9 (CH), 130.9 (Cq), 126.1 (CH), 124.2 (CH), 121.7 (CH), 114.4 (CH), 110.4 
(CH), 55.4 (CH3), 52.4 (CH3), 51.9 (CH), 35.4 (CH2, E), 31.8 (CH2, E), 26.6 (CH2, Z), 25.1 (CH2, Z).  
IR (ATR): 1732, 1607, 1586, 1499, 1469, 1224, 1230, 1150, 750, 611 cm
–1
.  
MS (ESI) m/z (relative intensity): 392 (100) [M+Na]
+
,
 
369 (90) [M]
+
.  
HR-MS (ESI) m/z calcd. for C21H24NO5
+ 
[M+H]
+
 370.1649, found 370.1652. 
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(2E,Z,2'E,Z)-Tetramethyl [4-methoxy-2-(pyridin-2-yl)-1,3-phenylenebis(but-2-ene-4,1-diyl)]di-
malonate [(E,Z)-153ba'']:  
1
H-NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.72–7.65 (m, 1H), 7.23–7.17 
(m, 1H), 7.14 (dt, J = 7.7, 1.1 Hz, 1H), 7.04–7.00 (m, 1H), 6.83 (d, J = 1.6 Hz, 1H), 5.51–5.39 (m, 
2H), 5.15–4.88 (m, 2H), 3.79 (s, 3H), 3.66 (s, 12H), 3.31 (t, J = 6.2 Hz, 2H), 3.11–2.80 (m, 4H), 
2.53–2.39 (m, 4H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 158.7 (Cq), 155.8 (Cq), 149.2 (CH), 141.0 (Cq), 135.5 
(CH), 132.5 (CH), 131.7 (CH), 130.2 (Cq), 127.6 (CH), 126.6 (Cq), 125.9 (CH), 125.1 (CH), 121.7 
(CH), 110.4 (CH), 55.7 (CH3), 52.4 (CH3), 52.0 (CH), 36.1 (CH2, E), 31.9 (CH2, E), 30.6 (CH2, Z), 
26.6 (CH2, Z).  
IR (ATR): 1732, 1584, 1466, 1434, 1257, 1151, 1033, 972, 731 cm
–1
.  
MS (ESI) m/z (relative intensity): 554 (80) [M+H]
 +
, 553 (100) [M]
+
.  
HR-MS (ESI) m/z calcd. for C30H36NO9
+ 
[M+H]
+
 554.2385, found 554.2389. 
 
 
 
 
(Z)-Dimethyl 2-{4-[2-(1H-pyrazol-1-yl)phenyl]but-2-en-1-yl}malonate [(Z)-153ca]:  
The general procedure F was followed using 1-phenyl-1H-pyrazole (152c) (72.1 mg, 0.50 mmol) and 
dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (110 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-153ca (117 mg, 71%, E/Z = 1:12) as a yellow 
oil.  
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1
H-NMR (500 MHz, CDCl3): δ = 7.66 (dd, J = 2.4, 0.7 Hz, 1H), 7.55 (dd, J = 2.4, 0.7 Hz, 1H), 
7.32–7.28 (m, 2H), 7.25–7.24 (m, 2H), 6.39–6.37 (m, 1H), 5.43 (dtt, J = 10.7, 7.5, 1.0 Hz, 1H), 5.32 
(dtt, J = 10.7, 7.5, 1.4 Hz, 1H), 3.66 (s, 6H), 3.34–3.31 (m, 3H), 2.59 (ddd, J = 7.6, 7.5, 1.0 Hz, 
1.84H), 2.53 (ddd, J = 7.6, 7.5, 1.0 Hz, 0.16H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.1 (Cq), 140.3 (CH), 139.5 (Cq), 136.3 (Cq), 130.6 (CH), 130.4 
(CH), 130.1 (CH), 128.6 (CH), 126.8 (CH), 126.4 (CH), 125.8 (CH), 106.2 (CH), 52.4 (CH3), 51.3 
(CH), 34.1 (CH2, E), 31.1 (CH2, E), 29.0 (CH2, Z), 26.5 (CH2, Z).  
IR (ATR): 1731, 1517, 1435, 1394, 1233, 1153, 911, 759, 730 cm
–1
.  
MS (ESI) m/z (relative intensity): 351 (20) [M+Na]
+
,
 
329 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C18H21N2O4
+ 
[M+H]
+
 329.1496, found 329.1497. 
 
 
 
 
(Z)-Dimethyl 2-{4-[5-fluoro-2-(1H-pyrazol-1-yl)phenyl]but-2-en-1-yl}malonate [(Z)-153da]:  
The general procedure F was followed using 1-(4-fluorophenyl)-1H-pyrazole (152d) (81.2 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-153da (114 mg, 66%, E/Z = 
1:17) as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): δ = 7.66–7.63 (m, 1H), 7.52–7.48 (m, 1H), 7.24–7.19 (m, 1H), 6.97 
(m, 2H), 6.38 (m, 1H), 5.45–5.32 (m, 2H), 3.66 (s, 6H), 3.32 (ddd, J = 7.6, 7.5, 1.4 Hz, 1H), 3.26 (d, 
J = 6.4 Hz, 1.89H, Z), 3.14 (d, J = 6.4 Hz, 0.11H, E), 2.57–2.52 (m, 2H).  
13
C-NMR (75 MHz, CDCl3): δ = 169.0 (Cq), 162.2 (Cq, 
1
JC−F = 248.2 Hz), 140.4 (CH), 139.2 (Cq, 
3
JC−F = 8.0 Hz), 135.6 (Cq, 
4
JC−F = 3.1 Hz), 130.8 (CH), 129.4 (CH), 128.1 (CH,
 3
JC−F = 9.0 Hz), 
126.7 (CH), 116.5 (CH, 
2
JC−F = 23.0 Hz), 113.5 (CH, 
2
JC−F = 22.7 Hz), 106.3 (CH), 52.4 (CH3), 51.2 
(CH), 34.0 (CH2, 
4
JC−F = 1.5 Hz, E), 31.3 (CH2, E), 28.8 (CH2, 
4
JC−F = 1.5 Hz, Z), 26.5 (CH2, Z).  
19
F-NMR (282 MHz, CDCl3): δ = ‒112.7 (E), ‒112.5 (Z). IR (ATR): 1731, 1518, 1497, 1434, 1267, 
1230, 1150, 1024, 755 cm
–1
.  
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MS (ESI) m/z (relative intensity):  369 (30) [M+Na]
+
,
 
347 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C18H20FN2O4
+ 
[M+H]
+ 
347.1402, found 347.1402. 
 
 
 
 
(E)-Dimethyl 2-{4-[5-fluoro-2-(1H-pyrazol-1-yl)phenyl]but-2-en-1-yl}malonate [(E)-153da']:  
The general procedure G was followed using 1-(4-fluorophenyl)-1H-pyrazole (152d) (41 mg, 
0.25 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 0.30 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded (E)-153da' (44.2 mg, 48%, E/Z = 
1:2) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): δ = 7.69–7.66 (m, 1H), 7.55–7.50 (m, 1H), 7.33–7.24 (m, 1H), 7.02–
6.92 (m, 2H), 6.45–6.38 (m, 1H), 5.55–5.23 (m, 2H), 3.70 (s, 6H), 3.41–3.32 (m, 1H), 3.28 (d, J = 
6.4 Hz, 1.20H, Z), 3.17 (d, J = 6.4 Hz, 0.80H, E), 2.62–2.52 (m, 2H).  
13
C-NMR (100 MHz, CDCl3): δ = 169.0 (Cq), 162.8 (Cq, 
1
JC−F = 248.1 Hz), 140.4 (CH), 138.9 (Cq, 
3
JC−F = 8.0 Hz), 135.6 (Cq, 
4
JC—F = 3.1 Hz), 130.8 (CH), 129.4 (CH), 128.2 (CH,
 3
JC−F = 9.0 Hz), 126.7 
(CH), 116.8 (CH, 
2
JC−F = 23.0 Hz), 113.7 (CH, 
2
JC−F = 22.7 Hz), 106.5 (CH), 52.5 (CH3), 51.4 (CH), 
34.4 (CH2, 
4
JC−F = 1.5 Hz, E), 31.2 (CH2, E), 29.0 (CH2, 
4
JC−F = 1.5 Hz, Z), 26.5 (CH2, Z).  
19
F-NMR (282 MHz, CDCl3): δ = ‒112.7 (E), ‒112.5 (Z). IR (ATR): 1732, 1518, 1497, 1435, 1334, 
1268, 1151, 755 cm
–1
.  
MS (ESI) m/z (relative intensity): 369 (20) [M+Na]
+
,
 
347 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C18H19FNaN2O4
+ 
[M+Na]
+
 369.1221, found 369.1221. 
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(Z)-Dimethyl 2-{4-[5-methyl-2-(1H-pyrazol-1-yl)phenyl]but-2-en-1-yl}malonat [(Z)-153ea]:  
The general procedure F was followed using 1-(p-tolyl)-1H-pyrazole (152e) (79.3 mg, 0.50 mmol) 
and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (110 mg, 0.60 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 3/1) yielded (Z)-153ea (118 mg, 69%, E/Z = 1:19) as a 
yellow oil.  
1
H-NMR (400 MHz, CDCl3): δ = 7.66–7.63 (m, 1H), 7.52–7.48 (m, 1H), 7.13 (d, J = 7.9 Hz, 1H), 
7.08–7.02 (m, 2H), 6.37 (m, 1H), 5.43 (dtt, J = 10.7, 7.4, 1.4 Hz, 1H), 5.32 (dtt, J = 10.7, 7.6, 1.4 Hz, 
1H), 3.66 (s, 6H), 3.32 (t, J = 7.8 Hz, 1H), 3.27 (d, J = 7.4 Hz, 1.90H, Z), 3.15 (d, J = 7.3 Hz, 0.10H, 
E), 2.57 (ddd, J = 7.6, 7.6, 1.4 Hz, 2H), 2.33 (s, 3H).  
13
C-NMR (100 MHz, CDCl3): δ = 169.1 (Cq), 140.1 (CH), 138.5 (Cq), 137.1 (Cq), 136.0 (Cq), 130.7 
(CH), 130.6 (CH), 130.5 (CH), 127.3 (CH), 126.2 (CH), 125.6 (CH), 106.0 (CH), 52.3 (CH3), 51.3 
(CH), 34.1 (CH2, E), 31.1 (CH2, E), 29.0 (CH2, Z), 26.5 (CH2, Z), 21.0 (CH3).  
IR (ATR): 1732, 1518, 1434, 1495, 1231, 1152, 1023, 916, 753, 624 cm
–1
.  
MS (ESI) m/z (relative intensity): 365 (10) [M+Na]
+
,
 
343 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C19H23N2O4
+ 
[M+H]
+
 343.1652, found 343.1655. 
 
 
 
 
(Z)-Dimethyl 2-{4-[2-fluoro-6-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate [(Z)-153fa]:  
The general procedure F was followed using 2-(3-fluorophenyl)pyridine (152f) (42.5 mg, 0.25 mmol) 
and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 0.30 mmol). Isolation by 
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column chromatography (n-hexane/EtOAc: 10/1->7/1->5/1) yielded (Z)-153fa (51.8 mg, 58%, E/Z = 
1:7) and (Z)-153fa' (12.5 mg, 14%, E/Z = 1:5) as yellow oils.  
1
H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 4.3, 1.6, 0.8 Hz, 1H), 7.79–7.72 (m, 1H), 7.38–7.26 
(m, 2H), 7.09–6.95 (m, 3H), 5.57 (dtt, J = 15.2, 7.2, 1.4, 0.13H, E), 5.46 (dtt, J = 10.8, 7.2, 1.4, 
0.87H, Z), 5.34–5.16 (m, 1H), 3.69 (s, 5.20H, Z), 3.64 (s, 0.80H, E), 3.51 (d, J = 7.2 Hz, 1.74H, Z), 
3.38 (d, J = 7.2 Hz, 0.26H, E), 3.28 (t, J = 7.7 Hz, 1H), 2.49 (ddd, J = 7.6, 7.6, 1.4 Hz, 2H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.3 (Cq), 161.5 (Cq, 
1
JC−F = 245.1 Hz), 158.6 (Cq, 
4
JC−F = 3.0 
Hz), 149.3 (CH), 142.4 (Cq, 
3
JC−F = 3.8 Hz), 136.5 (CH), 130.5 (CH), 127.4 (CH, 
3
JC−F = 9.2 Hz), 
126.0 (Cq, 
2
JC−F = 17.0 Hz), 125.5 (CH, 
4
JC−F = 3.2 Hz), 124.8 (CH), 124.2 (CH), 122.1 (CH), 115.3 
(CH, 
2
JC−F = 22.5 Hz), 52.5 (CH3), 51.4 (CH), 31.6 (CH2, E), 29.0 (CH2, E), 26.5 (CH2, Z), 24.2 
(CH2, Z).  
19
F-NMR (282 MHz, CDCl3): δ = ‒116.4 (Z), ‒116.7 (E).  
IR (ATR): 1732, 1585, 1565, 1471, 1434, 1232, 1194, 1150, 749 cm
–1
.  
MS (ESI) m/z (relative intensity):  380 (60) [M+Na]
+
,
 
358 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C20H21FNO4
+ 
[M+H]
+
 358.1449, found 358.1450.  
 
 
 
 
(Z)-Dimethyl 2-{4-[4-fluoro-2-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate [(Z)-153'fa]:  
1
H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.3, 1.6, 0.8 Hz, 1H), 7.77–7.71 (m, 1H), 7.35 (d, J 
= 7.8 Hz, 1H), 7.26 (ddd, J = 4.2, 2.4, 1.4 Hz, 1H), 7.22 (dd, J = 6.2, 3.8 Hz, 1H), 7.16–7.02 (m, 2H), 
5.57 (dtt, J = 15.3, 7.0, 1.2, 0.16H, E), 5.45 (dtt, J = 10.8, 7.0, 1.2, 0.84H, Z), 5.27–5.08 (m, 1H), 
3.70 (s, 5.17, Z), 3.65 (s, 0.83H, E), 3.51 (d, J = 7.0 Hz, 2H), 3.29 (dd, J = 7.6 Hz, 1H), 2.48 (ddd, J 
= 7.3, 7.2, 1.2 Hz, 2H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.3 (Cq), 161.1 (Cq, 
1
JC−F = 245.1 Hz), 158.6 (Cq, 
4
JC−F = 4.4 
Hz), 149.3 (CH), 141.6 (Cq, 
3
JC−F = 4.6 Hz), 136.6 (CH), 134.0 (CH), 131.6 (CH), 131.2 (Cq, 
4
JC−F = 
  Experimental Section  
163 
 
7.7 Hz), 125.2 (CH), 124.1 (CH), 122.2 (CH), 116.4 (CH, 
2
JC−F = 22.3 Hz), 115.3 (CH, 
2
JC−F = 22.3 
Hz), 52.5 (CH3), 51.5 (CH), 35.5 (CH2, E), 31.7 (CH2, E), 30.2 (CH2, Z), 26.6 (CH2, Z).  
19
F-NMR (282 MHz, CDCl3): δ = ‒117.3 (Z), ‒117.2 (E).  
IR (ATR): 1735, 1452, 1436, 1372, 1237, 1154, 1045, 778 cm
–1
.  
HR-MS (ESI) m/z calcd. for C20H21FNO4
+ 
[M+H
+
] 358.1449, found 358.1456.  
 
 
 
 
(E,Z)-Dimethyl 2-{4-[2-fluoro-6-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate [(E,Z)-153fa']:  
The general procedure G was followed using 2-(3-fluorophenyl)pyridine (152f) (42.5 mg, 0.25 mmol) 
and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 0.30 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/1->7/1->5/1) yielded (E,Z)-153fa' (21.4 mg, 24%, E/Z 
= 1:1) and (E,Z)-153fa'' (5.4 mg, 6%, E/Z = 1:1).  
1
H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.3, 1.6, 0.8 Hz, 1H), 7.77–7.71 (m, 1H), 7.35 (d, J 
= 7.8 Hz, 1H), 7.26 (ddd, J = 4.2, 2.4, 1.4 Hz, 1H), 7.22 (dd, J = 6.2, 4.2 Hz, 1H), 7.16–7.02 (m, 2H), 
5.57 (dtt, J = 15.2, 7.2, 1.4, 0.53H, E), 5.46 (dtt, J = 10.8, 7.2, 1.4, 0.47H, Z), 5.27–5.08 (m, 1H), 
3.70 (s, 2.66H, Z), 3.64 (s, 3.34H, E), 3.50 (d, J = 7.0 Hz, 0.84H, Z), 3.38 (d, J = 7.0 Hz, 1.16H, E), 
3.33−3.25 (m, 1H), 2.48 (ddd, J = 7.6, 7.5, 1.4 Hz, 2H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.3 (Cq), 161.4 (Cq, 
1
JC−F = 245 Hz), 158.5 (Cq, 
4
JC−F = 3.3 Hz), 
149.3 (CH), 142.5 (Cq, 
3
JC−F = 3.8 Hz), 136.5 (CH), 130.5 (CH), 127.4 (CH, 
3
JC−F = 9.2 Hz), 126.0 
(Cq, 
2
JC−F = 17.2 Hz), 125.5 (CH, 
4
JC−F = 3.2 Hz), 124.8 (CH), 124.2 (CH), 122.1 (CH), 115.3 (CH, 
2
JC−F = 22.8 Hz), 52.5 (CH3, Z), 52.4 (CH3, E), 51.8 (CH, E), 51.5 (CH, Z), 31.8 (CH2, E), 29.0 (CH2, 
E), 26.5 (CH2, Z), 24.2 (CH2, Z).  
19
F-NMR (282 MHz, CDCl3): δ = ‒116.4 (Z), ‒116.7 (E).  
IR (ATR): 1735, 1452, 1436, 1372, 1237, 1154, 1045, 778 cm
–1
.  
MS (ESI) m/z (relative intensity): 380 (60) [M+Na]
+
,
 
358 (100) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C20H21FNO4
+ 
[M+H
+
] 358.1449, found 358.1456.  
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(E,Z)-Dimethyl 2-{4-[4-fluoro-2-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate [(E,Z)-153fa'']:  
1
H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.3, 1.6, 0.8 Hz, 1H), 7.77–7.71 (m, 1H), 7.39–7.32 
(m, 1H), 7.31–7.27 (m, 1H), 7.25–7.19 (m, 1H), 7.12–6.98 (m, 2H), 5.57 (dtt, J = 15.2, 7.2, 1.4, 
0.50H, E), 5.46 (dtt, J = 10.8, 7.2, 1.4, 0.50H, Z), 5.34–5.21 (m, 1H), 3.71 (s, 3.00H, Z), 3.68 (s, 
3.00H, E), 3.47 (d, J = 7.0 Hz, 1H), 3.38–3.33 (m, 2H), 2.60–2.49 (m, 2H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.3 (Cq), 161.1 (Cq, 
1
JC−F = 245.4 Hz), 158.6 (Cq, 
4
JC−F = 4.4 
Hz), 149.3 (CH), 141.6 (Cq, 
3
JC−F = 4.6 Hz), 136.6 (CH), 134.0 (CH), 131.6 (CH), 131.2 (Cq, 
4
JC−F = 
7.7 Hz), 125.2 (CH), 124.1 (CH), 122.2 (CH), 116.4 (CH, 
2
JC−F = 22.3 Hz), 115.3 (CH, 
2
JC−F = 22.3 
Hz),  52.5 (CH3), 51.5 (CH), 35.5 (CH2, E), 31.7 (CH2, E), 30.2 (CH2, Z), 26.6 (CH2, Z).  
19
F-NMR (282 MHz, CDCl3): δ = ‒117.3 (Z), ‒117.2 (E).  
IR (ATR): 1735, 1452, 1436, 1372, 1237, 1154, 1045, 778 cm
–1
.  
HR-MS (ESI) m/z calcd. for C20H21FNO4
+ 
[M+H
+
] 358.1449, found 358.1456.  
 
 
 
 
(Z)-dimethyl 2-(4-(5-formyl-1-(pyridin-2-yl)-1H-pyrrol-2-yl)but-2-en-1-yl)malonate (153ga):  
The representative procedure F was followed using 1-phenyl-1H-pyrrole-2-carbaldehyde (152g) and 
dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (138a) (55.2 mg, 0.30 mmol). (85 mg, 0.50 mmol), 
Isolation by column chromatography(n-hexane/EtOAc: 10/1->7/1->5/1) yielded (E,Z)-153ga 
(138 mg, 78%, Z/E = 1:1) as a yellow oil.  
1
H NMR (300 MHz, CDCl3) δ = 9.39 (s, 1H), 8.60–8.53 (m, 1H), 7.82 (tdd, J = 7.6, 5.6, 1.9 Hz, 1H), 
7.40–7.33 (m, 1H), 7.32–7.24 (m, 1H), 7.01 (d, J = 3.9 Hz, 1H), 6.15 (dd, J = 6.9, 3.9 Hz, 1H), 5.55–
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5.43 (m, 1H), 5.40–5.30 (m, 1H), 3.67 (s, 6H), 3.39–3.25 (m, 1H), 3.28-3.18 (m, 2H), 2.49 (dd, J = 
12.5, 7.0 Hz, 2H).  
13
C NMR (125 MHz, CDCl3) δ = 177.7 (CHO), 168.9 (Cq), 150.6 (Cq), 149.0 (CH), 142.4 (Cq), 
138.0 (CH), 132.9 (Cq), 128.4 (CH), 127.6 (CH), 126.9 (CH), 123.6 (CH), 122.8 (CH), 109.8 (CH), 
52.5 (CH3), 51.5 (CH), 30.0 (CH2), 25.0 (CH2).  
IR (ATR): 1731, 1517, 1434, 1394, 1271, 1022, 760, 623 cm
–1
.  
HR-MS (ESI) m/z calcd for C19H21N2O5
+ 
[M+H
+
] 357.1445, found 357.1443. 
 
 
 
Decarboxylation 
 
 
 
A mixture of dimethyl (Z)-2-{4-[1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate (151aa) 
(113 mg, 300 µmol, 1.0 equiv), LiI (60.2 mg, 450 µmol, 1.5 equiv) and H2O (10.8 µl, 600 µmol, 
2.0  equiv) in 2,4,6-collidine (2.0 mL, 0.15 M) was stirred at 140 °C for 24 h. At ambient 
temperature, the mixture was diluted with EtOAc (5.0 mL), washed four times successively with 1 M 
HCl (5.0 mL) and sat. NaHCO3/brine (1:3, 5.0 mL), dried over MgSO4 and concentrated in vacuo to 
yield the product S-1 as a pale yellow liquid (72.0 mg, 75%).
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(Z)-Methyl 6-[1-(pyridin-2-yl)-1H-indol-2-yl]hex-4-enoate (S-1):  
1
H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.91–7.83 (m, 1H), 7.55 (ddd, 
J = 6.0, 3.1, 0.7 Hz, 1H), 7.43 (ddd, J = 3.9, 2.0, 1.0 Hz, 1H), 7.34–7.27 (m, 2H), 7.12–7.07 (m, 2H), 
6.42 (d, J = 1.0 Hz, 1H), 5.59–5.49 (m, 1H), 5.46–5.34 (m, 1H), 3.65 (s, 3H), 3.64–3.61 (m, 2H), 
2.34–2.29 (m, 4H).  
13
C-NMR (125 MHz, CDCl3): δ = 173.3 (Cq), 151.3 (Cq), 149.6 (CH), 139.5 (CH), 138.1 (Cq), 137.3 
(CH), 129.2 (CH), 128.5 (Cq), 127.1 (CH), 121.9 (CH), 121.7 (CH), 121.0 (CH), 120.6 (CH), 119.9 
(CH), 110.0 (Cq), 102.7 (CH), 51.6 (CH2), 34.0 (CH2), 26.0 (CH3), 22.8 (CH2).  
IR (ATR): 1733, 1586, 1469, 1455, 1435, 1151, 1024, 972, 747 cm
–1
.  
MS (ESI) m/z (relative intensity): 321 (20) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C20H21N2O2
+ 
[M+H]
+
 321.1598, found 321.1598. 
 
 
Hydrogenation 
 
 
 
To a solution of dimethyl (Z)-2-{4-[1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate 
[(Z)-151aa] (94.5 mg, 0.25 mmol) in MeOH (1.0 mL) was added Pd/C (9.5 mg, 10 wt.-%) and 
ammonium formate (79.0 mg, 5.0 equiv). The mixture was stirred at 25 °C for 20 h and then filtered 
through a short pad of celite. The residue was washed with EtOAc (10 mL), filtered and the combined 
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filtrate was concentrated in vacuo. The crude mixture was purified by flash column chromatography 
on silica gel (n-hexane/EtOAc: 5/1) to yield S-2 (88.4 mg, 93%) as a yellow oil. 
 
 
 
Dimethyl 2-{4-[1-(pyridin-2-yl)-1H-indol-2-yl]butyl}malonate (S-2):  
1
H-NMR (500 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 1.9, 0.7 Hz, 1H), 7.89 (dt, J = 7.8, 2.0 Hz, 1H), 
7.58–7.56 (m, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.34–7.31 (m, 2H), 7.14–7.11 (m, 2H), 6.44 (d, J = 0.6 
Hz, 1H), 3.71 (s, 6H), 3.31 (t, J = 7.7 Hz, 1H), 2.85 (ddd, J = 7.6,7.5, 1.0 Hz, 2H), 1.91–1.84 (m, 2H), 
1.64–1.57 (m, 2H), 1.37–1.30 (m, 2H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.9 (Cq), 151.5 (Cq), 149.7 (CH), 141.1 (Cq), 138.3 (CH), 137.3 
(Cq), 128.6 (Cq), 122.1 (CH), 121.7 (CH), 121.1 (CH), 120.6 (CH), 119.9 (CH), 110.1 (CH), 102.2 
(CH), 52.5 (CH3), 51.6 (CH), 28.6 (CH2), 28.1 (CH2), 27.2 (CH2), 26.9 (CH2).  
IR (ATR): 1731, 1570, 1469, 1435, 1148, 909, 781, 731 cm
–1
.  
MS (ESI) m/z (relative intensity): 403 (100) [M+Na]
+
, 381 (20) [M+H]
+
.  
HR-MS (ESI) m/z calcd. for C22H25N2O4
+ 
[M+H]
+
 381.1809, found 381.1810. 
 
 
Isomerization Experiments 
 
 
A solution of (Z)-151aa (94.5 mg, 0.25 mmol, 1.0 equiv), [Cp*Rh(CH3CN)3](SbF6)2 (20.0 mg, 
10 mol %) and NaOPiv (6.2 mg, 20 mol %) in DCE (1 mL, 0.25 M) was stirred at 50 °C for 20 h. At 
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ambient temperature, the solvent was removed and the crude mixture was purified by flash column 
chromatography on silica gel (n-hexane/EtOAc: 3/1) to yield (Z)-151aa (84.1 mg, 89%, E/Z = 1:11) 
as a pale yellow oil. 
 
 
 
 
A solution of (E)-151aa' (94.5 mg, 0.25 mmol, 1.0 equiv), [Cp*Co(CO)I2] (11.9 mg, 10 mol %) and 
NaOPiv (6.2 mg, 20 mol %) in DCE (1 mL, 0.25 M) was stirred at 50 °C for 20 h. At ambient 
temperature, the solvent was removed and the crude mixture was purified by flash column 
chromatography on silica gel (n-hexane/EtOAc: 3/1), yielding (E)-151aa' (88.9 mg, 94%, E/Z = 1.8:1) 
as a yellow oil. 
 
 
 
 
 
A solution of (Z)-151aa (94.5 mg, 0.25 mmol, 1.0 equiv) and I2 (1.6 mg, 5 mol %) in CH2Cl2 (1 mL, 
0.25 M) was irradiated by UV-light (254 nm) at 25 °C for 16 h. The solvent was removed and the 
crude mixture was purified by column chromatography on silica gel (n-hexane/EtOAc: 5/1) to yield 
(Z)-151aa'' (78.4 mg, 83%, E/Z = 1:2) as a yellow oil. 
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